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Abstract 
 Doxorubicin (Dox) is an antitumor drug that has been used as a chemotherapeutic agent 
in the clinic for over 30 years.  Dox treatments have been hindered by significant dose limiting 
cardiotoxic effects resulting in irreversible cardiomyopathy.  A Dox variant, Doxazolidine 
(Doxaz) is a Dox-formaldehyde conjugate discovered in the Koch lab.  Doxaz operates via a 
distinct mechanism, and exhibits an improved therapeutic profile compared to Dox.  Doxaz 
suffers from poor aqueous stability; however, stabilization of Doxaz has been achieved through 
the use of enzymatically activated carbamate prodrugs.  This thesis presents the synthesis and 
preliminary evaluation of Doxaz prodrugs intended for commercialization.  The prodrugs 
contain the active platform therapeutic (Doxaz), an enzyme cleavage site, a self-eliminating 
spacer to increase cleavage efficiency, and in some cases, a maleimide moiety for passive 
targeting through albumin biniding.  The enzymes targeted are proteases such as plasmin and 
cathepsin B.  Also presented are prodrugs aimed at tumor associated hypoxia and enzymes 
such as NQO1 and NQO2.  The synthesis of these prodrugs places an emphasis on scalable 
manufacturing processes.  These prodrugs are currently, or will be undergoing complete 
biological characterization and animal studies in varying species.  
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Chapter 1 Introduction 
1.1 History of Doxorubicin (Dox) 
 Daunorubicin, also known by its trade name Daunomycin, and related members of the 
anthracycline family of natural products have been prominent anti-cancer therapeutics since 
their discovery in the 1960’s by an Italian research company, Farmitalia Research Laboratories.  
An interesting strain of Streptomyces peucetius which contained a red pigmentation that was 
isolated from the soil surrounding a 13th century castle, Castel del Monte, produced the red 
daunorubicin.  The discovery was shared with a French group who discovered the compound at 
the same time.  The two groups cooperatively named the compound daunorubicin (Dau), 
combining the word Dauni, a pre-Roman tribe that occupied the area of Italy where the 
compound was discovered, and rubis, the French word for ruby which was descriptive of the 
red color.1  In the early 1960’s, daunorubicin had some success as a lymphoma and acute 
leukemia therapeutic until it became apparent that daunorubicin had a debilitating side effect, 
namely chronic cardiotoxicity.2   
 During this time, Farmitalia Research Laboratories discovered that small changes to the 
daunorubicin functional groups had a measurable effect on the biological activity.  Using N-
nitroso-N-methyl urethane, Streptomyces peucetius was mutated to produce a new strain, 
Streptomyces peucetius var caesius which afforded a different, biologically active, red colored 
antibiotic.  Arcamone et al. initially referred to this new compound as Adriamycin, after the 
Adriatic Sea, but later changed the name to doxorubicin to conform to the previous 
conventions.3  Doxorubicin showed better cytotoxicity toward both murine and human tumors, 
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especially solid tumors.2-4  The structures of some common anthracyclines, doxorubicin, 
daunorubicin and epirubicin are provided in Figure 1.1.1. 
 
Figure 1.1.1 Common Anthracycline Structures. The recognized ring and crbon numbering 
system of some common anthracyclines. 
 Doxorubicin was approved by the U.S. Food and Drug Administration in the 1970s and 
has historically been one of the most successful agents for the treatment of several types of 
cancers including leukemia, lymphoma, sarcoma, and solid tumors of the lung, ovaries and 
breast.5  Currently doxorubicin is used as a clinical therapeutic in many multidrug protocols in 
an attempt to improve its therapeutic index, and continues to be a lucrative pharmaceutical.  
For example, sales of CAELYX (pegylated liposomal doxorubicin hydrochloride) approved for the 
treatment of ovarian cancer, metastatic breast cancer and Kaposi's sarcoma, were $75 million 
for the fourth quarter and $284 million for the full year of 2010 as reported by Merck.  The 
marketing rights for CAELYX returned to Johnson & Johnson on Dec. 31, 2010.6 
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1.2 Doxorubicin Cardiotoxicity 
 Despite its vast utility in clinical oncology, doxorubicin hydrochloride or Adriamycin use 
is limited by a potentially fatal cardiomyopathy.  In early trials, the onset of congestive heart 
failure was observed to be abrupt with a very poor prognosis.  Fatality was reported in 70 – 80% 
of cases.7,8  Physicians currently monitor risk factors such as age,9 preexisting cardiac 
disease9,10,11 dosing regimen,9,12,13 and concomitant medications such as mitomycin, vinblatine 
sulfate, vincistine sulfate, decarbazine, bleomycin sulfate, etoposide, amascrine and megestrol 
acetate10,14-20  as they could contribute to the deleterious side effect.  Most importantly, the 
total dose of Dox given has the greatest impact on Dox induced cardiomyopathy. Many groups 
have shown that the incidence of cardiomyopathy sharply increases at lifetime doses above 550 
mg/m2 of body surface area.9,10,21  The current, clinically accepted lifetime limit of 
anthracyclines is 550 mg/m2. 
 To date, the mechanism of Dox dose and treatment limiting cardiotoxicies are poorly 
understood.  In vitro and in vivo, anthracyclines have been shown to stimulate superoxide 
production via the reduced form of  nicotinamide-adenine dinucleotide phosphate (NADPH).22-
24  The mechanism of this oxidative stress is hypothesized to be preceded by reduction of the 
anthracycline quinone to a semiquinone radical, with subsequent reaction with dioxygen to 
produce the superoxide.22  Superoxide radicals are toxic to tissues, and their initiation of a 
peroxide radical chain reaction can lead to the conversion of unsaturated fatty acids to lipid 
peroxides.  Lipid peroxides rapidly decompose to yield many products most notably 
malondialdehyde.24  Malondialdehyde was not detected in untreated heart tissue; however, 
after doxorubicin treatment, malondialdehyde was detected two to six days after 
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administration in rats.  Malondialdehyde was also observed in human platelet-rich plasma after 
doxorubicin treatment.25   
 The protection of cells from oxygen radicals such as superoxide and peroxides 
encompasses many enzymes such as the glutathione and selenium dependent glutathione 
peroxidase,26,27 catalase,23,26 and superoxide dismutase.28  It has been shown in animal models 
that cardiac concentrations of these protective enzymes are much lower than in other 
organs,22,23 and doxorubicin acutely depresses the protective glutathione peroxidase23 which 
renders the cell vulnerable to lipid peroxides and hydrogen peroxide.  The inhibition of enzymes 
meant to deplete toxic oxygen radicals causes doxorubicin to potentiate its own toxicity.  Thus, 
the lower concentration of detoxifying enzymes in cardiac tissue appears to elevate the risk of 
heart damage.  In addition, an acute reduction of glutathione in the heart after treatment with 
doxorubicin has been observed.29  The exact role of reduced glutathione in the myocardium is 
not entirely known; however, it has been found to have a significant role in muscle contraction, 
implicating that its depletion due to doxorubicin could lead to heart failure.30   
 Mitochondrial damage through the inhibition of coenzyme Q10 or ubiquinone, has also 
been postulated as a cause of doxorubicin induced cardiotoxicity.  Coenzyme Q10 is a coenzyme 
of mitochondrial succinoxidase and nicotinamide-adenine dinucleotide oxidase, which are 
involved in the electron-transfer process of respiration and coupled phosphorylation.31 
Doxorubicin can interfere with these enzyme systems.32  The high concentration of 
mitochondria in myocardial tissue coupled with the doxorubicin induced alteration of 
mitochondria implicates this mechanism.  The ability of doxorubicin to bind the apoenzyme has 
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been used as an explanation of the observed inhibitory effect because the doxorubicin 
apoenzyme conjugate disallows the binding of the true coenzyme Q10 due to structural 
similarity.   
 Additionally, Dox has been shown to play a role in iron depletion and iron homeostasis 
in cytosolic fractions of myocardia obtained from patients after surgery.33  Iron acts as a 
cofactor in many enzyme systems as varied as respiration and DNA synthesis.34  Iron Regulatory 
Protein 1 (IRP-1) is the cytosolic form of mitochondrial aconitase and is a bifunctional protein 
that regulates the concentration of metabolically available low molecular weight iron and 
modulates the iron uptake versus sequestration.37,38  IRP-1 can also be inactivated by a 
secondary alcohol metabolite of Dox, DOXol.33  DOXol is formed from Dox by reduction of the C-
13 carbonyl group to a secondary alcohol by NADPH-dependent aldo-keto reductases that are 
present in cytosolic fractions of human myocardium.35  This reduction is shown schematically in 
Figure 1.2.1.  DOXol inactivates IRP-1 by initiating redox mechanisms that sequester iron from 
the [4Fe-4S] cluster in aconitase forming Dox and Dox-Fe(II).33  This Dox-iron conjugate upsets 
the equilibrium between aconitase and IRP-1 by the irreversible modification of cysteine 
residues on IRP-1.  The disruption of this equilibrium is critical to iron homeostasis because 
under normal conditions, aconitase acts as an isomerase and uses the [4Fe-4S] center to 
convert citrate to isocitrate in the Krebs cycle.  When cellular iron levels fluctuate, the [4Fe-4S] 
center assembles or disassembles.  Under low iron levels, the [4Fe-4S] center disassembles and 
aconitase takes on the role of IRP-1, a translational regulator of both ferritin and the transferrin 
receptor (TfR).  IRP-1 negatively affects the transcription of the iron storage protein ferritin, and 
positively affects the iron uptake protein TfR.  Disruption of this equilibrium causes cardiac cells 
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to lose their ability to regulate iron, causing the malformation of many iron dependent enzymes 
such as catalase, lipoxygenase, cytochromes and myoglobin.36 
 
Figure 1.2.1 Reduction of Dox to DOXol.  The ketone at position 13 is reduced to an alcohol. 
1.3 Mechanism of Doxorubicin Antitumor Activity 
 Multiple mechanisms have been proposed for the efficacy of doxorubicin, but, like the 
observed Dox induced cardiotoxicity, the exact mechanism is still unclear.  Although the 
primary function has been ascribed to drug interference with DNA topoisomerase II, inhibition 
of DNA-dependent functions through intercalation of DNA, direct DNA damage, free radical 
formation and membrane interactions are also implicated.  A schematic representation of these 
processes is provided in Figure 1.3.1.  A mechanism studied by the Koch group amongst others 
is doxorubicin crosslinking of DNA via first its induction of formaldehyde through complexation 
with iron and production of reactive oxygen species and second its use of the formaldehyde to 
create a covalent bond between Dox and a DNA G-base. 
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Figure 1.3.1 Doxorubicin induced DNA damage.  Dox can damge DNA via induction of 
reactive oxygen species and formation of DNA strand breaks as a topoisomerase II poison. 
 DNA is recognized as the primary pharmacological target of doxorubicin.  The planar 
tetracyclic chromophore can insert itself between adjacent base pairs, while the electrostatic 
interactions between the phosphate groups of DNA and the positively charged amino group of 
the sugar moiety stabilize the DNA-Dox conjugate in the minor groove.  The cytotoxic activity is 
not only dependent on the drug’s ability to bind to DNA, based on the observation that the site 
of binding is more important than the binding affinity.  Effective intercalating agents have been 
found to possess an additional function: the ability to interfere with the function of 
Topoisomerase II (Topo II).40,41  Antitumor activity of Topoisomerase II inhibitors is achieved by 
forming DNA-drug-enzyme complexes that stabilize the cleavable complex.42 The ability of 
doxorubicin to intercalate into DNA places it at the interface of the enzyme active site and the 
 8 
DNA cleavage site, preventing DNA religation.  The resulting double stranded DNA breaks are 
lethal to the cell.   
 In addition to Topoisomerase II poisoning, free radical formation through the reduction-
oxidation pathway of the anthracycline quinone, as previously described, can cause DNA 
damage.  The intercalation of the semiquinone radical has been hypothesized to cause direct 
DNA damage; however, the free radical effect can only be detected at high drug levels.43  
Interestingly, the addition of Dox and antioxidants to tumor cells offered no protection against 
the cytotoxic potential of Dox.  It is therefore likely that the production of reactive oxygen 
species is not the only source of antitumor toxicity.44-47   
 The availability of formaldehyde as a result of doxorubicin and iron induced reactive 
oxygen species allows for the formation of a Dox-formaldehyde-DNA conjugate.  Crystal 
structures of both daunorubucin and epirubicin bound to DNA48,49 illustrate how the 
formaldehyde derived CH2 forms a bridge between the exocyclic amine of guanine to the 3’-
amino substituent of the anthracycline.  The sequence 5’-NGC-3’ is the most effective sequence 
to afford the covalent bond of the anthracycline to the guanine, while situating the 
anthracycline in a position to hydrogen bond to the guanine of the complementary strand.49,50  
This so called “virtual crosslink” thereby activates cell apoptosis via a Topoisomerase II 
independent mechanism51 and will be discussed further in section 1.6.   
1.4 Resistance to Doxorubicin 
 While being broadly used in clinical settings, doxorubicin still has deficiencies in addition 
to dose limiting cardiotoxicity, namely, the propensity for the majority of cancers to develop 
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resistance to doxorubicin therapy.52  The modest lipophilicity and net positive charge at 
physiological pH make anthracyclines efficient substrates for active transport drug efflux pumps 
such as P-glycoprotein.52  P-glycoprotein is expressed in normal tissues such as liver, colon, 
kidney and adrenal gland.  It is therefore not tumor specific, and functions as a transporter of 
hydrophobic metabolites, xenobiotics, and/or hormones.53  Tumors derived from tissues 
naturally expressing P-glycoprotein could be an explanation for their elevated resistance.  P-
glycoprotein is a member of the ATPase binding cassette (ABC) superfamily of transmembrane 
ATP-dependent transporters,54 and multidrug resistant cancers often overexpress this well 
characterized transmembrane protein.53  
1.5 Doxorubicin Modification and Delivery Methods 
 Decades have been dedicated to improving the therapeutic index of Dox.  Volumes of 
work have been published outlining the multitude of functional group variations and delivery 
methods.  Arcamone et al. explored many synthetic and biosynthetic variants of doxorubicin, 
including, but not limited to modification of functional groups, removal and/or modification of 
the sugar moiety and modification of the aglycone.55  The most clinically relevant molecules to 
arise from these investigations have been epirubicin,556,57 idarubicin,58 Iodo-doxorubicin,59 
Mitoxantrone,60 and Valrubicin.61  Each variant may have some advantage to Dox for certain 
indications, some even offering oral bioavailability;62 however none have surpassed Dox as a 
widely prescribed therapeutic.   
 The most clinically relevant advances surrounding Dox have been the reformulation of 
Doxorubicin HCl into liposomal drug delivery systems such as Myocet and Doxil.  These so called 
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“stealth” liposomes protect Dox from the immune system, and anecdotal evidence suggest they 
may have some tumor targeting qualities.  Doxil liposomes are functionalized with polyethylene 
glycol, and have in some instances been further modified to target folate receptor63 with some 
success.64  Passive targeting of liposomal Dox has been demonstrated using 
               targeting RGD peptides65,66 and steric modification of stealth liposomes has 
been attempted to take advantage of the enhanced permeability and retention effect (EPR), 
also with limited success. 67,68  
 The EPR effect was first reported in 1986 by Matsumura and Maeda68 and has 
subsequently been reviewed by Maeda and others68,69  The combination of poor blood vessel 
architecture and the production of large amounts of various vascular permeability factors in 
solid tumors was observed.  These factors ensure that the tumor has a sufficient supply of 
oxygen and nutrients to perpetuate rapid growth.  Macromolecules larger than 40 kDa can 
therefore leak through vessels near the tumor and accumulate in tumor tissues, while smaller 
molecules, such as cancer therapeutics, can easily diffuse back into the blood.  Constrained 
lymphatic vessels in the tumor area exacerbates the situation, allowing the tumor to 
accumulate many macromolecules.  In normal tissues, there is no such accumulation, and the 
EPR effect has therefore become an attractive principle in tumor-targeting chemotherapy.  A 
schematic representation of the EPR effect is shown in Figure 1.5.1.  The Koch group has 
designed albumin binding prodrugs to exploit the EPR effect, and discussion of these 
compounds can be found in Chapter 5.   
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Figure 1.5.1 Schematic representation of the EPR effect.  Macromolecules larger than 40 kDa 
accumulate in the leaky vasculatre formed during angiogenisis. 
 Covalent modification of doxorubicin with targeting moieties to guide the prodrug to 
tumor expressed surface proteins has been widely investigated and has been reviewed 
elsewhere.70  Briefly, conjugates of monoclonal antibodies to deliver Dox to the tumor target 
have been reviewed71 and one of these targeting moieties conjugated to the highly potent 
cytotoxin calicheamicin has been approved by the FDA.  Other Dox-immunoconjugates seek to 
take advantage of cathepsin cleavable moieties upon internalization of the conjugate by the 
endosome/lysosome.72  Many other examples of prodrug therapies such as Antibody-Directed 
Enzyme Prodrug Therapy (ADEPT), Bacterial-directed enzyme prodrug therapy (BDEPT), Gene-
directed enzyme prodrug therapy (GDEPT) and Lectin-directed enzyme-activated prodrug 
therapy (LEAPT) have been investigated and will not be discussed here, however These 
strategies have been reviewed by Florent and Monneret.70 
 Tumor associated enzymes have been targeted as well.73  Dox conjugates with peptide 
moieties cleaved by prostate specific sntigen (PSA),74 plasmin,75,76 matrix metalloproteinases 
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(MMP),77 and endopeptidase lugumain,78 just to name a few, have been synthesized.  In all 
cases, in vitro analysis has shown that addition of extracellular enzyme raises the cytotoxicity of 
the prodrug, implying that the peptide moieties are indeed cleaved by the desired enzyme, 
releasing Dox.  Not all investigators examined the cardiotoxic effects of the prodrugs; however, 
those that did found that the prodrugs exhibited lower cytotoxicity than Dox alone.   
1.6 A Modification of Doxorubicin: Doxazolidine 
 With the vast collection of research surrounding the most profitable cytotoxin in history, 
the discovery of additional effectual modifications seemed unlikely.  However, while examining 
the interaction of Dox with DNA, Koch et al. made an astonishing discovery.  Building on the 
observation by Wang et al. that daunorubicin and doxorubicin, using formaldehyde, can create 
a virtual crosslink to DNA, 48 Koch et al. showed that the combination of daunorubicin or 
doxorubicin and DNA in transcription buffer containing ferric ion and dithiothreitol produced 
the same viritual crosslink,39 as shown in Figure 1.6.1.80    The cellular mechanism for the 
formation of formaldehyde is not entirely clear;39 however, MCF-7 human breast cancer cells 
with daunorubicin or doxorubicin causes an internal increase in the concentration of 
formaldehyde.81  These observations prompted the synthesis of doxorubicin conjugates that 
already contained a formaldehyde equivalent.  The two compounds were called Doxoform 
(DoxF)82 and Doxsaliform (DoxSF)83 and are shown in Figure 1.6.2.  Note that due to the use of 
excess formaldehyde, DoxF is composed of two doxorubicin molecules bound together by three 
formaldehyde derived methylene equivalents.   
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Figure 1.6.1 Crystal Structure of DNA-daun virtual crosslink. Covalent bonds to one DNA 
strand and Hydrogen bonds to the other creates a virtual crosslink80. 
 
Figure 1.6.2 Structures of DosF and DoxSF 
 DoxF was shown to have a short half life of only a few minutes at 25:C in RPMI 1641 cell 
culture medium, ultimately hydrolyzing to Dox.82   Regardless of the rapid hydrolysis, DoxF was 
shown to inhibit the growth of both sensitive and multidrug-resistant tumor cells approximately 
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equally, exhibiting a 10 to 10,000 time higher effectiveness when compared to Dox control,82 
eluding to the possibility that this compound was somehow escaping the multidrug resistance 
P-170 glycoprotein.  The Koch group showed that DoxF reacts with DNA to yield the same 
virtual cross-links observed with the reaction of Dox, DNA and formaldehyde.82  They concluded 
that DoxF was acting as a prodrug, releasing a monomeric species, dubbed doxazolidine 
(Doxaz), capable of forming DNA cross links.80    The half life of doxazolidine hydrolysis to Dox 
was determined to be 3-4 minutes at pH 7.4 and 37 :C,80 which has direct implications on the 
effectiveness of Doxaz as a standalone cancer therapeutic.  The structure of doxazolidine is 
provided in Figure 1.6.3.   
 
Figure 1.6.3 Structure of doxazolidine (Doxaz). 
 In an attempt to deliver doxorubicin and a formaldehyde equivalent in a hydrolytically 
stable prodrug, Koch et al. exploited the formation of an N-Mannich base by condensing the 
dox 3’ primary amine with various alkyl and aryl primary amines in the presence of 
formaldehyde.83  A molecule of particular interest, doxsaliform (DoxSF) emerged from these 
studies as a compound capable of releasing dox bearing a formaldehyde equivalent in a time 
dependent manner under physiological conditions.83  The proposed hydrolytic mechanism is 
shown in Figure 1.6.4.  This mechanism suggests that the protonation of the carbonyl oxygen by 
the phenolic hydrogen of salicylamide allows the free electron pair of the amine to participate 
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in the elimination of the salicylimidic acid while forming the dox-Schiff base.  The imidic acid 
subsequently tautomerizes to salicylamide, and most importantly, the dox-Schiff base retains 
the formaldehyde equivalent and equilibrates between dox-Schiff and the dox-aminol (see 
Figure 1.6.4).  With a cogent time release trigger in hand, Koch et al. sought effective tumor 
targeting of DoxSF.  The αvβ3 integrin has been an attractive target for cancer therapeutics, and 
the utility of this integrin has recently been reviewed.84  Conjugation of DoxF to short RGD motif 
containing peptides, RGD-4C and cyclic-(N-Me-VRGDf) known to preferentially bind the αvβ3 
integrin84 via a short hydroxylamine ether tether afforded the first prodrugs designed by Koch 
et al. to contain both a targeting motif and a time release trigger.  They hypothesized that that 
a prodrug with this design would bind αvβ3 and localize in/or near the tumor and vascular 
endothelial cells of the developing blood supply. Upon hydrolysis of the N-Mannich base, the 
conjugate would release the doxorubicin active metabolite locally.  It was found that the cyclic 
RGD peptide exhibited better binding affinity, and the prodrug as a whole was more effective 
than Dox at inhibiting growth of MDA-MB-435 cells in vitro, but less active than doxsaliform 
alone.  No in vivo studies were performed with these molecules.  The focus of the group was 
instead directed at the functionalization of Doxaz and the exploration of enzymatically 
activated triggers, largely due to the superior activity of Doxaz and Doxf.80 
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Figure 1.6.4 Mechanism of the DoxSF time release trigger.   
 The proposed model for doxazolidine binding to DNA proceeds through a tautomer of a 
G base that, in this tautomeric state, the nitrogen has a lone pair of electrons on the exocyclic 
amine available to approach the oxazolidine carbon in a SN2 fashion, and is depicted in Figure 
1.6.5.  Subsequent proton rearrangement and intercalation completes the virtual crosslink.80   
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Figure 1.6.5 Doxazolidine covalently bonds one strand of DNA.  A G-base on one strand of 
DNA must tautomerize to allow a concred ring opening mechanism and formation of a covalent  
In an attempt to explain the difference in Doxaz and Dox activity, experiments designed 
to investigate cell cycle distribution profiles were performed comparing the two drugs.  Dox 
induced cell cycle arrest at the G2/M transition state, while Doxaz induced apoptosis.  In 
addition, Dox was less effective against Topo II deficient cells than Doxaz, implicating a Topo II 
independent mechanism for Doxaz.85  Comparative analysis of data from experiments at the 
National Cancer Institute measuring the toxicity of Doxaz demonstrated that the activity of 
Doxaz correlated more closely with DNA crosslinking agents than with the parent Dox 
molecule.85  The exciting conclusion is that Doxaz is a potent cytotoxin with a mechanism of 
action different from that of Dox.85 
1.7 Doxazolidine as a Prodrug 
 The hydrolytic instability of Doxaz needed to be addressed to provide a commercially 
viable therapeutic.  The hypothesized solution was to stabilize the oxazolidine moiety by 
forming a carbamate.  Not only would this stabilize the vulnerable oxazolidine, but it would 
provide a tumor specific targeting moiety to evade release of the cytotoxic Doxaz in normal 
tissues, and especially the heart.  The pursuit of this solution is indeed the focus of this thesis, 
and unexpectedly, the synthetic routes to a doxazolidine prodrug have proven to be difficult.  
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Learning about irinotecan and capecitabine suggested our use of a carbamate functional group, 
and will be discussed further in Chapter 4. 
1.8 Investigations Presented in this Thesis 
 Presented in this thesis are the synthesis and biological evaluation of prodrugs designed 
to exploit tumor associated enzymes.  Proteases involved in tissue remodeling, enzymes 
associated with hypoxic processes in solid tumors and a serine esterase have been selected as 
possible targets.  Presented also is an albumin binding prodrug capable of becoming ensnared 
in the leaky vasculature surrounding a newly forming tumor actively involved in angiogenesis.  
Both the successful and unsuccessful synthetic routes to obtain these surprisingly elusive 
prodrugs will be presented, as well as the biological activity and potential for commercial 
development.   
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Chapter 2    Protease Activated Prodrugs of Doxazolidine 
2.1 Introduction 
 Proteases act through a regulatory process known as proteolysis, and play important 
roles in many biological and pathological systems.  The human degradome, a complete list of 
proteases synthesized by human cells, is made up of more than 569 (and growing) proteases 
that are sorted into five broad classes: metalloproteinases, serine, cysteine, threonine and 
aspartic proteases.1  Due to the strong evidence linking protease involvement to diseases, 
proteases serve an important role in drug development.  
 Contrary to normal tissues, cancerous tumors are growing quickly and have heightened 
metabolic activity, requiring additional nutrients, and physical space for growth.  The 
overexpression of extracellular proteases aids the tumor by degrading the extracellular matrix 
(ECM) and paving the way for vascularization through angiogenesis.  Proteases can also assist 
tumor cells in breaking free of the primary tumor and metastasizing to other tissues and 
regions of the body.  The overexpression of proteases has been observed in cancerous cells at 
many times higher than in healthy cells,2 and has also been observed in non cancerous cells 
recruited to the tumor site.3  Currently, it is believed that urokinase plasminogen activator 
(uPA), cathepsin B, and membrane-type matrix metalloproteinase (MMP) activate pro-MMP’s 
which allow ECM degradation by extracellular serine proteases such as uPA, urokinase 
plasminogen activator receptor (uPAR), plasminogen, and MMP’s.  These activities foster 
cellular motility, invasiveness and can release growth factors sequestered in the ECM such as 
vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) 2, and transforming 
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growth factor (TGF)-β causing a cascade of tumor growth factors in a disasterous feedback 
loop promoting tumor growth.2,4-8   
 The plasminogen activator uPA originates in kidney cells and was first discovered in 
urine, hence the urokinase designation.9,10  Originating as a single chain known as pro-kinase, 
rapid conversion of uPA by plasmin to the two chain form with a bridging disulfide bond occurs.  
Both the single chain and single chain forms bind to the uPA receptor (uPAR),11 forming a 
complex that facilitates plasminogen activation by uPA to plasmin.  uPAR is anchored to the cell 
surface by a glycosyl-phophatidylinositol domain,12 and has a high affinity for uPA.  An inhibitor 
of uPA, plasmin activator inhibitor (PAI-1), can bind uPA, however uPAR can bind uPA already 
bound to PAI-1, forming a complex. This complex is rapidly internalized, degraded and uPAR is 
recycled to the cell surface in a different area.13  This complex is therefore implicated in cell 
migration due to the directional nature of the recycling to the cell surface.12  The enzymes in 
the plasmin system, uPA, uPAR and PAI-1 have been extensively studied as prognostic markers 
for many types of invasive and metastatic cancers.14-16  A schematic representation of the 
plasmin system is shown in Figure 2.1.1 
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Figure 2.1.1 The Plasminogen-plasmin system.  uPAR can bind uPA; when uPA is bound to 
PAI-1, the complex is internalized and uPA and PAI-1 are degraded while uPAR is recycled to the 
surface, and assists in cell motility.  When free uPA binds uPAR, uPA is activated and can 
convert plasminogen to plasmin. 
 The plasminogen-plasmin system role in tumor biology is complex and involves several 
important steps.  Many factors assist plasminogen and plasmin in tumor progression.  The 
major ways in which the plasminogen-plasmin system affects tumors are cell proliferation, 
apoptosis, cell migration/invasion and angiogensis.17-20   
 The membrane bound uPAR when bound to uPA has the ability to bind growth factors 
and ECM proteins such as vitonectin or fibronectin, and can cause growth stimulation.21,22  In 
this respect the uPA bound to uPAR is mitogenic.  The role of PAI-1 and PAI-2 is not completely 
understood. Added PAI-1 has been shown to inhibit apoptosis23 and enhance tumor growth by 
inhibiting uPA.24  Likewise, PAI-2 is poorly understood, and this remains an area of investigation.  
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Cell migration is influenced by uPA, uPAR and PAI-1 by the aforementioned method of uPAR 
recycling.  When uPAR is recycled to a localized position, enhanced activation of plasminogen to 
plasmin can occur.  With heightened plasmin activity, the ECM is preferentially degraded, and 
frees the cell from adhesion in this area, allowing cell migration.12,13  Vitronectin can influence 
the distribution of uPAR.  Both monomeric and dimeric forms of uPAR are present on the cell 
surface,25,26 and vitronectin prefers the dimeric form.27  The uPA-uPAR-PaI-1 complex can bind 
vitronectin on the cell surface, changing  the cell shape and cell adhesion to the ECM.  When 
the complex is internalized, adhesion is affected (detached), and when the uPAR is recycled to 
the cell surface, adhesion resumes,26 thus the cell migration is controlled.  The plasminogen-
plasma system also plays a role in angiogenisis.  Complexing with tumor derived cytokines and 
VEGF, uPA and PAI-1 can modulate endothelial cell proliferation, thus encouraging 
angiogenesis.  The uPA mediated activation of plasminogen to plasmin can also be anti-
angiogenic.28  Plasmin can be reduced by plasmin reductase and co-factors to free kringle 
structures.  Kringle structures are loop domains within proteins containing architectures 
influenced by disulfide bonds, and are exemplified by angiostatin.  Angiostatin has powerful 
inhibitory activity agains the proliferation of microvascular endothelial cells.29   
 Prodrugs designed to be activated by proteases have had various success, some 
currently in clinical trials.28  A very interesting prodrug using unnatural amino acids 
homophenylalanine and citrulline showed 20-fold greater dosage acceptance the the maximum 
tolerated dose of dox.30  A xenograft model of mice containing MMP-positive HT1080 human 
fibrosarcoma cells showed that the prodrug exhibited significant activity when compared to 
dox.  Additional prodrugs aimed at MMP’s and coupled to dox have had limited success31,32 
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however recent prodrugs aimed at MMP’s and utilizing passive albumin targeting  have shown 
more success, and will be discussed in Chapter 4.  Use of paclitaxel, mitomycin C33 and 
methotrexate34 with protease triggers aimed at both plasmin and cathepsin B have also been 
evaluated.  These prodrugs contained a D-Ala-Phe-Lys (aFK) peptide sequence known to be 
cleaved by plasmin and cathepsin B.  A dox prodrug with the same aFK sequence was later 
synthesized and evaluated, with positive results.35-37   
 It was the aFK trigger that was most appealing to the Koch group, and based on in vivo 
efficacy of the plasmin-activated aFK Dox prodrug, development of a doxaz variant was 
undertaken.  The doxaz prodrug was designed to employ the aFK trigger and the 
Katzenellenbogen spacer.  The following chapter describes the synthesis and evaluation of this 
molecule, and subsequent modifications to develop a scalable doxaz prodrug.   
2.2 Experimental Methods 
2.2.1  General Remarks 
 Clinical samples of doxorubicin hydrochloride formulated with lactose were gifted by 
FeRx (Aurora, CO).  Unless otherwise noted, all reagents and amino acids for solid-phase 
peptide synthesis were purchased from Nova Biosciences (La Jolla, CA) and other chemicals and 
reagents were acquired from Aldrich (Milwaukee, WI).  Analytical HPLC was performed on 
Agilent 1050/1100 hybrid instruments equipped with a 1050 series autoinjector, a 1100 series 
UV/visible diode-array detector, and a 1046A fluorescence detector.  An Agilent Zorbax 
octadecylsilyl (C18) reverse phase column (4.6 mm i.d. x 150 mm, 5 µm) was used for 
chromatography.  Unless specifically indicated, elution was performed at 1 mL/min and room 
temperature with gradients of acetonitrile and 20 mM sodium phosphate buffer, pH 4.6, 
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containing 0.02% sodium azide.  Method 1 had acetonitrile percentages of: 20% from 0 to 1.5 
min, 30% at 5 min, 80% from 15 to 20 min, 20% at 24 min.  Method 2 consisted of acetonitrile 
percentages: 20% to 40% from 0 – 5 min, 50% from 8 – 9 min, and 20% at 11 min.  The presence 
of anthracycline-containing molecules was monitored by absorbance at 480 nm and retention 
times are noted individually.  All NMR spectra were taken at 400 or 500 MHz on a Varian Unity 
INOVA spectrometer (Palo Alto, CA) or a Bruker-Avance III 300 MHz spectrometer (Billerica, 
MA) in deuterated solvents from Cambridge Isotope Laboratories, Inc (Andover, MA).  Chemical 
shifts are reported in δ values of ppm and were standardized by the residual solvent peak in 
MestReNova NMR software (Mestrelab Research, Santiago de Compostela, Spain).  UV-vis 
spectroscopy was performed on a Hewlett-Packard /Agilent 8452A diode array instrument.  
Electrospray mass spectra were obtained with a Perkin-Elmer Sciex API III+ (Waltham, MA) or 
ABI Pulsar QqT high resolution instrument (Foster City, CA), equipped with an ion-spray source 
at atmospheric pressure.  Purification by radial chromatography purification was done with a 
Harrison Research Model 7924T Chromatotron (Palo Alto, CA).  Analysis by flow cytometry was 
performed with a Becton-Dickinson Biosciences FACscan (San Jose, CA) and a PowerWave X 
plate reader (BIO-TEK Instruments, Winooski, VT) was used for analyzing 96-well plate growth 
inhibition assays. 
General Tissue Culture.  All tissue culture reagents were acquired from Gibco Life Sciences 
(Grand Island, NY) and plates from Sarstedt, Inc (Newton, NC) or Corning, Inc. (Corning, NY) 
unless otherwise noted.  All cells were acquired from the American Type Culture Collection 
(Rockville, MD) except for NCI/RES-Adr (a gift from William Wells, Michigan State University, 
Lansing, MI), L3.3, L3.5, and L3.6PL (all gifts of Wells Messersmith, University of Colorado, 
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Anschutz Medical Campus, Denver, CO).  NCI/RES-Adr and SHP77 were maintained in RPMI-
1640, supplemented with 10% (v/v) fetal calf serum and 1% (v/v) pencillin-streptomycin stock 
solution.  MCF-7, MiaPaCa2, BxPC3, L3.3, L3.5, L3.6PL, and the non-tumor-derived HEK-293T 
were grown in Dulbecco’s modified essential medium (DMEM) containing the same above 
supplements and the same concentrations.  All of the above cells were grown in a humidified 
incubator under an atmosphere of 5% CO2/95% air at 37 ºC. 
2.2.2  Synthesis of Doxazolidine 
Doxorubicin Free Base from Clinical Samples.  Lyophilized pellets of expired clinical 
samples of doxorubicin HCl (20 – 50 mg) containing 100 – 250 mg lactose monohydrate 
(Bedford Laboratories, Bedford, OH) were dissolved in methanol to a final concentration of 2 
mg/mL and combined in a separatory funnel.  The methanol solution was diluted with 100 mM 
sodium phosphate buffer, pH 8.5, for a final concentration of 0.4 mg/mL dox HCl as a mixture of 
precipitated and solubilized material.  The free base of dox was extracted from the solution by 
two washes with equal volumes of chloroform, leaving almost no red color in the aqueous 
fraction.  The chloroform was dried with anhydrous sodium sulfate, filtered, and removed by 
rotary evaporation to yield a red solid.  The solid was dried thoroughly under high vacuum (10-2 
torr) for at least 2.5 h to yield pure dox free base in a final yield of 98%, as indicated by optical 
density at 480 nm and a molar extinction coefficient of 11,500 M-1 cm-1 in 75% DMSO/25% 
water. 
Doxazolidine.  Dox free base was dissolved to a final concentration of 5 – 10 mg/mL in 
deuteriochloroform and 1.1 – 2 equiv. of prilled paraformaldehyde (Aldrich, Milwaukee, WI) 
was added.  The reaction mixture was monitored by 1H NMR, with complete consumption of 
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dox occurring after 2 – 3 days, as evidenced by the appearance of the doxaz methylene AX 
pattern at 4.31 and 4.68 ppm and doxf AX pattern at 4.21 and 4.73 ppm in the 1H NMR 
spectrum.  Loss of dox was evident by the dox-specific aromatic triplet pattern for the proton at 
the 2-position, which appears at 7.81 ppm (as compared to 7.78 for doxaz and 7.70 for doxf).  
The amount of paraformaldehyde added determines the doxaz/doxoform ratio, since doxaz 
reacts with an additional equiv of formaldehyde to form doxf.  Complete assignments of the 1H 
NMR spectra for doxaz and doxf have been published.38  The reaction mixture was then filtered 
and the deuteriochloroform removed by rotary evaporation.  The doxaz/doxf mixture was used 
without further purification, since doxf readily hydrolyzes to produces 2 equiv of doxaz.   
2.2.3  Synthesis of Ac-Gly-D-Ala-L-Phe-L-Lys(alloc)-PABA (Ac-
GaFK(alloc)-PABA) coupled to the polystyrene resin. 
Fmoc-p-aminobenzyl alcohol (Fmoc-PABA,). N-(Fluorenylmethyloxycarbonyloxy)-
succinimide (N-Fmoc-N-hydroxysuccinimide, 6.0 g, 17.8 mmol) in p-dioxane (60 mL) was added 
dropwise to p-aminobenzyl alcohol (PABA, 2.5 g, 20.5 mmol) in p-dioxane (30 mL).  After 48 h of 
stirring, 90 ml of deionized H20 was added and the desired product immediately precipitated.  
The product was isolated by filtration, and washed 4 times with deionized H20 (60 mL).  Fmoc-
PABA (5.9 g, 95%) was isolated that showed the following spectral properties:  1H NMR (CDCl3): 
δ 4.26 (t, 1H, J = 7 Hz, Fmoc-CH), 4.53 (d, 2H, J = 7 Hz, Fmoc-CH2), 4.63 (s, 2H, PABA-CH2), 6.62 
(bs, 1H, NH), 7.30 (t, 2H, J = 7 Hz, Fmoc), 7.34 (d, 2H, J = 7 Hz, PABA), 7.36 (b, 2H, PABA), 7.40 (t, 
2H, J = 7 Hz, Fmoc), 7.60 (d, 2H, J = 7 Hz, Fmoc), 7.77 ppm (d, 2H, J = 7 Hz, Fmoc); ESI-MS, 
observed m/z = 384.1014; calculated m/z for (M + K+) = 384.0996. 
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Loading of Fmoc-PABA to 2-Chlorotrityl Resin.  Fmoc-PABA (2 equiv) was added to 1.0 g 
of 2-chlorotrityl polystyrene resin in 10 mL dry THF followed by 4 equiv of dry pyridine.  The 
solution was stirred and heated at 60 ºC in an oil bath for 16 h under argon.  The solution was 
filtered through a coarse sintered glass frit, and the resin was washed with DCM/MeOH/DIEA 
17:2:1 mL (3x), followed by DCM 10 mL (2x), DMF 10 mL (2x), DCM 10 mL (3x).  The resin was 
dried under high vacuum (10-2 torr) overnight and then checked for loading level according to 
previous published methods.39 
Solid Phase Peptide Synthesis.  The peptide was synthesized by the solid phase method 
using Fmoc strategy starting with preloaded Fmoc-PABA.  The peptide was prepared on a 0.25 
mmol scale by single amino acid couplings using a 4-fold excess of N-acetyl-Gly and the Fmoc-
protected amino acids D-Ala (Chem-Impex, International, Wood Dale, IL), L-Phe, and L-Lys-alloc.  
Activation was done with 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluoro-
phosphate (HBTU)/N-hydroxy-benzotriazole (HOBT) and the synthesis was performed on an ABI 
433A peptide synthesizer (Applied Biosystems, Carlsbad, CA).  Owing to the poor nucleophilicity 
of the aniline nitrogen of PABA, the coupling of the first amino acid, Fmoc-Lys(alloc), required 
an extended coupling time by modifying the software instructions to vortex the reaction for 60 
sec, then allow it to sit for 10 min.  This cycle was repeated 88 times.  Fmoc groups were 
removed by sequential treatment (3x) with 20% piperidine/DMF, and all other amino acid 
couplings followed standard conditions, to yield Ac-Gly-D-Ala-L-Phe-L-Lys(alloc)-PABA (Ac-
GaFK(alloc)-PABA) coupled to the polystyrene resin. 
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2.2.4  Synthesis of Ac-GaFK(alloc)-PABA-pNP Carbonate Ester. 
Cleavage of Ac-GaFK(alloc)-PABA (8) from the Resin and Activation to Ac-GaFK(alloc)-
PABA-pNP Carbonate Ester (9).  The resin was placed into a medium-grain fritted funnel and 
washed twice with DCM (20 mL). Pyridine/MeOH (10% v/v, 20 mL) was added to the receiving 
flask to protect the peptide after cleavage.  TFA/DCM (2% v/v, 10 mL) was then added and 
swirled for 1 min. The mixture was then gently vacuum filtered, without allowing the resin to 
proceed to dryness.  This step was repeated 3 times followed by a 20 mL DCM wash.  The 
filtrate contained the peptide and pyridine/TFA salt and was rotary-evaporated to ~10% of the 
original volume.  Approximately 40 mL of deionized water was added to the flask.  Upon 
swirling, the peptide began to precipitate.  The solution was allowed to cool in an ice bath for at 
least 10 min.  The precipitate was collected on a fritted funnel and washed with deionized 
water 10 mL (3x), followed by ether 10 mL (2x).  An oven dried round bottom flask equipped 
with a magnetic stir bar was cooled under argon and charged with 25.0 mL of tetrahydrofuran 
(distilled from sodium metal and benzophenone) and 8 (376.6 mg, 0.577 mmoles). To the 
stirring heterogeneous mixture, 1.1 equiv p-nitrophenyl chloroformate (127.9 mg) was added 
followed immediately by 1.1 equiv pyridine (51.33 µL). Over the course of 20 min, all solids 
went into solution, after which the reaction progress was monitored by RP-HPLC (Method 1) 
until complete, as evidenced by the disappearance of starting material (eluting at 13.4 min), 
which typically required overnight reaction. The reaction mixture was then diluted with 250 mL 
of ethyl acetate and washed once with 150 mL deionized water, followed by extractions with 
150 mL of saturated sodium bicarbonate until the aqueous layer no longer turned yellow 
(typically 5 extractions). The organic layer was dried over sodium sulfate and concentrated by 
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rotary evaporation to yield 400 mg of a pale yellow solid that was used without further 
purification, with a final yield of 85%.  Ac-GaFK(alloc)-PABA-pNP  was characterized by the 
following spectroscopic data with NMR assignments made from 1H NMR(DMSO, 500 MHz): δ 
0.94 (d, 3H, J=7.0 Hz, Ala-CH3), 1.32 – 1.27 (m, 1H, Lys-’), 1.40 – 1.33 (m, 1H, Lys-), 1.49 – 1.40 
(m, 2H, Lys-), 1.70 – 1.61 (m, 1H, Lys-’), 1.77 – 1.71 (m, 1H, Lys-), 1.82 (s, 3H, N-Acetyl), 2.75 
(dd, 1H, J=13.7, 10.7 Hz, Phe-), 2.98 (apparent q, 2H, J=6.3 Hz, Lys-), 3.09 (dd, 1H, J=13.7, 3.5 
Hz, Phe-’), 3.62 and 3.66 (AB of ABX pattern, 2H, JAB=16.5, JAX=5.8, JBX=5.7 Hz, Gly-), 4.24 
(apparent p, 1H, J=7.0 Hz, Ala-), 4.35 (apparent q, 1H, J=7.7 Hz, Lys-), 4.43 (d, 2H, J=5.3 Hz, 
alloc), 4.56 (ddd, 1H, J=10.7, 8.6, 3.5 Hz, Phe-), 5.14 (dd, 1H, J=10.6, 3.0 Hz, alloc),  5.25 (s, 2H, 
Bz), 5.88 (ddt, 1H, J=17.0, 10.6, 5.3 Hz, alloc), 7.18 – 7.12 (m, 1H, p-Ph), 7.29 – 7.18 (m, 5H, o,m-
Ph and Lys--NH), 7.42 (d, 2H, J=8.5 Hz, PABC-H2,6), 7.60 – 7.53 (AA’XX’ pattern, 2H, PNP-H2,6), 
7.67 (d, 2H, J=8.5 Hz, PABC-H3,5), 8.00 (d, 1H, J=7.3 Hz, Ala--NH), 8.04 (X of ABX, 1H, JAX=5.8, 
JBX=5.7 Hz, Gly--NH), 8.22 (d, 1H, J=7.4 Hz, Phe--NH), 8.24 (d, 1H, J=6.2 Hz, Lys--NH), 8.36 – 
8.28 (AA’XX’ pattern, 2H, PNP-H3,5), 10.05 (s, 1H, PABC-NH) ppm. 
2.2.5  Synthesis of Ac-GaFK-PABC-Doxaz, phosphate salt. 
Ac-GaFK(alloc)-PABC-Doxaz (10).  An oven dried round bottom flask equipped with a 
magnetic stir bar was cooled under argon and charged with 9 (126.13 mg, 0.1161 mmoles), 1-
hydroxybenzotriazole (23.61 mg, 1 equiv) and 500 µL dry DMSO (stored over 4Å molecular 
sieves for at least 3 days). To this, 1 equiv doxaz (85.68 mg) dissolved in 500 µL of similarly dried 
DMSO was added and the mixture was left to stir under argon in the dark and monitored by 
HPLC (Method 1) until complete, as evidenced by the disappearance of carbonate starting 
material (approximately 36 h). The reaction mixture was then diluted with an additional 2 mL of 
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DMSO. A 15 mL medium fritted sintered glass funnel was charged with 10 mL cold PBS, pH 7.4. 
The red reaction mixture was added dropwise and the resulting red precipitate was washed 
four times with 10 mL of PBS and then two washes with 10 mL of deionized water. The 
precipitate was washed from the filter with a mixture of 10:1 chloroform/methanol and 
concentrated by rotary evaporation.  The majority of the crude red solid, which was a mixture 
containing a 46% yield of 10, was moved forward without any additional purification.  However, 
to fully purify 10 for characterization, the red solid was purified by preparative TLC, spotted in 
and eluted with 10:1 chloroform:methanol. The desired product (the major band) was excised, 
suspended and vortexted in the elution solvent, and centrifuged to remove the silica gel.  The 
solvent was removed by rotary evaporation to produce solid, pure Ac-GaFK(alloc)-PABC-doxaz 
that was characterized by the following spectroscopic data with NMR assignments made from 
1D 1H NMR, homonuclear COSY, ROESY, HSQC, and HMBC spectra: 1H NMR at 55 ºC (500 MHz, 
CDCl3) 1.20 (d, 3H, J = 7 Hz, a-Me), 1.31 (d, 3H, J = 5 Hz, 5’-Me), 1.32 (m, 2H, K-), 1.44 
(m, 1H, K-), 1.50 (broad m, 1H, K-), 1.73 (m, 1H, K-), 1.75 (m, 1H, 2ʹ), 1.87 (m, 1H, K-), 
1.88 (s, 3H, Ac), 2.1 (dt, 1H, J = 14, 4 Hz, 8), 2.17 (broad m, 1H, 2’), 2.41 (d, 1H, J = 14, Hz, 8), 
3.01 (d, 1H, J = 18 Hz, 10), 2.98 (dd, 1H, J = 9, 5 Hz, F-), 3.09 (m, 2H, K-), 3.23 (m, 1H, F-), 
3.23 (d, 1H, J = 18 Hz, 10), 3.98 (dd, 1H, J = 5, 1 Hz, 4’), 4.03 (s, 3H, 4-OMe), 4.10 (m, 1H, a-
), 4.08-4.12 (m, 2H, 3’ and 5’), 4.45 (dd, 1H, J = 9, 5, K-), 4.49 (broad, 2H, 3’’’), 4.55 (dd, 
1H, J = 9, 6 Hz, F-), 4.70 (s, 2H, 14), 4.90 (d, 1H, J = 4 Hz, OCH2N), 4.96 (broad, 1H, 
OCH2N), 5.06 and 5.8 (broad AB pattern, 2H, J = 11 Hz, Bn),  5.14 (d, 1H, J = 10 Hz, 1’’’c 
ROESY), 5.23 (d, 1H, J=18 Hz, 1’’’t ROESY), 5.26 (m, 1H, 7), 5.39 (t, 1H, J = 5 Hz, 1’), 5.85 
(ddt, 1H J = 16, 10, 5 Hz, 2’’’), 7.15 (m, 1H,  F-p-Ph), 7.16 (m, 2H, F-o-Ph), 7.22 (m, 2H, F-m-
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Ph), 7.26 (d, 2H, J = 8 Hz, 2’’ ROESY), 7.37 (d, 1H, J = 8 Hz, 3), 7.56 (d, 2H, J = 8 Hz, 3’’), 
7.74 (t, 1H, J = 8 Hz, 2), 7.99 (d, 1H, J = 8 Hz, 1); 
13
C NMR chemical shifts from HSQC 15.75 
(5ʹ-Me), 16.19 (a-Me), 22.25 (Ac), 22.54 (K-), 29.11 (K-29.27 (2’), 30.49 (K-), 34.09 
(10) 36.73 (F-), 35.84 (8), 40.33 (K-), 42.79 (G-, 49.83 (a-), 53.68 (K-), 55.16 (F-), 
56.59 (4-OMe), 65.05 (14), 65.33 (3’ and 5’), 65.61 (3’’’), 66.79 (Bn), 68.95 (7), 77.60 (4’), 
78.83 (O-CH2-N), 99.59 (1’), 117.29 (1’’’), 118.97 (3), 119.76 (1), 120.11 (3’’), 126.88 (p-Phe), 
128.81 (o-Phe), 128.79 (2’’), 128.52 (m-Phe), 132.79 (2’’’), 135.54 ppm (2); some unprotonated 
carbons from HMBC  121.7 (4a), 133.8 (6a), 161.5 (4), 170.5 (K-CO), 171.8 (Ac-CO), 170.8 
(G-CO), 171.9 (F-CO), 173.7 (a-CO), 213.9 ppm (13); MS-ESI
+
, observed MH
+
 1234.4832; 
calculated M 1233.4754. 
Deprotection to Ac-GaFK-PABC-Doxaz, phosphate salt (2b).  Compound 10 (5.3 mg, 
0.0043 mmoles) was dissolved in 600 uL of 5:1 DCM:AcOH. To this, 1 equiv of 
tetrakis(triphenylphosphine) Pd0 was added (4.96 mg). The reaction was left in the dark for 80 
min, at which point the DCM was removed by rotary evaporation. The acidic solution was 
diluted with 6 mL 20 mM phosphate buffer, pH 4.6, and extracted 3 times with 6 – 7 mL of ethyl 
acetate to remove any triphenylphosphine oxide produced during the deprotection, spinning 
briefly at 1500 xg to produce a clean interface.  The desired product was purified from the 
extracted aqueous solution by preparative HPLC on a C-18 Dyanmax 100 Å 25 cm semi-
preparatory column (10 mm i.d.) run isocraticly with 50% acetonitrile, 50% 20 mM phosphate 
buffer, pH 4.6, at 3 mL/min  The product eluted at 10 min. The eluent was lyophilized to yield a 
red solid consisting of a mixture of the final material and sodium phosphate in 95% yield, 
relative to the fraction of 9 in the crude starting material.  The prodrug was dissolved away 
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from the majority of the sodium phosphate by 5 washes with 50 µL 9:1 DMSO:water, to yield an 
acidic water-DMSO solution of 2b.  Cold storage (> 3 weeks at -20 ºC) of 2b in this form 
eventually resulted in multiple red products by HPLC, presumably due to a low level reactivity 
of DMSO with the small percentage of deprotonated Lys-ε-NH3
+.  Therefore, following removal 
of the majority of the phosphate salts, the DMSO was evaporated by speedvac (10-2 torr) and 
the pure final material dissolved in saline containing 10% PEG-400.  To add to the stability of 
the product, 5 mM sodium phosphate, pH 4.6, was added to this solution.  Cold storage of this 
formulation has shown good stability for at least 2 months.  The final yield of the formulated 
final 2b, was 78% yield, relative to fraction of 9 in the crude starting material.  Ac-GaFK-PABC-
doxaz was characterized by the following spectroscopic data with NMR assignments made from 
1D 1H NMR, homonuclear COSY, ROESY, HSQC, and HMBC spectra: 1H NMR at 50 ºC (500 
MHz, DMSO-d6/D2O phosphate pH 4) 1.01 (d, 3H, J = 7 Hz, a-Me), 1.17 (d, 3H, J = 7 Hz, 5’-
Me), 1.24-1.42 (broad m, 2H, K-), 1.55 (p, J = 8 Hz, 2H, K-), 1.6-1.76 (broad m, 2H, K-), 
1.84 (m, 2H, 2’), 1.83 (s, 3H, Ac), 2.13 (dd, 1H, J = 14, 5 Hz, 8), 2.18 (dd, 1H, J = 14, 3 Hz, 8), 
2.75 (m, 2H, K-), 2.89 and 2.91 (AB pattern, 2H, J = 18 Hz, 10), 2.79 (m, 1H, F-), 3.04 (m, 
1H, F-), 3.97 (dd, 1H, J = 6, 2 Hz, 4’), 4.14 (q, J = 6 Hz, 1H, a-), 3.93 (s, 3H, 4-OMe), 4.04 (q, 
J = 6 Hz, 1H, 3’), 4.24 (m, 1H, 5’), 4.26 (m, 1H, K-), 4.42 (dd, 1H, J = 11, 2 Hz, F-), 4.54 and 
4.55 (AB pattern, J = 20 Hz, 2H, 14), 4.82 and 4.83 (AB pattern, 2H, J = 3 Hz, OCH2N), 4.95 
(dd, J = 5, 3 Hz, 1H, 7), 4.99 and 5.01 (AB pattern, 2H, J = 13 Hz, Bn), 5.22 (t, 1H, J = 4 Hz, 1’), 
7.10 (broad m, 1H, F-p-Ph), 7.16 (broad m, 4H, F-o- and m-Ph), 7.25 (d, 2H, J = 7 Hz, 2’’ 
ROESY), 7.37 (d, 1H, J = 8 Hz, 3), 7.51 (broad, 2H, 3’’), 7.56 (m, 1H, 2), 7.84 (m, 2H, 1 and 3); 
13
C NMR chemical shifts from HSQC 16.15 (5’-Me), 17.76 (a-Me), 22.50 (Ac), 26.57 (K-), 
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22.57 (K-29.27 (2’), 30.99 (K-), 32.47 (10) 37.15 (F-), 36.95 (8), 48.82 (K-), 42.37 (G-, 
48.86 (a-), 49.7 (3’), 53.99 (K-), 54.58 (F-), 56.91 (4-OMe), 63.86 (14), 64.20 (5’), 66.40 
(Bn), 69.85 (7), 77.45 (4’), 78.25 (O-CH2-N), 99.49 (1’), 11.46 (1 and 3), 120.03 (3’’), 129.37 
(F-p- and o-Phe), 128.61 (2’’), 128.52 (F-m-Phe), 135.54 ppm (2); some unprotonated carbons 
from HMBC  75.58 (9), 119.78 (12a), 135.18 (4a), 134.56 (6a), 161.39 (4), 161.42 (12), 171.73 
(Ac-CO), 170.20 (G-CO), 171.9 (F-CO), 173.15 (a-CO), 214.12 ppm (13); MS-ESI
+
, observed 
MH
+
 1150.4590; calculated M 1149.4454. 
2.2.5  Synthesis of bis-tBoc-aFK-PABC-Doxaz (11). 
 Bis-tBoc-aFK-PABA and Bis-tBoc-aFK-PABA-PNP.  The loading of Fmoc-PABA to resin, 
the SPPS and cleavage of bis-tBoc-aFK-PABA and the activation of the benzyl alcohol to the pNP 
carbonate ester were all performed with the same stoichiometry and solvent molarity as 
described in Sections 2.2.2 to 2.2.3.   
Bis-tBoc-aFK-PABC-Doxaz (11).  An oven dried round bottom flask equipped with a 
magnetic stir bar was cooled under argon and charged with bis-tBoc-aFK-PABA-pNP (9.62 mg, 
0.0.011 mmoles), 1-hydroxybenzotriazole (1.67 mg, 1 equiv) and 300 µL dry DMSO (stored over 
4Å molecular sieves for at least 3 days). To this, 1 equiv doxaz (6.04 mg) dissolved in 200 µL of 
similarly dried DMSO was added and the mixture was left to stir under argon in the dark and 
monitored by HPLC (Method 1) until complete, as evidenced by the disappearance of carbonate 
starting material (approximately 29 h). The reaction mixture was then diluted with an additional 
2 mL of DMSO. A 15 mL medium fritted sintered glass funnel was charged with 10 mL cold PBS, 
pH 7.4. The red reaction mixture was added dropwise and the resulting red precipitate was 
washed four times with 10 mL of PBS and then two washes with 10 mL of deionized water. The 
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precipitate was washed from the filter with a mixture of 35:1 chloroform/methanol and 
concentrated by rotary evaporation.  The majority of the crude red solid, which was a mixture 
containing a 62% yield of 11.  The red solid was purified by radial silica chromatography eluted 
with 35:1 chloroform:methanol. The desired product (the major band) was collected.  The 
solvent was removed by rotary evaporation to produce solid, pure bis-tBoc-aFK-PABC- doxaz 
was characterized by the following spectroscopic data with NMR assignments made from 1D 1H 
NMR, and homonuclear COSYspectra: 1H NMR at 50 ºC (500 MHz, DMSO-d6) 0.95 (d, 3H, J 
= 7 Hz, a-Me), 1.17 (d, 3H, J = 7 Hz, 5’-Me), 1.38-1.44 (broad m, 2H, K-), 1.57-1.58 (p, 2H, K-
), 1.6-1.76 (broad m, 2H, K-), 1.84 (m, 2H, 2’), 2.13 (dd, 1H, J = 14, 5 Hz, 8), 2.18 (dd, 1H, J 
= 14, 3 Hz, 8), 2.79 (dd, J = 13.9, 10.1 Hz, 1H, F-), 2.89 and 2.91 (AB pattern, 2H, J = 18 Hz, 
10), 2.9 (m, 2H, K-), 3.11 (dd, J – 13.9, 3.8 Hz, 1H, F-), 3.85 (dd, 1H, J = 6, 2 Hz, 4’), 3.95 (q, 
J = 6 Hz, 1H, a-), 3.97 (s, 3H, 4-OMe), 4.07 (q, J = 6 Hz, 1H, 3’), 4.21 (m, 1H, 5’), 4.36 (m, 
1H, K-), 4.53 (dd, 1H, J = 11, 2 Hz, F-), 4.6 and 4.64 (AB pattern, J = 20 Hz, 2H, 14), 4.82 
and 4.83 (AB pattern, 2H, J = 3 Hz, OCH2N), 4.95 (dd, J = 5, 3 Hz, 1H, 7),  5.22 (t, 1H, J = 4 Hz, 
1’), 5.25 (s, 2H, Bn), 7.10 (broad m, 1H, F-p-Ph), 7.2 (broad m, 4H, F-o- and m-Ph), 7.25 (d, 2H, 
J = 7 Hz, 2), 7.43 (m, 2H, PABA), 7.52 (d, 1H, J = 8 Hz, 3), 7.69 (m, 2H, PABA), 8.11 (d, J = 8 
Hz, 1H, a-NH), 8.16 (d, J = 7 Hz, 1H, K-NH), 8.21 (d, J = 7 Hz, 1H, F-NH), 9.31 (t, J = 5.7 Hz, 
1H, K-ε-NH), 9.92 (s, 1H, anilide) 
2.2.6 Synthesis of bis-TFA-GaFK-PABC-Doxaz(12). 
The loading of Fmoc-PABA to resin, the SPPS and cleavage of bis-TFA-GaFK-PABA and 
the activation of the benzyl alcohol to the pNP carbonate ester were all performed by the same 
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procedures and with the same stoichiometry and solvent molarity as described in Sections 2.2.2 
and 2.2.3.   
Bis-TFA-GaFK(alloc)-PABC-Doxaz (12)  An oven dried round bottom flask equipped with 
a magnetic stir bar was cooled under argon and charged with bis-TFA-GaFK-PABA-pNP (5.00 
mg, 0.0.0057 mmoles), 1-hydroxybenzotriazole (0.867 mg, 1 equiv) and 225 µL dry DMSO 
(stored over 4Å molecular sieves for at least 3 days). To this, 1 equiv doxaz (3.14 mg) dissolved 
in 100 µL of similarly dried DMSO was added and the mixture was left to stir under argon in the 
dark and monitored by HPLC (Method 1) until complete, as evidenced by the disappearance of 
carbonate starting material (approximately 44 h). The reaction mixture was then diluted with 
an additional 2 mL of DMSO. A 15 mL medium fritted sintered glass funnel was charged with 10 
mL cold PBS, pH 7.4. The red reaction mixture was added dropwise and the resulting red 
precipitate was washed four times with 10 mL of PBS and then two washes with 10 mL of 
deionized water. The precipitate was washed from the filter with a mixture of 30:1 
chloroform/methanol and concentrated by rotary evaporation.  The majority of the crude red 
solid, which was a mixture containing a 64% yield of 12.  The red solid was purified by radial 
silica chromatography eluted with 30:1 chloroform:methanol. The desired product (the major 
band) was collected.  The solvent was removed by rotary evaporation to produce solid, pure 
bis-TFA-GaFK-PABC-doxaz that was characterized by the following spectroscopic data with NMR 
assignments made from 1D 1H NMR, homonuclear COSY, HSQC and HMBC spectra.  1D 1H 
NMR at 55⁰C (500 MHz, DMSO-d6) δ 0.99 (d, J = 7.0 Hz, 3H, 5’-Me),  1.24 (d, J = 6.6 Hz, 3H, 
a-Me), 1.27 – 1.44 (m, 2H, K-γ), 1.51 (p, J = 7.4 Hz, 2H, K-δ), 1.67 – 1.78 (m, 2H, K-β), 1.79 – 
1.94 (m, 2H, 2’), 2.13 – 2.28 (m, 2H, 8), 2.77 (dd, J = 13.9, 10.1 Hz, 1H, F-β), 2.98 (tight AB, 
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2H, 10), 3.09 (dd, J = 13.9, 4.1 Hz, 1H, F-β), 3.17 (m, 2H, K-ε), 3.79 and 3.83 (AB of ABX 
pattern, 2H, JAB =16, JAX=JBX=6, G-α), 3.94 – 3.98 (m, 1H, 4’), 3.99 (s, 3H, OMe), 4.07 (dt, J = 
7.7, 5.8 Hz, 1H, 3’), 4.27 (q, J = 8 Hz, 1H, a-α), 4.30 – 4.42 (m, 1H, K-α, 1H, 5’), 4.50 – 4.63 
(m, 1H, F-α, 2H, 14), 4.81 – 4.92 (m, 2H, OCH2N), 4.97 – 5.14 (m, 2H, Bn, 1H, 7), 5.27 (t, J = 
4.3 Hz, 1H, 1’), 7.08 – 7.18 (m, 1H, F-p-Ph), 7.17 – 7.24 (m, 4H, F-Ph), 7.29 (d, J = 8.2 Hz, 2H, 
PABA), 7.57 (d, J = 8.1 Hz, 2H, PABA), 7.64 (dd, J = 7.7, 2.0 Hz, 1H, 3’), 7.82 – 7.96 (m, 1H,1, 
1H, 2), 8.06 (d, J = 7.7 Hz, 1H, a-NH), 8.13 (d, J = 7 Hz, 1H, K-NH), 8.14 (d, J = 7 Hz, 1H, F-
NH), 9.28 (t, J = 5.7 Hz, 1H, K-ε-NH), 9.41 (s, 1H, G-NH), 9.82 (s, 1H, anilide). 
2.2.7  Synthesis of bis-Ac-GaFK-PABC-Doxaz (13). 
 Bis-Ac-GaFK(alloc)-PABA and Bis-Ac-GaFK(alloc)-PABA-PNP  The loading of Fmoc-PABA 
to resin, the SPPS and cleavage of bis-Ac-GaFK-PABA and the activation of the benzyl alcohol to 
the pNP carbonate ester were all performed by the same procedures and with the same 
stoichiometry and solvent molarity as described in Sections 2.2.2 and 2.2.3.   
Bis-Ac-GaFK(alloc)-PABC-Doxaz (13)  An oven dried round bottom flask equipped with a 
magnetic stir bar was cooled under argon and charged with bis-Ac-GaFK-PABA-pNP (6.41 mg, 
0.0.0083 mmoles), 1-hydroxybenzotriazole (1.58 mg, 1 equiv) and 100 µL dry DMSO (stored 
over 4Å molecular sieves for at least 3 days). To this, 1 equiv doxaz (4.59 mg) dissolved in 100 
µL of similarly dried DMSO was added and the mixture was left to stir under argon in the dark 
and monitored by HPLC (Method 1) until complete, as evidenced by the disappearance of 
carbonate starting material (approximately 27 h). The reaction mixture was then diluted with 
an additional 2 mL of DMSO. A 15 mL medium fritted sintered glass funnel was charged with 10 
mL cold PBS, pH 7.4. The red reaction mixture was added dropwise and the resulting red 
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precipitate was washed four times with 10 mL of PBS and then two washes with 10 mL of 
deionized water. The precipitate was washed from the filter with a mixture of 30:1 
chloroform/methanol and concentrated by rotary evaporation.  The majority of the crude red 
solid, which was a mixture containing a 52% yield of 13.  The red solid was purified by radial 
silica chromatography eluted with 30:1 chloroform:methanol. The desired product (the major 
band) was collected.  The solvent was removed by rotary evaporation to produce solid, pure 
bis-Ac-GaFK-PABC-doxaz that was characterized by the following spectroscopic data with NMR 
assignments made from 1D 1H NMR, homonuclear COSY, HSQC and HMBC spectra.  1D 1H NMR 
at 55:C (500 MHz, DMSO-d6) δ 1.00 (d, J = 7.0 Hz, 3H, 5’-Me), 1.24 (d, J = 6.6 Hz, 3H, a-Me), 
1.26 – 1.36 (broad m, 2H, K-γ), 1.40 (m,  1H, K-δ), 1.65 (m, 1H, K-δ), 1.73 (, 1H, 2’), 1.77 (s, 3H, K-
Ac), 1.83 (s, 3H, G-Ac), 1.84 – 1.91 (m, 1H, 2’), 2.14 – 2.26 (m, 2H, 8), 2.78 (dd, J = 13.9, 10.1 Hz, 
1H, F-β), 2.99 (s, 2H, 10), 3.00 – 3.05 (m, 2H, K-ε), 3.09 (dd, J = 13.9, 4.1 Hz, 1H, F-β’), 3.62 and 
3.66 (AB of ABX pattern, 2H, JAB =17, JAX=JBX=6, G-α), 3.96 (dd, J = 5.9, 2.2 Hz, 1H, 4’), 4.00 (s, 3H, 
4-OMe), 4.06 (dt, J = 7.6, 5.8 Hz, 1H, 3’), 4.23 (p, J = 7.0 Hz, 1H, 5’), 4.30 – 4.37 (m, 2H, a-α), 4.53 
(dd, J = 9.8 Hz, 1H, F-α), 4.56 (dd, J = 5.9, 4.4 Hz, 3H), 4.50 – 4.59 (m, 3H), 4.71 (t, J = 5.9 Hz, 1H),  
4.86 (d, J = 3.6 Hz, 1H, OCH2N),  4.89 (d, J = 3.5 Hz, 1H, OCH2N), 4.97-5.11 (m, 2H, Bn, 1H, 7), 
5.27 (t, J = 4.2 Hz, 1H, 1’), 7.10 – 7.17 (m, 1H, p-F), 7.17 – 7.26 (m, 4H, F-Ph), 7.29 (d, J = 8.2 Hz, 
2H, PABA), 7.58 (d, J = 8.2 Hz, 2H, PABA), 7.63 – 7.70 (m, 1H, K-NH), 7.86 – 7.97 (m, 1H, 3, 1H, G-
NH, 1H, 2, a-NH, 1H), 8.00 (d, J = 7.8 Hz, 1H, 1), 8.07 (d, J = 8.2 Hz, 1H, F-NH),  9.77 (s, 1H, K-ε-
NH), 10.09 (s, 1H, anilide), 13.25 (s, 1H, 6-OH), 14.03 (s, 1H, 11-OH). 
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2.2.8  In vitro assays (Performed by Dr. Ben Barthel) 
IC50 Assays.  Initial characterization of PAD was performed in MiaPaCa2 human 
pancreatic carcinoma and MCF-7 human breast cancer lines.  The cells were seeded into 96-well 
plates at a density of 1000 cells/well and allowed to adhere overnight.  The media was replaced 
with 90 µL of serum-free media containing one or more of plasmin (0.2 U/well), trypsin (0.2 
U/well), cathepsin B (0.2 U/well), aprotinin (5 µM, Research Products International, Mt 
Prospect, IL), or Complete Mini protease inhibitors (1X according to package instructions, Roche 
Applied Science, Indianapolis, IN).  PAD (10 µL) was added to the wells for final concentrations 
between 2000 nM and 1 nM and controls received only vehicle (either DMSO or saline with 
10% PEG).  The cells were treated with PAD and activator/inhibitor for 24 h, at which point the 
treatment media was replaced with complete media and the cells allowed to grow for 5 days or 
until the control wells reached 80% confluency, whichever was shorter.  The cells were then 
fixed with 5% formalin in PBS for 10 min and stained with crystal violet (0.01% w/v in water) for 
20 – 30 min.  The plates were rinsed and air-dried and the stain redissolved either in a mixture 
of ethanol, water, and methanol (6:3:1) or in 2-propanol:water (1:1) with 2% sodium 
dodecylsulfate (SDS).  Cell density was measured by absorbance at 582 nm.  Percent optical 
density, relative to control wells, was fit to a variable slope sigmoidal dose-response curve by 
non-linear regression analysis in GraphPad Prism 5.0.  These experiments indicated that pure 
DMSO formulations or saline/PEG/phosphate formulations of PAD resulted in identical growth 
inhibition. 
Following initial tests in MiaPaCa-2 and MCF-7 cells, tests with PAD alone or with 
plasmin (0.2 U/well) were performed on an array of pancreatic cancer lines (BxPC3, L3.3, L3.5, 
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and L3.6PL), a small-cell lung cancer line (SHP77), and on an ovarian cancer line (NCI-RES/Adr), 
as well as a non-tumor derived cell line (HEK-293T).  All experiments were performed identically 
as described above. 
Cellular Uptake.  MCF-7 or MiaPaCa-2 cells were plated into 6-well plates at a density of 
250,000 cells/well and allowed to adhere overnight.  The media was then replaced with serum 
free media and 0.5 µM PAD or 0.5 µM PAD + 0.2 U plasmin was added (final concentrations).  
The cells were incubated for up to 5 h, then trypsinized and analyzed for the presence of the 
anthracycline fluorophore by flow cytometry (FL3 channel).  The mean fluorescence values 
were converted fold-over-background, in which background was defined as cells receiving no 
PAD. 
2.3 Results and Discussion 
 In an attempt to synthesize a Doxaz prodrug targeted to plasmin, a strategy analogous 
to the de Groot et al. procedure was employed.36  The Dox prodrug de Groot and co-workers 
synthesized had on average a 15 fold reduced cytotoxicity toward seven human tumor cell 
lines.  This was attributed to the varying concentrations of uPA or plasmin expressed in the 
tumor lines.  Incorporation of a second self-eliminating spacer exhibited improved activity.37  
Plasmin is a particularly attractive enzyme for prodrug therapy, and we hypothesized that with 
the elevated activity of Doxaz relative to Dox, prodrugs using similar targeting moieties 
tethered to Doxaz would exhibit better cytotoxic activity toward human cancer cell lines.  
 The desire to work toward scalable syntheses using commercially available materials 
seemed realistic based on the reagents used by de Groot.  Synthesis of D-Ala-L-Phe-L-Lys-PABC-
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Doxaz (aFKPABCDoxaz) was therefore attempted.  The use of the unnatural isomer of alanine 
was designed to safeguard the prodrug from non-specific exopeptidases found in the body.40-42  
Originally the synthesis was hypothesized to be straightforward.  This was not the case. 
 Synthesis of the three amino acid peptide was first done on an automatic peptide 
synthesizer, and cleavage from the resin was accomplished using standard trifluoroacetic acid 
(TFA) conditions.  Addition of the p-aminobenzyl alcohol (PABA) spacer analogous to literature 
procedures37 required the use of a coupling strategy in which the carboxy terminus of the 
peptide was activated with a chloroformate.  This chloroformate was then displaced with p-
aminobenzyl alcohol.  The synthetic scheme reportedly37 produced yields of 93% and is shown 
in Scheme 2.3.1.  In our hands, difficulty in controlling the addition of the chloroformate to the 
carboxy terminus was observed, and side products were observed.   
 
Scheme 2.3.1 Addition of p-aminobenzyl alcohol spacer to the bis alloc protected aFK 
peptide. 
 To circumvent this problem, the addition of PABA to the polystyrene resin was 
performed.  To function harmoniously with the peptide synthesizer, Fmoc-PABA was 
synthesized as shown in Scheme 2.3.2.  Use of a slight excess of the water soluble PABA allowed 
a rapid and scalable reaction of the hydrophobic Fmoc-PABA.  Simple washing with water 
removed the excess starting materials and afforded the desired product in high yield and purity.  
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This synthesis has been performed on a 10 gram scale.  Addition of the Fmoc-PABA to the resin 
using standard techniques was straightforward.  Automated synthesis using standard Fmoc 
synthetic procedures originally resulted in very poor yields.   
 
Scheme 2.3.2 Slight excess of PABA allows large scale synthesis of needed Fmoc-PABA. 
 It was concluded that the deprotection of the resin bound Fmoc-PABA went smoothly; 
however, the lower reactivity of the aniline nitrogen caused the poor yield.  Relatively involved 
reprogramming of the peptide synthesizer allowed us to create a custom method in which the 
aniline nitrogen was allowed to react with the activated carboxy-terminus of the N-Fmoc-
protected lysine for over sixteen hours with agitation cycles.  The isolated peptide with the 
incorporated spacer was easily cleaved from the resin, and activated to the desired p-
nitrophenyl mixed carbonate as shown in Scheme 2.3.3. 
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Scheme 2.3.3 Cleavage of peptide from resin and activation with p-nitrobenzyl 
chloroformate. 
 With the mixed carbonate in hand, the coupling of Doxazolidine was attempted using 
the conditions used by de Groot.  It was thought that Doxazolidine would be a strong enough 
nucleophile to displace the stable p-nitrophenolate leaving group.  Unfortunately, even the 
hindered nucleophilic nitrogen of triethylamine was able to react more quickly, and form an 
unwanted contaminant with the evolution of ethylene gas as shown in Scheme 2.3.4.   Multiple 
modifications of the solvent system and reagents used were attempted.  The side products 
from triethylamine (TEA) and a suitable substitute, diisopropylethylamine (DIEA) were difficult 
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to remove.  Purification by radial silica gel chromatography afforded the desired product, but in 
yields less than 50%.   
 
Scheme 2.3.4 Formation of an unwanted contaminant.  Triethylamine can act as a better 
nucleophile than Doxaz, forming unwanted products. 
 
 The Pd0 mediated deprotection shown in Scheme 2.3.5 using literature conditions37 
went poorly.  In fact, NMR analysis of the final product seemed acceptable; however the drug 
showed little or no activity toward cells in culture.  Purification by RP-HPLC afforded active 
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drug.  It was hypothesized that the presence of Pd0 was somehow inactivating the activating 
enzyme.  This hypothesis was overshadowed by the observation that epimerization of the D-
alanine was occurring.  Closer inspection of NMR data showed 15% contamination of the 
epimer.  The epimerization was traced to the acidification of the liberated Lys-ε-amino by HCl 
dissolved in ethyl acetate to afford the HCl salt of the final product.   
 
Scheme 2.3.5 Mechanism of alloc deprotection. 
 To address the epimerization, alternate amino acid protecting groups were used.  The 
use of commercially available tert-butyloxycarbonyl (tBoc) protected amino acids afforded the 
final product shown in Figure 2.3.1.  Multiple (>32) deprotection conditions were employed 
using standard solvents and reagents.  The overwhelming conclusion was that the acidic nature 
of the conditions needed to remove tBoc caused the loss of the daunosamine sugar, resulting in 
the isolation of aglycone as the predominant product.  The aglycone is shown in Figure 2.3.2.   
 
Figure 2.3.1 Structure of bis-tBoc-aFK-PABC-Doxaz. 
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Figure 2.3.2 Structure of the aglycone after acid hydrolysis of the daunosamine sugar. 
 Armed with the knowledge surrounding the deprotection, we designed the so called 
fourth generation protease prodrug, Ac-GaFK(alloc)-PABC-Doxaz shown in Figure 2.3.3.  The 
rationale was that the use of Glycine at the amino–terminus would both eliminate the 
possibility of epimerization, and remove the need for a second protected amino acid.  The 
peptide would effectively be “capped”.  All syntheses went smoothly, and scalable methods 
were attempted.  The discovery that the activated prodrugs could be precipitated from 
phosphobuffered saline at pH 7.4 led to the synthesis of protected products on the 100 mg 
scale. Unfortunately, the the final deprotection once again proved problematic.  Use of catalytic 
Pd0 was ineffective.  Stoichiometric amounts of Pd0 afforded an isolable product.  This product 
was unfortunately unstable and not easily characterized.  NMR conditions necessitated 
dissolution in d6-DMSO and the heating of the product to above 50:C.  The vast knowledge 
pertaining to the stability and solubility of prodrugs of this type obtained throughout this 
project coupled with extensive experimentation led to acceptable deprotection conditions.  
 53 
 
Figure 2.3.3 Structure of Ac-GaFK(alloc)-PABC-Doxaz. 
 Interestingly, the prodrugs were stable to, and soluble in, acetic acid.  The use of a 
mixed solvent composed of five parts anhydrous dichloromethane and one part acetic acid 
easily dissolved the protected starting material, did not harm the molecule with excessive 
acidity, and immediately protonated the free Lys-ε-amine upon deprotection.  Rotary 
evaporation of the dichloromethane and dissolution in preparative RP-HPLC eluent allowed 
direct injection of the crude reaction mixture onto the preparative RP-HPLC and subsequent 
purification.  Although larger amounts than previously possible were isolated, it was observed 
by NMR that triphenylphosphine oxide, resulting from the tetrakis(triphenylphosphine)Pd0 
reagent, was contaminating the sample, even after purification.  To address this, the crude 
reaction mixture upon removal of the dichloromethane, was diluted with 20 mM  sodium 
phosphate buffer at pH 4.6.  This is also the aqueous phase of the preparative RP-HPLC 
purification.  Extraction of this aqueous acidic phase with ethyl acetate removed the 
triphenylphosphine oxide, and subsequent purification afforded the desired product as the 
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phosphate salt.  The phosphate salt was more stable than the preceding salts. The final 
structure is shown in Figure 2.3.4. 
 
Figure 2.3.4 Ac-GaFK(H2PO4)-PABC-Doxaz.  The final product is isolated as a phosphate salt.  
 Concurrently, the syntheses of bis-Ac-GaFK-PABC-Doxaz and bis-TFA-GaFK-PABC-Doxaz 
were being performed.  Ironically, the use of TFA as a protecting group under basic 
deprotection conditions led to the epimerization of the D-Alanine.  The use of exogenous 
enzymes such as porcine acylase to remove the acetyl and TFA protecting groups failed, but led 
to the idea that perhaps the body could facilitate the deprotection of the prodrug.  A review of 
the literature43-48 showed that histone deacetylases, or HDAC’s encompass a large family, and 
are commonly overexpressed in cancer.  In fact, HDAC’s are considered targets themselves.49  
Interestingly, HDAC’s have been shown to remove the TFA group from the Lysine-ε-amine.48  
The idea of a “double filter” quickly emerged.  Perhaps even more selective targeting could be 
achieved by using the two groups.  Cell experiments were therefore undertaken by Dr. Ben 
Barthel, and the results are summarized in Tables 2.3.1 and 2.3.2.  A reminder to the reader is 
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that the more negative the number in an IC50 the better the response to the drug.  Inspection of 
these results begs the question if they are statistically relevant.  It did however lead us to 
examine other proteases, such as cathepsin B, as possible activators.  This assisted in the design 
of prodrugs presented in Chapter 3.  Further investigation is currently underway.   
Drug MiaPaCa-2 nM 
Dox -6.8±0.2 158 
     + Plasmin -6.7±0.3 200 
Doxaz -8.5±0.3 3 
aFKPABC-Dox -6.6±0.6 251 
     + Plasmin -6.1±0.1 316 
aFKPABC-Doxaz -6.9±0.3 126 
     + Plasmin -7.4±0.4 32 
Bis-TFA-GaFK-PABC-Doxaz -7.0±0.2 100 
     + Plasmin -7.4±0.3 40 
     + Acylase -6.9±0.2 126 
     + Plasmin and Acylase -6.8±0.2 158 
Peptide No Change  
     + Plasmin No Change  
     + Acylase No Change  
     + Plasmin and Acylase -5.3±0.4 5012 
Table 2.3.1  Comparison of prodrugs and drugs with and without added activating 
enzymes. MiaPaCa-2 are pancreatic cancer cells. 
 
Drug Cell Line IC50 
Bis-TFA-GaFK-PABC-Doxaz MCF-7 -6.8±0.3 
     +Plasmin -7.18±0.1 
Bis-TFA-GaFK-PABC-Doxaz MiaPaCa -6.8±0.1 
     +Plasmin -6.9±0.1 
Bis-Ac-GaFK-PABC-Doxaz MCF-7 -6.3±0.3 
     +Plasmin -6.7±0.1 
Bis-Ac-GaFK-PABC-Doxaz MiaPaCa -6.3±0.1 
     +Plasmin -6.4±0.1 
Table 2.3.2 Comparison of prodrugs and drugs with and without added activating enzymes 
against two cell lines.  MCF-7 are from a breast cancer line, and MiaPaCa are from a pancreatic 
cancer line. 
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 With the improved synthetic methods, and increased enzymatic activity,  Ac-GaFK-
PABC-Doxaz became the tier one compound.  Growth inhibition of a panel of cell lines by 24 h 
treatment with PAD and PAD with 0.2 U of human plasmin, represented by the IC50 in log M 
units was performed by Dr. Barthel.  BxPC3, L3.3, L3.5, and L3.6PL are pancreatic cancer, SHP77 
are small-cell lung cancer, and NCI-RES/Adr are ovarian cancer cells.  The latter two lines are 
dox-resistant.  HEK-293T cells are non-tumor derived human embryonic kidney cells.  Values for 
individual cell lines are the mean ± standard error of at least 12 measurements. The values for 
cancer cells were averaged and are shown in the Cancer Cell Mean row ± the standard 
deviation.  It is clear that plasmin is activating these prodrugs, as shown by Table 2.3.3.  These 
promising results have prompted further study, and preliminary in vivo studies are currently 
underway.  
 PAD Alone PAD + Plasmin (0.2 U) 
BxPC3 -6.0 ± 0.1 -7.4 ± 0.1 
L3.3 -6.6 ± 0.1 -8.40 ± 0.07 
L3.5 -6.65 ± 0.04 -8.58 ± 0.04 
L3.6PL -6.50 ± 0.08 -8.50 ± 0.04 
SHP77 a -5.80 ± 0.03 -7.53 ± 0.05 
NCI-RES/Adr a -6.04 ± 0.05 -7.93 ± 0.05 
Cancer Cell Mean -6.3 ± 0.3 -8.1 ± 0.5 c 
HEK-293T b -6.7 ± 0.1 -8.52 ± 0.04 
Table 2.3.3  Activity of prodrugs agains eight cancer lines, with and without additional 
plasmin. 
2.4 Conclusions 
 At the conception of this project, we thought the synthesis of a protease activated 
Doxaz prodrug would be straightforward.  This was not the case.  The pathway to this molecule 
has been difficult, yet the lessons learned have led to the capability to regularly synthesize the 
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final prodrug at a 50 mg scale, without the assistance of specialized equipment.  Consultation 
with a local manufacturing facility has indicated that synthesis on the scale needed for larger 
species and human trials is possible.  This prodrug could have wide utility against resistant and 
metastatic cancers.  Our focus is on the underserved pancreatic cancer indication.  As a 
preliminary step toward commercialization, this project was a success.   
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Chapter 3 Prodrugs Activated by Hypoxic Conditions 
3.1 Introduction 
3.1.1 The Role of Hypoxia in Cancer   
 The biology of tumors and their responses to therapy can be influenced by many 
factors, one of which is hypoxia.  The highly abnormal nature of tumor vascularization and 
limitations to oxygen diffusion can lead to hypoxic conditions.  The diffusion range of oxygen is 
up to ~200 µm and is dependent on the oxygen concentration in blood plasma in the vicinity of 
the tumor as well as unstable blood flow in tumor microvasculature1.  Dewhirst et al. reviewed 
the eight dominant features of oxygen deficient transport1.  Sparse arteriolar supply, inefficient 
orientation of microvessels, low vascular density, extreme variation in microvessel red blood 
cell flux (many tumor vessels do not carry red blood cells, but vessels bypassing the tumor, 
known as shunt vessels do), oxygen gradients caused by the limited arteriolar supply creating 
low pO2 in tissue distant from the arteriolar supply, sluggish blood flow due to high blood 
viscosity of rigid hypoxic red blood cells, large diameter shunts directing blood away from the 
tumor, and finally the cyclic nature of the hypoxia exhibiting the inherent instability of the 
tumor environment, are all factors that can affect the oxygen diffusion range.  Hypoxia also 
influences the genomic stability of tumor cells in many ways.   
 While hypoxic conditions are often associated with resistance to therapy through 
varying mechanisms, it is important to note that hypoxic conditions have also been observed to 
result in drug sensitivity.2  A limited number of these sensitivities or resistances are shown in  
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Resistance 
Effect of hypoxia Mode of Action Therapies affected Example 
Resistance to 
apoptosis 
Downregulation of 
BID and BAX 
Multiple Etoposide 
Cell cycle arrest in G1 
and G2 
Repair before 
progression to S and 
M phase 
Cycle selective drugs 5’ fluorouracil 
Extracellular 
acidification 
Decreased uptake Basic Drugs Doxorubicin 
Distance from 
vasculature 
Reduced drug 
exposure 
Drugs bound in tumor 
cells 
Taxanes 
Sensitivity 
Cell cycle arrest in S 
phase 
Collapse of stalled 
replication forks 
PARP inhibitors Veliparib (ABT-888) 
Supression of DNA 
repair 
Downregulation of 
NER 
Bulky DNA 
methylating agents 
Many 
Extracellular 
acidification 
Increased intake Acidic drugs Chlorambucil 
Table 3.1.1 Examples of hypoxic tumor sensitivity and resistance to therapeutics.   
 The genetic events triggered by hypoxia are many and varied and include expression of 
genes that suppress apoptosis3, anabolic changes in metabolism4, tumor angiogenisis5, 
vasculogenis6, suppression of immune reactivity, and transition of epithelial to mesenchymal 
cells.7  Perhaps the two most important are generation of reactive oxygen species8 and 
downregulation of DNA repair pathways.9   
 Hypoxia Inducible Factor 1 (HIF1) is perhaps the most important player, and has been 
referred to as the “master regulator of oxygen homeostasis”10  HIF1 is a transcription factor 
responsible for the expression of many genes implicated in cell survival, migration, 
homeostasis, angiogenesis, therapeutic resistance and most importantly, anaerobic 
metabolism.1  In addition, HIF1 has been shown to be regulated by growth factors,11 oncogenes 
and free radicals.8,12   The enzymatic conversion of superoxide (O2
-) to hydrogen peroxide (H2O2) 
by superoxide dismutase (SOD) has been shown to produce elevated levels of H2O2 which in 
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turn can regulate the activity of HIF1.  Another free radical, Nitric oxide (NO), has been 
observed at elevated concentrations in many cancers13,14 due to the overexpression of nitric 
oxide synthases.  The observation that ρ: cells, chemically stripped of mitochondria cannot 
increase HIFα levels in response to hypoxia, thereby stabilizing HIF1  by Schumacker and 
Chandel led to the conclusion that reactive oxygen species formed by the mitochondria under 
hypoxia are ultimately partially responsible for the overexpression of hypoxia enzymes.12,15  
These enzymes are attractive targets for cancer prodrugs.   
3.1.2 Cancer Therapeutics Activated by Hypoxic Conditions 
 Originally, the observation that some nitroimidazoles sensitized tumors to radiation 
began the investigation into hypoxia as a hallmark of cancer. Clinical trials of nitroimidazoles 
concluded that the drugs were ineffective at sufficiently sensitizing the cells due to their toxicity 
limiting the maximum tolerated dose.16  These observations prompted the design of many 
prodrugs to exploit hypoxic conditions, with varying success.  For example, β-glucoronide 
metabolites of an aniline nitrogen mustard in tumors with identified β-glucoronidase activity 
have been generally ineffective due to unpredictable tumor expression levels of the desired 
activating enzyme.17  Other areas of investigation have been the bioreduction of chemical 
moieties under hypoxic conditions such as nitro groups, quinones, aromatic N-oxides, aliphatic 
N-oxides and transition metals.   
 Our group has been particularly interested in the reduction of nitro aryl groups. A group 
of two-electron reductases capable of bypassing the oxygen-sensitive free radical intermediate 
through the transfer of a hydride from NAD(P)H have been shown to reduce quinones, nitro 
compounds and aromatic N-oxides.2  Two enzymes of particular interest are NAD(P)H 
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dehydrogenase [quinone] 1 (NQO1); also known as DT diaphorase and NAD(P)H dehydrogenase 
[quinone] 2 (NQO2).  Both of these enzymes have been shown to reduce CB1954 (tretazicar) to 
its active metabolite18 (see Figure 3.1.1), with preference for NQO2.19-21  Although NQO1 is a 
less effective activator, the similarity to exogenous E. coli nitroreductase has prompted 
investigation into the latter as a useful Gene Directed Enzyme Prodrug Therapy (GDEPT) 
agent.22   
 
Figure 3.1.1  Proposed activation of CB1954 by NQO2. 
 NQO2 is of special interest because it is expressed at high levels in several human cancer 
cell lines.23  The discovery that CB1954 was a substrate for NQO2 opened the possibility of its 
use as a conventional prodrug, obviating the need for the DEPT strategies.  CB1954 is currently 
under clinical investigation.24  NQO2 is also advantageous due to the observation that the 
exogenous E. coli nitroreductase (NTR) used in the DEPT strategies can reduce both nitro 
groups, therefore rendering half of the therapeutic ineffective, while human NQO2 catalyzes 
the reduction at the 4 position only.25,26   
 While NQ01 and NQ02 expression has been a driving factor for the advancement of 
some therapies, another prodrug, PR104, has recently begun phase 1 clinical trials for the 
breast cancer indication.27  PR104 is a nitrogen mustard prodrug that sequentially reacts with 
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phosphatases then reductases in hypoxic tissue to form first, PR-104A and then the active 
metabolites Pr-104M and PR104H (See Figure 3.1.2). One reductase that has been shown to 
activate PR-104 is AKR1C3,28 and the wide expression of this reductase in hepatocellular 
carcinomas and non-small cell lung cancers has led to the investigation of this prodrug in acute 
myeloid leukemia (AML).29 
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Figure 3.1.2  Proposed activation pathway of PR104H from prodrug PR10428. 
 
PR-104A can also be activated under hypoxia by other members of the diflavin 
reductase family, NADPH-dependent diflavin oxidoreductase 1 (NDOR1) and methionine 
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synthase reductase (MTRR).30  Other flavoproteins capable of one-electron prodrug activation 
include NADH-cytochrome b5 reductases,31 ferredoxin reductase (FDXR),32 xanthine oxidase33 
and xanthine dehydrogenase, which is also capable of two-electron reduction.34  However, 
investigation into the relative activity of these and other reductases in hypoxic regions of 
human tumors is still needed.   
 Another interesting class of hypoxia activated compounds containing reducible nitro aryl 
groups are prodrugs containing p-nitrobenzyl carbamate triggers.  Members of this class of 
prodrugs have been shown to be activated by xanthine oxidase (XO) and NADH:cytochrome 
P450 reductase (NPR) under hypoxic conditions, but not in air,35 demonstrating the utility of 
this trigger.  One such example is β-aminopropionitrile (BAPN), an inhibitor of lysyl oxidase 
(LOX).  LOX overexpression in hypoxic tumour cells has recently been determined and, at the 
same time, LOX has been proven to play a key role in the promotion of the metastatic process 
of several solid tumours.36  The extremely simple BAPN molecule itself cannot be used as a 
therapeutic due to unselective biological interactions and its role in lathyrism, a neurological 
disease affecting humans and livestock correlating to the over ingestion of legumes high in 
BAPN.37,38  A prodrug of BAPN, pro-BAPN has been designed and shown to go through 
bioreductive activation, and after 1,6-elimination of the quinone methide and loss of CO2 
produces BAPN under hypoxic tumor conditions in vitro39 (See Figure 3.1.3).  Giglia et al. used 
the same p-nitrobenzyl trigger to create an interesting imaging agent capable of being activated 
in hypoxic tissue.40  This bioreductive pharmacophore can activate the corresponding 
technetium and rhenium complexes to selectively image hypoxic tumor tissues.  These 
compounds are shown in Figure 3.1.4. 
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Figure 3.1.3 Reduction and 1,6-elimination of pro-BAPN to release the active BAPN. 
  
Figure 3.1.4 Imaging agents activated in hypoxic tissues.  Reduction of the nitro group allos 
1,6-elimination of the quinon methide, activating the imaging agent.  
 The interest in p-nitrobenzyl prodrugs activated by exogenous enzymes, often coupled 
to antibodies has also been explored.  Antibody Directed Enzyme Prodrug Therapy (ADEPT) will 
not be discussed in detail here, but briefly, an exogenous enzyme is coupled to a cancer specific 
antibody, and administered to the patient or test animal.  Subsequently, a prodrug with a 
moiety activated by the exogenous enzyme is then administered, and theoretically, the 
antibody/enzyme conjugate would be localized to the tumor, and the prodrug activated at the 
tumor site.  Mauger et al. created just such prodrugs, with p-nitrobenzyl triggers, to be 
activated by E. Coli nitroreductase (NTR)41.  The nitrobenzyl moiety was added to actinomycin D 
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(AMD), mitomycin C, and doxorubicin, as well as a nitrogen mustard compound, 4-[bis(2-
chloroethyl)amino]aniline, and these prodrugs are depicted in Figure 3.1.5.  The overall 
conclusion was that the prodrugs were less cytotoxic than their parent drug to normal tissues 
and cells, and NTR activated all the prodrugs except the doxorubicin prodrug.  
 
Figure 3.1.5 p-Nitrobenzyl prodrugs of:  4-[bis( 2-chloroethyl)amino]aniline 1; doxorubicin 
2; actinomycin D 3; and mytomycin C 4. 
 Hay et al. investigated several molecules with the p-nitrobenzyl moiety, but of particular 
interest was the addition of a self immolative Katzenellenbogen spacer to the doxorubicin 
prodrug in a study focused on Gene Directed Enzyme Prodrug Therapy (GDEPT).42  This prodrug 
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is depicted in Figure 3.1.6.  Hay and colleagues observed that this prodrug was not toxic to 
hamster ovary cells in culture, and in vivo, the MTD of the prodrug was 40 times higher than 
that of doxorubicin alone.  The prodrug was also activated in nitroreductase transfected cells in 
culture, but showed little efficacy, explained by poor tumor penetration, in vivo.  
 
Figure 3.1.6 p-Nitrobenzyl doxorubicin containing a self immolative Katzenellenbogen 
spacer. 
3.1.3 Development of a Doxaz Prodrug Activated by Hypoxia 
 Using nitro-aromatic prodrugs as templates, carbamate prodrugs of Doxaz were 
designed to be activated by two-electron reducing enzymes overexpressed in tumor associated 
hypoxic conditions.  The design contains a p-nitrobenzyl moiety, and, in one case, a self 
eliminating Katzenellenbogen spacer as described previously.  This chapter describes the 
design, synthesis, and characterization of the p-nitrobenzyl carbamate Doxaz prodrugs. 
3.2 Experimental Methods 
3.2.1 General Remarks 
 Doxorubicin hydrochloride clinical samples (formulated with lactose) were a gift from 
FeRx (Aurora, CO).  NMR solvents were purchased from Cambridge Isotope Laboratories, Inc. 
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(Andover, MA).  All other chemicals were purchased from Aldrich (Milwalkee, WI).  Analytical 
HPLC was performed on a Hewlet-Packard/Agilent 1050/1100 hybrid instrument equipped with 
a 1050 autoinjector, a 1100 UV-vis diode array detector, and a 1046A fluorescence detector.  
Chromatography was performed using an Agilent Zorbax 4.6 mm i.d. x 15 cm, 5 µm reverse-
phase octadecylsilane (ODS) column, eluting with a gradient of room temperature 
acetonitrile/20 mM sodium phosphate buffer, pH 4.6 (buffer ramped down from 80% to 20% 
over 10 min, held isocratic until 14.5 min, then returned to 80% by 16 min) at 1.0 mL/min.  The 
presence of anthracycline-containing molecules was monitored by absorbance at 280 and 480 
nm.  NMR spectra were taken using a Varian Unity 500 MHz spectrometer (Palo Alto, CA). 
Electrospray mass spectra were measured on a Sciex API III+ (Toronto, Canada) or ABI Pulsar 
QqT high resolution instrument (Foster City, CA) equipped with an ion spray source and run at 
atmospheric pressure. Preparative radial chromatography was performed using a 
Chromatotron 7924T (T-Squared Technology, Inc., San Bruno, CA) equipped with a FMI Lab 
Pump (Fluid Metering, Inc., Oyster Bay, NY).   
3.2.2 Synthesis of Doxaz 
Doxaz was synthesized as previously described (Section 2.2.2) 
3.2.3 Synthesis of PNBDoxaz 
 p-Nitrobenzyl chloroformate (5.05 mg, 23.3 µmol) was added to a solution of Doxaz 
(13.0 mg, 23 µmol) in 10.0 mL of DCM followed immediately by pyridine (1.89 µl, 23.3 µmol).  
The reaction mixture was stirred for 90 min at room temperature.  The reaction mixture was 
washed once with 15.0 mL of brine, and dried over sodium sulfate.  Evaporation of the solvent 
afforded PNBDoxaz (15.74mg, 21.4 µmol) as a pale red solid in 92% yield, and 95% purity as 
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evidenced by HPLC.  1H NMR assignments made using 1D 1H NMR and homonuclear COSY.   1H 
NMR (500 MHz, Chloroform-d) δ 1.30 (d, J = 6.6 Hz, 3H, 5’-Me), 1.77 (td, J = 13.2, 4.2 Hz, 1H, 2’), 
1.82 (d, J = 8.0 Hz, 1H, 4’-OH), 1.90 (dd, J = 13.5, 5.1 Hz, 1H, 2’), 2.18 (dd, J = 14.7, 4.1 Hz, 1H, 8), 
2.34 (d, J = 14.7 Hz, 1H, 8), 2.99 (t, J = 5.0 Hz, 1H, 14-OH), 3.04 (d, J = 18.8 Hz, 1H, 10), 3.29 (d, J 
= 18.8 Hz, 1H, 10), 3.67 (d, J = 7.3 Hz, 1H, 4’), 3.84-3.93 (m, 1H, 3’), 4.09 (s, 3H, 4-OMe), 4.14 (t, J 
= 6.7 Hz, 1H, 5’), 4.49 (s, 1H, 9-OH), 4.75 (dd, J = 5.0, 2.3 Hz, 2H, 14), 4.90 (d, J = 3.8 Hz, 1H,), 
4.95 (d, J = 3.8 Hz, 1H, OCH2N), 5.05 – 5.16 (m, 2H, Bn), 5.17 – 5.26 (m, 1H, NHCO), 5.30 (s, 1H, 
7), 5.51 (d, J = 4.1 Hz, 1H, 1’), 7.41 (d, J = 8.6, Hz, 1H, 3), 7.46 (m, 2H, PNB), 7.80 (dd, J = 8.4, 7.7 
Hz, 1H, 2), 8.06 (m, 2H, PNB), 8.19 (d, J = 8.5 Hz, 2H, 1).  Calculated (MH+) m/z 734.1959. Found 
734.1957. 
3.2.4 Synthesis of PNBPABAPNP 
 
Figure 3.2.4.1 PNBPABAPNP 
Under an argon atmosphere, a solution of p-nitrobenzyl chloroformate (200.0 mg, 0.928 
mmol) in 20 mL freshly distilled THF was added dropwise over 60 min to a solution of p-
aminobenzyl alcohol (114.3 mg, 0.928 mmol) and pyridine (149.50 µl, 1.856 mmol) in 20 mL 
freshly distilled THF.  To this reaction mixture, a solution of p-nitrophenyl chloroformate (187.0 
mg, 0.928 mmol) in 20 mL freshly distilled THF was added dropwise over 60 min.  The reaction 
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mixture was left to stir for 16 h at room temperature under static argon, whereupon an off 
white precipitate formed.  Vacuum filtration through a medium fritted glass funnel afforded 
PABAPNBPNP (342.6 mg, 0.733 mmol) in 79% yield and 90% purity as evidenced by HPLC, and 
was used without further purification.  1H NMR in (CD3)2SO was in agreement with published 
assignments42. 
3.2.5 Synthesis of PNBPABADoxaz. 
 To a solution of Doxaz (44.6 mg, 80.25 µmol) and HOBT (12.3 mg, 80.25 µmol) in 0.6 mL 
of anhydrous DMSO, PNBPABAPNP (25.0 mg, 53.48 µmol) and the reaction vessel purged with 
argon.  The reaction mixture was left to react under static argon and monitored by HPLC until 
the peak corresponding to the PNBPABAPNP disappeared, usually around three days.  The 
reaction mixture was then diluted with 1.0 mL of DMSO, and then added dropwise to 10 mL of 
PBS buffer, pH 7.4 affording a red precipitate.  The precipitate was isolated by vacuum filtration 
using a medium fritted funnel, and purified by radial chromatography with 30:1 
chloroform/methanol eluent.  The final product was obtained in 45% yield and 91% purity as 
evidenced by HPLC.  1H NMR assignments made using 1D 1H NMR and homonuclear COSY.   1H 
NMR (400 MHz, Chloroform-d) δ 1.29 (d, J = 6.6 Hz, 3H, 5’-Me), 1.77 (broad m, 1H, 2’), 2.08 
(overlapping d, J = 14.7 Hz, 1H, 8; J = 4.2 Hz, 1H, 2’), 2.37 (d, J = 14.8 Hz, 1H, 8), 2.97 (d, J = 18.8 
Hz, 1H, 10), 3.17 (dd, J = 19.1, 2.0 Hz, 1H, 10), 3.98 (d, J = 7.3 Hz, 1H, 4’),  3.99 (s, 3H, 4-OMe), 
4.04 – 4.16 (m, 1H, 3’; 1H, 5’), 4.65 (s, 2H, 14), 4.91 (d, J = 3.8 Hz, 1H, OCH2N), 4.95 (d, J = 3.8 Hz, 
1H, OCH2N), 5.17 – 5.19 (m, 2H, Bn), 5.20 – 5.27 (m, 2H, 7), 5.37 (t, J = 5.3 Hz, 1H, 1’), 7.22 – 
7.27 (m, 1H, PNB), 7.34 (d, J = 8.5 Hz, 2H, PABA),  7.64 (tt, J = 7.7, 1.8 Hz, 2H, PNB), 7.71 (t, J = 
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8.1 Hz, 1H, 2), 7.91 – 7.98 (m, 2H, PABA), 8.06 – 8.19 (m, 2H, 1), 8.42 – 8.50 (m, 1H, PNB).  
Calculated (MH+) m/z 883.2436. Found 883.2431. 
3.3 Results and Discussion 
3.3.1 Synthesis of Doxaz PNB 
 Doxaz was synthesized on a 500 mg scale as described previously.  The oxazolidine 
nitrogen in this case was sufficiently reactive to form the carbamate with p-nitrobenzyl 
chloroformate in 92% yield and 95% yield, using pyridine as a catalyst.  Compared to other 
coupling reactions with Doxaz, this coupling was incredibly straightforward as was the workup.  
As with the compounds previously described, the Doxaz carbamates did not produce adequate 
NMR spectra at ambient temperature, presumably due to the Doxaz daunosamine sugar flip 
from chair to twist boat.43  The synthetic pathway is shown in Scheme 3.3.1 
 
Scheme 3.3.1 Synthesis of Doxaz PNB. 
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3.3.2 Synthesis of DoxazPABAPNB 
3.3.2.1 Synthesis of PNBPABAPNP or 4-nitrobenzyl (4-((((4-
nitrophenoxy)carbonyl)oxy)methyl)phenyl)carbamate 
 Hay et al.42 utilized a tert-butyldimethylsilyl ester protected p-aminobenzyl alcohol 
(PABA) and p-nitrobenzyl chlorformate (PNB chloroformate) to produce a carbamate with a 
protected alcohol that was then deprotected to produce a free benzyl alcohol which was 
subsequently reacted with p-nitrophenyl chloroformate (PNP chloroformate) to yield a mixed 
carbonate as depicted in Scheme 3.3.2.1.1.  Also shown in the scheme are the representative 
yields for each step, which culminate in a yield of 8% over three steps.  Commercialization of 
the Doxaz technology being in the forefront of our minds in tandem with the knowledge that at 
our current state of experience with the coupling of Doxaz to a mixed p-nitrophenyl carbonate 
results in large losses in the ultimate or penultimate step of any Doxaz prodrug synthetic 
pathway, the overall yield of 8% to the final product, 4-nitrobenzyl (4-((((4-
nitrophenoxy)carbonyl)oxy)methyl)phenyl)carbamate (PNBPABAPNP) was unacceptable.   
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Scheme 3.3.2.1.1  PNBPABAPNP synthetic scheme.  Hay et al. synthetic scheme for 
preparation of 4-nitrobenzyl (4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)carbamate. 
 In an attempt to improve this yield, previous experience with p-aminobenzyl alcohol and 
chloroformates was drawn upon.  Firstly, efforts were put forward to eliminate the protection-
deprotection steps and the use of triethylamine or diisopropylethyl amine.  It had been 
observed that these bases can react with the chloroformates or mixed carbonates, forming 
products that were difficult to remove and decreasing the yield of the desired product.  An 
example of this reaction is shown in Scheme 3.3.2.1.2.  The hypothesis that controlled addition 
PABA to p-nitrobenzyl chloroformate would create a solution phase scenario in which the PABA 
was in excess, and the more reactive aniline nitrogen (relative to the benzyl alcohol) would 
react first, and this was indeed the case.  Analysis of the reaction progression by HPLC revealed 
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that this first step went in less than one hour and incredibly cleanly.  Isolation of the product 
was straightforward, however, again considering large scale production, the exploration of a 
one-pot synthesis followed.  Many iterations were attempted, but the simple slow addition of 
PNP chloroformate to the reaction mixture in the presence of pyridine afforded the best 
product yield and purity.  The fortuitous precipitation of the hydrophobic product from 
anhydrous THF afforded an overall yield of 79%, a nearly ten fold improvement over the 
literature procedure,42 and a potentially scalable sequence.   
 
Scheme 3.3.2.1.2 Reaction of base with chloroformate or mixed carbonate.  Triethylamine 
can act as a nucleophile and form unwanted products.  
3.3.2.2 Synthesis of DoxazPABAPNB 
 The coupling of PNP mixed carbonates to Doxaz has historically been problematic.  In 
certain cases, a small excess of the PNP mixed carbonate has proven successful, however, this 
was not the case with PNBPABAPNP.  We hypothesized that the PNBPABAPNP was “pi-stacking” 
with the doxazolidine, affecting the reactivity.  Catalysis with HOBT improved yields from 15% 
to 26%; however, use of excess Doxaz, previously contrary to our experience, afforded a yield 
of 46%.  The reaction mixture in DMSO was diluted and then added dropwise to a buffer 
solution, and the highly hydrophobic prodrug precipitated.  The excess Doxaz was quickly 
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hydrolyzed upon workup to Dox, and washed away with the aqueous filtrate.  Although the 
yield in the final step was low, precipitation of the intermediates and the final product were 
favorable for commercial scale up.  The overall synthetic scheme is presented in Scheme 
3.3.2.2.1. 
 
Scheme 3.3.2.2.1 Complete synthetic pathway to DoxazPABAPNB 
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3.4 Conclusions 
 The purpose of this project was to demonstrate that simple, scalable prodrugs of Doxaz 
could be synthesized.  In this respect the project was a success.  The exploration of alternate 
reaction pathways is critical to the success of any Doxaz commercialization endeavor.  Because 
specialized cell culture equipment is required for creating and ultimately testing hypoxic tumor 
cell lines, no in vitro analyses were performed.  The Koch group is currently seeking 
collaborative partners to examine DoxazPNB and DoxazPABAPNB.  Determining which hypoxic 
cell lines are sensitive to these prodrugs will be followed by exploration of the potential 
enzymes responsible for activation.   
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Chapter 4 Prodrug Albumin Conjugates 
4.1 Introduction 
 The previously described prodrug technologies employ active targeting strategies, 
exploiting the overexpression of endogenous enzymes in certain cancer types to activate 
prodrugs.  Passive targeting of cancer by exploitation of the enhanced permeability and 
retention effect (EPR) has gained some attention, and therapeutics aimed at diabetes, hepatitis 
C, rheumatoid arthritis and cancer using albumin as a drug carrier are currently in clinical trials, 
and two agents for treating diabetes and one agent for treating solid tumors have gained 
market approval from the Food and Drug Administration (FDA).1   
 The study of the most abundant protein in blood, albumin, has been extensive, yet 
albumin has not been exploited for use in drug delivery until recently.  An article by Dr. Felix 
Kratz of the Tumor Biology Center, Division of Macromolecular Prodrugs in Freiburg, Germany 
in 2008 prompted many researchers to begin exploring the possibility of albumin as a candidate 
for drug delivery.2  Interestingly, the utility of albumin had been overlooked by Kratz himself 
during his early work in 1989.3  While investigating transferrin-mediated drug delivery, Kratz 
tested the efficacy of an acid-sensitive doxorubicin-transferrin conjugate in the MDA-MB-435 
melanoma  model.4  The negative control chosen was a doxorubicin-albumin conjugate.  There 
was no observed difference in efficacy between the two drug conjugates in a panel of tumor 
cell lines, nor in a breast cancer model in vivo.4  Under the assumption that albumin had no 
beneficial delivery effect, it was concluded that the amount of transferrin receptors on the 
target cells was insufficient to create a therapeutic advantage for a common anticancer agent 
such as doxorubicin.  Professor Maeda’s work on the enhanced permeability and retention 
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effect (EPR), aimed at demonstrating the accumulation of an experimental antibody has shown 
clearly that albumin (and the test article) accumulates in the tumor area.5,6  The work by Kratz, 
coupled with the subsequent research by Maeda et al. makes it apparent that albumin is as 
effective as transferrin at delivering drug to the target site.   
 Albumin is the most abundant protein in the body, with approximately 500 grams being 
distributed between the blood, lymphatic system, extracellular and intracellular compartments.  
In fact, albumin itself is a very profitable drug with annual sales upwards of $1.3 B worldwide in 
2010.1  Of the 4% of whole blood that is protein, albumin comprises 55%, and is primarily used 
as a blood substitute for malnourished or cachexic cancer patients.  As a therapeutic, albumin 
has been used to carry drugs or peptide and antibody based prodrugs as covalent 
conjugates/complexes or in nanoparticles.  
 To illustrate the utility of albumin as a drug delivery vehicle, an inspection of prevalent 
diseases shows that there were 285 million cases of types 1 and 2 diabetes, which shockingly is 
6.5% of the world population.  As a comparison, cancer accounts for approximately 12 million 
cases per year.  An insulin detemir, Levemir® is an albumin binding porcine insulin drug.  A 
lysine at the B9 position of porcine insulin is modified with a fatty acid that is capable of binding 
albumin.7  Insulin detemir in circulation is 98% albumin-bound, however the complex slowly 
dissociates, allowing long lasting administration of insulin.8  Only the free insulin is available to 
interact with the insulin receptor and the insulin bound to albumin offers a distinct advantage 
to other administrations such as glargine (Sanofi-Aventis) and NPH insulin (Novo Nordisk) that 
commonly form crystalline deposits.9  Scientists at Novo Nordisk attached a glucagon-like 1 
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peptide (GLP-1) to albumin to treat diabetes and market the product under the tradename 
Victoza®.  The biologically active forms of GLP-1 are formed in the pancreas, and stimulate 
insulin secretion;10 however, naturally formed GLP-1 has a very short half-life of 1.5-2 min due 
to degradation by ubiquitous enzymes.  When bound to albumin, the half-life of GLP-1 is 
extended to 11-15 min, allowing one daily administration. 
 Treatment of another prevalent disease, hepatitis C, which affects 180 million people 
worldwide,11 has also benefited from albumin delivery.  Interferon-α-2B (INFα-2b) weighing 
approximately 19 kDa has effective antiviral qualities, yet a short half-life in humans of 2-3 
hours.  The short half-life requires that daily injections be administered.  The currently 
marketed drug, Pegasys® is a pegylated version of INFα-2b and has a molecular weight of 40 
kDa.   Pegasys® is the current standard of care.11  Albinterferon-α-2b is an albumin bound 
version of INFα-2b and has entered phase III clinical trials in direct comparison to Pegasys®.  It 
was found that Albinterferon-α-2b could be administered subcutaneously once every four 
weeks and invokes a comparable response to Pegasys®.11-13  Albumin binding drugs, fusion 
compounds such as antibodies, imaging agents and nitric oxide carriers amongst others are 
currently in many phases of development, and have recently been reviewed.1 
 Abraxane® is the first approved use of a nanoparticle albumin bound (nab) technology, 
exploiting the association of paclitaxel with albumin, to treat solid tumors.  The nab technology 
increases solubility of lipophilic drugs by forming colloidal suspensions of albumin and, in 
Abraxane®, paclitaxel under high pressure.14  The hydrophobic portions of albumin associate 
with drug, while the negative regions of albumin form the hydrophilic outer surface of the 
 86 
nanoparticle.  Particles on average of 130 nm are formed, but quickly dissolve into smaller 
complexes of around 10 nm upon injection.  These smaller particles are small enough to avoid 
the blockage of capillaries.15  Abraxane® has an advantage over the commercially available 
paclitaxel which is formulated with polyoxyethylated castor oil (Cremophor EL®), with an 
ethanol vehicle and a competitor compound, Docetaxel, which is formulated in polysorbate 80 
(Tween 80®) with an ethanol diluent.  Both drugs are further diluted with normal saline or 5% 
dextrose solution for administration.16,17  Cremophor EL can cause acute hypersensitivity 
reaction,18 severe, life-threatening reactions with dyspnea and hypotension in 1.5-3% of 
patients,19 neutropenia20 and peripheral neuropathy.21  Although Abraxane® has shown 
improved administration dynamics relative to approved drugs, the significant treatment limiting 
toxicities such as fatigue, myalgia, myelosuppression, fluid retention neuropathy and 
hypersensitivity22 have not produced an improved therapeutic index.  Administering higher 
drug doses in breast cancer patients has produced increased toxicity without clinically 
meaningful benefits.23  Other tumor indications including non-small cell lung carcinoma 
(NSCLS), pancreatic cancer, melanoma, and head and neck cancer, some in combination with 
approved therapies, is ongoing.24-26 
 An interesting development from the preclinical and clinical studies surrounding 
Abraxane® is the insight gained into the mode of albumin-bound drug delivery.  As indicated 
before, upon injection, Abraxane® forms albumin-bound paclitaxel complexes comparable to 
the size of free albumin.  The albumin-bound paclitaxel complexes accumulate in the tumor 
through the enhanced permeability and retention (EPR) effect.  Tumor uptake can be further 
explained by an albumin transport pathway mediated by glycoprotein gp60, a 60 kDa protein 
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also known as albondin.  Albondin is located on the surface of endothelial cells and has been 
shown to play a role in the tumor uptake of Abraxane® and release of paclitaxel.26.27 Aldonin 
also assists in the even distribution of the prodrug throughout the tumor.28  Circulating albumin 
and Abraxane® can bind gp60 in the nanomolar range26 which induces gp60 clustering and 
transcytosis, transporting gp60 bound albumin or gp60 bound albumin-paclitaxel conjugates in 
caveolae.  The formation of caveolae encapsulates vessel fluid, and additional Abraxane® and 
albumin.  The caveolae transport the particles through the endothelium and releases paclitaxel 
in the subendothelial space.26  The albumin-paclitaxel conjugate then binds with SPARC 
(Secreted Protein, Acidic and Rich in Cysteine), a 43 kDa matricellular glycoprotein with 
significant homology to gp60.29  SPARC plays an important role in modulating cell migration and 
extracellular matrix proliferation, and SPARC overexpression correlates to tumor invasion and 
metastasis.25,30  SPARC expression correlated to improved Abraxane® response when compared 
to Taxol®/Cromphore EL, and is therefore thought to play an important role in the efficacy of 
Abraxane®.26 
 The ease with which a drug can be attached and selectively cleaved from albumin is of 
great interest for albumin-bound therapeutics.  Kratz demonstrated that the thiol in the 
exposed cysteine-34 of albumin quickly reacts with maleimide of a doxorubicin derivative 
DOXOEMCH to form a (6-maleimidocaproyl)hydrazone albumin-doxorubicin conjugate.31  The 
structure of DOXOEMCH is presented in Figure 4.1.1.  Intravenous administration of 
DOXOEMCH is followed by in situ coupling to circulating albumin.  The (6-
maleimidecaproyl)hydrazone is sensitive to the acidic microenvironment of the tumor and 
releases the chemotherapeutic in close proximity of the tumor.  DOXOEMCH showed high 
 88 
plasma stability in its album-bound form, and was put forward as a clinical candidate.  Renamed 
INNO-206, the albumin-binding doxorubicin prodrug exhibited a favorable toxicity profile and 
reduced cardiotoxicity.32,33  INNO-206 completed a phase 1 study enrolling patients with breast,  
small cell lung cancer and sarcoma in which the acid sensitive chemotherapeutic exhibited a 
good safety profile.34  The Phase Ib study focused on sarcoma, and a Phase II study for gastric 
cancer is ongoing.  Interestingly, the localization of INNO-206 through the EPR effect and the 
diffusion-mediated delivery of clinically available doxorubicin prompted Kratz to perform a 
combined therapy evaluation in an ovarian A2780 xenograft model.35  The combined therapy 
reacted synergistically, and complete remissions in the xenograft model were observed. 
 Concurrently, studies combining DOXOEMCH and polyglycerol dendrimers with free 
thiols or amines afforded conjugates with varying particle size and Dox loading.  The resulting 
particles were water soluble and of optimal size for EPR passive targeting.  Also, the hydrazone 
linkage was effectively cleaved in acidic conditions.  In ovarian cancer xenograft models, the 
dendritic conjugates exhibited less body weight change when compared to dox, suggesting 
better tolerability.  Statistically significant antitumor effects compared to both vehicle control 
and doxorubicin were observed and remissions lasting 30 days were seen in mice receiving the 
dendritic conjugates.36   
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Figure 4.1.1 DOXOEMCH The albumin-binding acid sensitive doxorubicin conjugate known as 
DOXOEMCH 
 While multiple methods of passive targeting using several drugs aimed at differing 
diseases are at varying stages of preclinical and clinical development, researchers have also 
explored the use of combination targeting.  Albumin binding prodrugs with active targeting 
moieties appear in the literature, with varying results.  While these prodrugs with “double 
filters” have not progressed as far, they are of incredible interest.  Most noticeably are prodrugs 
of doxorubicin that incorporate both passive targeting with albumin binding maleimides and 
active targeting with enzymatically cleaved triggers.   
 One example of a doxorubicin prodrug with both active and passive targeting is an 
albumin-binding prodrug containing a peptide sequence selectively cleaved by gelatinase A, a 
matrix metalloproteinase (MMP) that plays a critical role in the degradation of membranes and 
the extracellular matrix.37-39  Gelatinase A specifically known as MMP-2, has been shown to play 
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a critical role in tumor progression, angiogenesis and metastasis.40  Melanoma patients have 
historically responded marginally to chemotherapy due to non-selective therapeutic agents41 
and the correlation between overexpression of MMP-2 in melanoma and tumor progression 
has been demonstrated in preclinical and clinical investigations.42-44  A prodrug of doxorubicin 
containing the MMP-2 substrate peptide sequence Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln and an 
albumin binding moiety was synthesized.45  A maleimidotriethylenglycol group functioned as 
the albumin binding moiety, and the incorporation of the triethyleneglycol increased the water 
solubility of the molecule overall.45  A schematic representation of the prodrug is provided in 
Figure 4.1.2.  The prodrug was tested against A375 melanoma expressing high amounts of 
MMP-2 and showed superior efficacy to doxorubicin both in vitro and in vivo.  Nude mice in a 
A375 melanoma model showed a maximum tolerability dose (MTD) for the prodrug four times 
higher than that for free doxorubicin.45  The optimal dose of doxorubicin in in vivo experiments 
was found to be 2 doses of 13.3 µmol/kg each and produced a moderate inhibition in tumor 
growth that was comparable with the therapeutic results of the prodrug with 2 doses of 13.3 
µmol/kg each. Due to the tolerability of the prodrug, administration of three doses at 
39.9µmol/kg produced a good antitumor effect with mice showing remissions of up to 40 days 
in length.45   
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Figure 4.1.2 Albumin-binding prodrug of doxorubicin with a MMP-2 cleavage site. 
 As discussed above, and in Chapter 2, targeting enzymes (especially proteases) involved 
in tissue remodeling are attractive when producing prodrugs.  A very interesting prodrug aimed 
at extracellular and intracellular proteases while utilizing the passive targeting of an albumin-
binding moiety is EMC-Phe-Lys-PABC-Doxorubicn (EMCFKDox) first reported by Kratz et al. in 
2009.46  As mentioned previously, the cysteine protease cathepsin B is principally located in the 
endosomal/lysosomal compatment47, but there is evidence that cathepsin B expression 
correlates with angiogenesis and promotes the remodeling of the extracellular matrix to permit 
neovascularization.48,49  Analogous to the MMP-2 prodrug described above, EMCFKDox 
incorporates a maleimide moiety for passive targeting through albumin-binding and a short 
peptide sequence recognizable by cathepsin B (Phe-Lys).  EMCFKDox also contains the 1,6-self-
immolative spacer utilized in prodrugs described in Chapters 2 and 3, and is shown in Figure 
4.1.3.  This prodrug exhibited effective binding to, and cleavage from albumin in tumor 
homogenates at pH 5.0.46  Interestingly, EMCFKDox was approximately 6 times less toxic to 
human tumor cell lines MDA-MB-231 LN (breast carcinoma and AsPCI LN (pancreatic 
carcinoma) than doxorubicin, but was significantly more active in vivo compared to doxorubicin 
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in an equitoxic comparison.  Comparison of dox at its optimal conditions of 2 doses at 8 mg/kg 
and the prodrug at three doses of 24 mg/kg, in a nude mouse model (MDA-MB 435) showed 
clear antitumor response for the prodrug, and tumor progression in the dox treated mice.  In 
fact, the tumors in dox treated mice increased by a factor of approximately 11, whereas the 
prodrug treatment resulted in an increase by a factor of three.46   
 
Figure 4.1.3 Albumin-binding doxorubicin prodrug with a cathepsin B peptide trigger. 
 Previously, the Koch group synthesized targeted prodrugs of the highly active 
doxorubicin derived chemotherapeutic, Doxazolidine (Doxaz).50-54  Doxaz has been shown to be 
a 100-10,000 times more active chemotherapeutic than Dox.  A targeted prodrug of 
Doxazolidine known as pentyl-PABC-Doxaz (PPDoxaz) aimed at carboxylesterases CES1 and 
CES2 has previously been evaluated.50-52  PPDoxaz exploits the overexpression of CES2, as do 
marketed therapeutics Irinotecan and capecitabine (Xeloda).  Irinotecan and capecitabine both 
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contain alkyl carbamates, and are transformed to their respective active metabolites SN-38 and 
5-flurouracil (5-FU) by CES1 and/or CES2 as shown in Figure 4.1.4.  PPDoxaz is similar to 
capecitabine.  Capecitabine was first approved in 1998 as treatment for metastatic colorectal 
cancer, and has since been approved for other indications and combination therapies.55-57  The 
search for prodrugs of doxazolidine with commercial potential has been challenged by 
manufacturing and synthetic difficulties.  The successful synthesis of a scalable prodrug with 
both active and passive (albumin mediated) targeting has been recently accomplished in the 
Koch lab, and due to intellectual property concerns, will not be discussed.  However, in vitro 
and in vivo testing has shown promise.  The second generation molecule, protected under  
previous patents, is herein described.   
 
 
Figure 4.1.4 Alkyl carbamte drugs Capecitabine and Irinotecan and their enzymatic 
activation. 
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 Analogously, the synthesis of a doxazolidine prodrug (EMCFKDoxaz) containing both 
active and passive (albumin mediated) targeting utilizing a protease trigger (activated by 
cathepsin B) is also described.  EMCFKDoxaz was hypothesized to be a scalable drug with 
straightforward manufacturing.  Contrary to original thought, the synthesis presented 
significant challenges, but allowed for exploration of varying synthetic schemes.  The structure 
of the proposed prodrug EMCFKDoxaz is shown in Figure 4.1.5. 
 
Figure 4.1.5 Structures of albumin-binding, enzymatically activated prodrugs of doxaz.   
4.2 Experimental Methods 
4.2.1 General Remarks 
 Clinical samples of doxorubicin hydrochloride formulated with lactose were gifted by 
FeRx (Aurora, CO).  Unless otherwise noted, all reagents and amino acids for solid-phase 
peptide synthesis were purchased from Nova Biosciences (La Jolla, CA) and other chemicals and 
reagents were acquired from Aldrich (Milwaukee, WI).  Analytical HPLC was performed on 
Agilent 1050/1100 hybrid instruments equipped with a 1050 series autoinjector, an 1100 series 
UV/visible diode-array detector, and a 1046A fluorescence detector.  An Agilent Zorbax 
octadecylsilyl (C18) reverse phase column (4.6 mm i.d. x 150 mm, 5 µm) was used for 
 95 
chromatography.  Unless specifically indicated, elution was performed at 1 mL/min and room 
temperature with gradients of acetonitrile and 20 mM sodium phosphate buffer, pH 4.6, 
containing 0.02% sodium azide.  Method 1 had acetonitrile percentages of: 20% from 0 to 1.5 
min, 30% at 5 min, 80% from 15 to 20 min, 20% at 24 min.  Method 2 consisted of acetonitrile 
percentages: 20% to 40% from 0 – 5 min, 50% from 8 – 9 min, and 20% at 11 min.  The presence 
of anthracycline-containing molecules was monitored by absorbance at 480 nm and retention 
times are noted individually.  All NMR spectra were taken at 400 or 500 MHz on a Varian Unity 
INOVA spectrometer (Palo Alto, CA) or a Bruker-Avance III 300 MHz spectrometer (Billerica, 
MA) in deuterated solvents from Cambridge Isotope Laboratories, Inc (Andover, MA).  Chemical 
shifts are reported in δ values of ppm and were standardized by the residual solvent peak in 
MestReNova NMR software (Mestrelab Research, Santiago de Compostela, Spain).  UV-vis 
spectroscopy was performed on a Hewlett-Packard /Agilent 8452A diode array instrument.  
Electrospray mass spectra were obtained with a Perkin-Elmer Sciex API III+ (Waltham, MA) or 
ABI Pulsar QqT high resolution instrument (Foster City, CA), equipped with an ion-spray source 
at atmospheric pressure.  Purification by radial chromatography purification was done with a 
Harrison Research Model 7924T Chromatotron (Palo Alto, CA).  Photo deprotection was 
performed using a Rayonet Reactor (Southern New England Ultraviolet Co.).  Shown below is 
the reference system for 1H NMR assignments. 
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4.2.2 Doxorubicin Free Base from Clinical Samples. 
 Lyophilized pellets of expired clinical samples of doxorubicin HCl (20 – 50 mg) containing 
100 – 250 mg lactose monohydrate (Bedford Laboratories, Bedford, OH) were dissolved in 
methanol to a final concentration of 2 mg/mL and combined in a separatory funnel.  The 
methanol solution was diluted with 100 mM sodium phosphate buffer, pH 8.5, for a final 
concentration of 0.4 mg/mL dox HCl as a mixture of precipitated and solubilized material.  The 
free base of Dox was extracted from the solution by two washes with equal volumes of 
chloroform, leaving almost no red color in the aqueous fraction.  The chloroform was dried with 
anhydrous sodium sulfate, filtered, and removed by rotary evaporation to yield a red solid.  The 
solid was dried thoroughly under high vacuum (10-2 torr) for at least 2.5 h to yield pure dox free 
base in a final yield of 98%, as indicated by optical density at 480 nm and a molar extinction 
coefficient of 11,500 M-1 cm-1 in 75% DMSO/25% water. 
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4.2.3 Synthesis of Doxazolidine (Doxaz) 
 Dox free base was dissolved to a final concentration of 5 – 10 mg/mL in 
deuteriochloroform and 1.1 – 2 equiv. of prilled paraformaldehyde (Aldrich, Milwaukee, WI) 
was added.  The reaction mixture was monitored by 1H NMR, with complete consumption of 
Dox occurring after 2 – 3 days, as evidenced by the appearance of the Doxaz methylene AX 
pattern at 4.31 and 4.68 ppm and doxf AX pattern at 4.21 and 4.73 ppm in the 1H NMR 
spectrum.  Loss of Dox was evident by the dox-specific aromatic triplet pattern for the proton at 
the 2-position, which appears at 7.81 ppm (as compared to 7.78 for Doxaz and 7.70 for Doxf).  
The amount of paraformaldehyde added determines the Doxaz/doxoform ratio, since Doxaz 
reacts with an additional equiv of formaldehyde to form Doxf.  Complete assignments of the 1H 
NMR spectra for Doxaz and Doxf have been published.58  The reaction mixture was then filtered 
and the deuteriochloroform removed by rotary evaporation.  The Doxaz/Doxf mixture was used 
without further purification, since Doxf readily hydrolyzes to produce tow equiv of Doxaz.   
4.2.4 Synthesis of Fmoc-p-aminobenzyl alcohol (Fmoc-PABA) 
 N-(Fluorenylmethyloxycarbonyloxy)-succinimide (N-Fmoc-N-hydroxysuccinimide, 6.0 g, 
17.8 mmol) in p-dioxane (60 mL) was added dropwise to p-aminobenzyl alcohol (PABA, 2.5 g, 
20.5 mmol) in p-dioxane (30 mL).  After 48 h of stirring, 90 mL of deionized H20 was added and 
the desired product immediately precipitated.  The product was isolated by filtration, and 
washed 4 times with deionized H20 (60 mL).  Fmoc-PABA (5.9 g, 95%) was isolated that showed 
the following spectral properties:  1H NMR (CDCl3): δ 4.26 (t, 1H, J = 7 Hz, Fmoc-CH), 4.53 (d, 2H, 
J = 7 Hz, Fmoc-CH2), 4.63 (s, 2H, PABA-CH2), 6.62 (bs, 1H, NH), 7.30 (t, 2H, J = 7 Hz, Fmoc), 7.34 
(d, 2H, J = 7 Hz, PABA), 7.36 (b, 2H, PABA), 7.40 (t, 2H, J = 7 Hz, Fmoc), 7.60 (d, 2H, J = 7 Hz, 
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Fmoc), 7.77 ppm (d, 2H, J = 7 Hz, Fmoc); ESI-MS, observed m/z = 384.1014; calculated m/z for 
(M + K+) = 384.0996. 
4.2.5 Loading of Fmoc-PABA to 2-Chlorotrityl Resin 
 Fmoc-PABA (2 equiv) was added to 1.0 g of 2-chlorotrityl polystyrene resin in 10 mL dry 
THF followed by 4 equiv of dry pyridine.  The solution was stirred and heated at 60 ºC in an oil 
bath for 16 h under argon.  The solution was filtered through a coarse sintered glass frit, and 
the resin was washed with DCM/MeOH/DIEA 17:2:1 mL (3x), followed by DCM 10 mL (2x), DMF 
10 mL (2x), DCM 10 mL (3x).  The resin was dried under high vacuum (10-2 Torr) overnight and 
then checked for loading level according to previous published methods.59 
4.2.6 Solid Phase Peptide Synthesis 
 The peptide was synthesized by the solid phase method using Fmoc strategy starting 
with preloaded Fmoc-PABA.  The peptide was prepared on a 0.25 mmol scale by single amino 
acid couplings using a 4-fold excess of N-acetyl-Gly and the Fmoc-protected amino acids D-Ala 
(Chem-Impex, International, Wood Dale, IL), L-Phe, and L-Lys-alloc.  Activation was done with 2-
(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluoro-phosphate (HBTU)/N-hydroxy-
benzotriazole (HOBT) and the synthesis was performed on an ABI 433A peptide synthesizer 
(Applied Biosystems, Carlsbad, CA).  Owing to the poor nucleophilicity of the aniline nitrogen of 
PABA, the coupling of the first amino acid, Fmoc-Lys(alloc, Nvoc or azide), required an extended 
coupling time by modifying the software instructions to vortex the reaction for 60 sec, then 
allow it to sit for 10 min.  This cycle was repeated 88 times.  Fmoc groups were removed by 
sequential treatment (3x) with 20% piperidine/DMF. 6-maleimidocaproic acid (EMCA) was 
loaded as a standard amino acid, and all other amino acid couplings followed standard 
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conditions, to yield EMC-L-Phe-L-Lys(alloc, Nvoc or azide)-PABA (EMCFK(alloc Nvoc or azide)-
PABA) coupled to the polystyrene resin. 
4.2.7 Cleavage of EMCFK(alloc Nvoc or azide)-PABA from the Resin 
 The resin was placed into a medium-grain fritted funnel and washed twice with DCM (20 
mL). Pyridine/MeOH (10% v/v, 20 mL) was added to the receiving flask to protect the peptide 
after cleavage.  TFA/DCM (2% v/v, 10 mL) was then added and swirled for 1 min. The mixture 
was then gently vacuum filtered, without allowing the resin to proceed to dryness.  This step 
was repeated 3 times followed by a 20 mL DCM wash.  The filtrate contained the peptide and 
pyridine/TFA salt, and the solvent was rotary-evaporated to ~10% of the original volume.  
Approximately 40 mL of deionized water was added to the flask.  Upon swirling, the peptide 
began to precipitate.  The solution was allowed to cool in an ice bath for at least 10 min.  The 
precipitate was collected on a fritted funnel and washed with deionized water 10 mL (3x), 
followed by ether, 10 mL (2x).  The isolated amount of product and NMR assignments are 
presented in Table 4.2.7.1.  1H NMR assignments for EMCFK(alloc)-PABA as the most illustrative 
representative of the group is provided.  1H NMR assignments were made using 1D 1H NMR and 
homonuclear COSY.  1H NMR (500 MHz, DMSO-d6) δ 1.03 (q, J = 7.9 Hz, 2H, K-γ), 1.37 (dp, J = 
22.9, 7.5 Hz, 6H, C, D, E), 1.66 (m, 2H, K-β), 2.00 (t, J = 7.3 Hz, 2H, B), 2.72 (dd, J = 13.9, 10.3 Hz, 
1H, F-β), 2.96 (q, J = 6.5 Hz, 2H, K-ε), 3.02 (dd, J = 13.8, 4.1 Hz, 1H, F-β), 3.31 (t, J = 7.2 Hz, 2H, 
A),  4.36 (q, J = 7.8 Hz, 1H, K-α), 4.43 (m, 2H, Bn; 2H, alloc H1), 4.56 (td, J = 9.7, 4.1 Hz, 1H, F-α), 
5.11 (t, J = 5.7 Hz, 1H, Bn-OH), 5.14 (dt, J = 10.6, 1.6 Hz, 1H, alloc-H3), 5.24 (dq, J = 17.2, 1.8 Hz, 
1H, alloc-H4), 5.87 (ddd, J = 22.4, 10.5, 5.3 Hz, 1H, alloc-H2), 7.00 (s, 2H, maleimide), 7.13 – 7.17 
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(m, 1H, K-ε-NH), 7.18 – 7.31 (m, 5H, F; 2H, PABA), 7.50 – 7.59 (m, 2H, PABA), 8.01 (d, J = 8.4 Hz, 
1H, F-NH), 8.14 (d, J = 7.7 Hz, 1H, K-NH), 9.95 (s, 1H, anilide). 
 
 EMCFK(alloc)-PABA EMCFK(Nvoc)-PABA EMCFK(azide)-PABA 
Amount isolated (mg) 153.26 191.10 64.86 
Amount isolated 
(mmoles) 
0.227 0.230 0.105 
Yield 91% 92% 42% 
Table 4.2.7.1  Experimental Details of mixed carbonates. 
 
4.2.8 Activation to EMCFK(alloc)-PABA-pNP Carbonate Ester 
 An oven dried round bottom flask equipped with a magnetic stir bar was cooled under 
argon and charged with 4.0 mL of tetrahydrofuran (distilled from sodium metal and 
benzophenone) and EMCFK(alloc)PABA (53.43 mg, 0.079 mmol).  To the stirring heterogeneous 
mixture, 1.1 equiv p-nitrophenyl chloroformate (17.5 mg, 0.087 mmol) was added followed 
immediately by 1.1 equiv pyridine (7.03 µL). Over the course of 20 min, all solids went into 
solution, after which the reaction progress was monitored by RP-HPLC (Method 1) until 
complete, as evidenced by the disappearance of starting material (eluting at 17.0 min), which 
typically required overnight reaction. The reaction mixture was then diluted with 50 mL of ethyl 
acetate and washed once with 50 mL deionized water, followed by extractions with 50 mL of 
saturated sodium bicarbonate until the aqueous layer no longer turned yellow (typically 5 
extractions). The organic layer was dried over sodium sulfate and concentrated by rotary 
evaporation to yield 59.85 mg of a pale yellow solid that was used without further purification, 
with a final yield of 90%.  EMCFK(alloc)-PABA-pNP was characterized by the following 
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spectroscopic data with NMR assignments made from 1D 1H NMR and homonuclear COSY.  1H 
NMR (500 MHz, DMSO-d6) δ 1.03 (q, J = 8.0 Hz, 2H, K-γ), 1.37 (dp, J = 14.9, 7.4 Hz, 6H, C, D, E), 
1.67 (m, 2H, K-β), 2.00 (t, J = 7.4 Hz, 2H, B), 2.72 (dd, J = 13.8, 10.3 Hz, 1H, F-β), 2.96 (t, J = 6.5 
Hz, 2H, K-ε), 3.02 (dd, J = 13.8, 4.1 Hz, 1H, F-β), 3.31 (t, J = 7.2 Hz, 2H, A), 4.37 (m, 1H, K-α), 4.42 
(dd, J = 4.3, 2.9 Hz, 2H, alloc-H1), 4.56 (td, J = 9.4, 9.0, 4.0 Hz, 1H, F-α), 5.13 (dd, J1=J2 = 1.4 Hz, 
1H, alloc-H3), 5.24 (dq, J = 17.3, 1.6 Hz, 1H, alloc-H4), 5.24 (s, 2H, Bn), 5.87 (ddd, J = 22.3, 10.5, 
5.4 Hz, 1H, alloc-H2), 7.00 (s, 2H, maleimide), 7.12 – 7.29 (m, 5H, F), 7.42 (m, 2H, PABA), 7.52 – 
7.60 (m, 2HpNP), 7.61 – 7.71 (m, 2H, PABA),  8.01 (d, J = 8.3 Hz, 1H, F-NH), 8.18 (d, J = 7.8 Hz, 
1H, K-NH), 8.23 – 8.39 (m, 2H, pNP), 10.11 (s, 1H, anilide). 
 
4.2.9 Activation to EMCFK(Nvoc)-PABA-pNP Carbonate Ester 
 An oven dried round bottom flask equipped with a magnetic stir bar was cooled under 
argon and charged with 4.0 mL of tetrahydrofuran (distilled from sodium metal and 
benzophenone) and EMCFK(Nvoc)PABA (67.20 mg, 0.081 mmol).  To the stirring heterogeneous 
mixture, 1.1 equiv p-nitrophenyl chloroformate (17.9 mg, 0.089 mmol) was added followed 
immediately by 1.1 equiv pyridine (7.04 µL). Over the course of 50 min, all solids went into 
solution, after which the reaction progress was monitored by RP-HPLC (Method 1) until 
complete, as evidenced by the disappearance of starting material (eluting at 15.8 min), which 
typically required overnight reaction. The reaction mixture was then diluted with 50 mL of ethyl 
acetate and washed once with 50 mL deionized water, followed by extractions with 50 mL of 
saturated sodium bicarbonate until the aqueous layer no longer turned yellow (typically 5 
extractions). The organic layer was dried over sodium sulfate and concentrated by rotary 
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evaporation to yield 70.9 mg of a pale yellow solid that was used without further purification, 
with a final yield of 88%.  EMCFK(Nvoc)-PABA-pNP slowly degraded over time, even at lower 
temperatures, and in the solid phase, and was therefore not characterized by NMR. 
4.2.10  Activation to EMCFK(azide)-PABA-pNP Carbonate Ester 
 An oven dried round bottom flask equipped with a magnetic stir bar was cooled under 
argon and charged with 1.0 mL of tetrahydrofuran (distilled from sodium metal and 
benzophenone) and EMCFK(azide)PABA (15.56 mg, 0.025 mmol).  To the stirring heterogeneous 
mixture, 1.1 equiv p-nitrophenyl chloroformate (5.59 mg, 0.028 mmol) was added followed 
immediately by 1.1 equiv pyridine (2.26 µL). Over the course of 20 min, all solids went into 
solution, after which the reaction progress was monitored by RP-HPLC (Method 1) until 
complete, as evidenced by the disappearance of starting material (eluting at 15.4 min), which 
typically required overnight reaction. The reaction mixture was then diluted with 50 mL of ethyl 
acetate and washed once with 50 mL deionized water, followed by extractions with 50 mL of 
saturated sodium bicarbonate until the aqueous layer no longer turned yellow (typically 5 
extractions). The organic layer was dried over sodium sulfate and concentrated by rotary 
evaporation to yield 10.24 mg of a pale yellow solid that was impure by HPLC, with a final yield 
by extrapolation from the HPLC chromatogram of 52%.  Due to the high amounts of impurities, 
EMCFK(azide)-PABA-pNP was not characterized by NMR. 
4.2.11  Synthesis of EMCFK(alloc)-PABC-Doxaz 
 An oven dried round bottom flask equipped with a magnetic stir bar was cooled under 
argon and charged with EMCFK(alloc)-PABC-pNP (59.85 mg, 0.0711 mmol), 1-
hydroxybenzotriazole (10.89 mg, 1 equiv) and 500 µL dry DMSO (stored over 4Å molecular 
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sieves for at least 3 days). To this, 1 equiv doxaz (39.54 mg) dissolved in 500 µL of similarly dried 
DMSO was added and the mixture was left to stir under argon in the dark and monitored by 
HPLC (Method 1) until complete, as evidenced by the disappearance of carbonate starting 
material (approximately 36 h). The reaction mixture was then diluted with an additional 2 mL of 
DMSO. A 15 mL medium fritted sintered glass funnel was charged with 10 mL cold PBS, pH 7.4. 
The red reaction mixture was added dropwise and the resulting red precipitate was washed 
four times with 10 mL of PBS and then two washes with 10 mL of deionized water. The 
precipitate was washed from the filter with a mixture of 10:1 chloroform/methanol and 
concentrated by rotary evaporation.  The majority of the crude red solid, which was a mixture 
containing a 40% yield of EMCFK(alloc)-PABC-Doxaz, was moved forward without any additional 
purification.  However, to fully purify EMCFK(alloc)-PABC-Doxaz for characterization, the red 
solid was purified by preparative silica gel TLC, spotted in and eluted with 10:1 
chloroform:methanol. The desired product (the major band) was excised, suspended and 
vortexted in the elution solvent, and centrifuged to remove the silica gel.  The solvent was 
removed by rotary evaporation to produce solid, pure EMCFK(alloc)-PABC-Doxaz that was 
characterized by 1H NMR assignments made using 1D 1H NMR and homonuclear COSY.   1H NMR 
(500 MHz, DMSO-d6) δ 1.00 (d, J = 7.0 Hz, 3H, 5’-Me), 1.03 (q, J = 8.0 Hz, 2H, K-γ), 1.37 (dp, J = 
14.9, 7.4 Hz, 6H, C, D, E), 1.67 (m, 2H, K-β), 1.73 (m, 1H, 2’), 1.84 – 1.91 (m, 1H, 2’), 2.00 (t, J = 
7.4 Hz, 2H, B), 2.14 – 2.26 (m, 2H, 8), 2.72 (dd, J = 13.8, 10.3 Hz, 1H, F-β), 2.96 (t, J = 6.5 Hz, 2H, 
K-ε), 2.99 (s, 2H, 10), 3.02 (dd, J = 13.8, 4.1 Hz, 1H, F-β), 3.31 (t, J = 7.2 Hz, 2H, A), 3.96 (dd, J = 
5.9, 2.2 Hz, 1H, 4’), 4.06 (dt, J = 7.6, 5.8 Hz, 1H, 3’), 4.10 (s, 3H, 4-OMe), 4.23 (p, J = 7.0 Hz, 1H, 
5’), 4.37 (m, 1H, K-α), 4.42 (dd, J = 4.3, 2.9 Hz, 2H, alloc-H1), 4.56 (td, J = 9.4, 9.0, 4.0 Hz, 1H, F-
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α), 4.75 (dd, J = 5.0, 2.3 Hz, 2H, 14), 4.86 (d, J = 3.6 Hz, 1H, OCH2N), 4.89 (d, J = 3.5 Hz, 1H, 
OCH2N), 4.97-5.11 (m, 2H, Bn, 1H, 7), 5.13 (dd, J = 1.4 Hz, 1H, alloc-H3), 5.24 (dq, J = 17.3, 1.6 
Hz, 1H, alloc-H4), 5.24 (s, 2H, Bn), 5.87 (ddd, J = 22.3, 10.5, 5.4 Hz, 1H, alloc-H2), 5.27 (t, J = 4.2 
Hz, 1H, 1’), 6.65 (s, 2H, maleimide), 7.12 – 7.29 (m, 5H, F), 7.42 (m, 2H, PABA), 7.61 – 7.71 (m, 
2H, PABA), 7.86 – 7.97 (m, 1H, 3, 1H, 2), 8.00 (d, J = 7.8 Hz, 1H, 1), 8.01 (d, J = 8.3 Hz, 1H, F-NH), 
8.18 (d, J = 7.8 Hz, 1H, K-NH), 10.11 (s, 1H, anilide) 13.25 (s, 1H, 6-OH), 14.03 (s, 1H, 11-OH). 
4.2.12  Synthesis of EMCFK(Nvoc)-PABC-Doxaz 
 An oven dried round bottom flask equipped with a magnetic stir bar was cooled under 
argon and charged with EMCFK(Nvoc)-PABC-pNP (24.75 mg, 0.0249 mmol), 1-
hydroxybenzotriazole (3.80 mg, 1 equiv) and 600 µL dry DMSO (stored over 4Å molecular sieves 
for at least 3 days). To this, 1 equiv doxaz (13.80 mg) dissolved in 600 µL of similarly dried 
DMSO was added and the mixture was left to stir under argon in the dark and monitored by 
HPLC (Method 1) until complete, as evidenced by the disappearance of carbonate starting 
material (approximately 36 h). The reaction mixture was then diluted with an additional 2 mL of 
DMSO. A 15 mL medium fritted sintered glass funnel was charged with 10 mL cold PBS, pH 7.4. 
The red reaction mixture was added dropwise and the resulting red precipitate was washed 
four times with 10 mL of PBS and then two washes with 10 mL of deionized water. The 
precipitate was washed from the filter with a mixture of 10:1 chloroform/methanol and 
concentrated by rotary evaporation.  The majority of the crude red solid, which was a mixture 
containing a 52% yield of EMCFK(alloc)-PABC-Doxaz, was moved forward without any additional 
purification.  However, to fully purify EMCFK(alloc)-PABC-Doxaz for characterization, the red 
solid was purified by preparative silica gel TLC, spotted in and eluted with 10:1 
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chloroform:methanol. The desired product (the major band) was excised, suspended and 
vortexted in the elution solvent, and centrifuged to remove the silica gel.  The solvent was 
removed by rotary evaporation to produce solid, pure EMCFK(alloc)-PABC-Doxaz that was 
immediately used without characterization to preclude degradation.  
4.2.13  Synthesis of EMCFK(PO4)-PABC-Doxaz from 
EMCFK(Nvoc)-PABC-Doxaz 
 An oven dried convex pyrex vessel was cooled under argon and charged with 
EMCFK(Nvoc)-PABC-Doxaz (15.26 mg, 0.0127 mmol) and 1.0 mL of methylene chloride and 200 
µL of glacial acetic acid.  The vessel was sealed, located 0.5 cm awar from a single black lamp 
and irradiated at 310-400 nm (principal emission at 350 nm) for 45 min.  The reaction was 
diluted with 500 µL of glacial acetic acid, and the methylene chloride removed by rotary 
evaporation.  The reaction mixture was further diluted with 500 µL of the HPLC initial 
conditions solvent system of 80% aq. Phosphate buffer and 20% acetonitrile.  Purification by 
RP-HPLC yielded 72% (11.61 mg, 0.0091 mmol) of EMCFK(PO4)-PABC-Doxaz which was 
characteriezed by 1H NMR assignments made using 1D 1H NMR and homonuclear COSY.   1H 
NMR (500 MHz, DMSO-d6) δ 0.97 (d, J = 7.2 Hz, 3H, 5’-Me), 1.05 (q, J = 8.1 Hz, 2H, K-γ), 1.34 
(dp, J = 15.0, 7.2 Hz, 6H, C, D, E), 1.64 (m, 2H, K-β), 1.71 (m, 1H, 2’), 1.82 – 1.89 (m, 1H, 2’), 2.02 
(t, J = 7.2 Hz, 2H, B), 2.10 – 2.22 (m, 2H, 8), 2.75 (dd, J = 13.8, 10.3 Hz, 1H, F-β), 2.94 (t, J = 6.5 
Hz, 2H, K-ε), 3.01 (s, 2H, 10), 3.05 (dd, J = 14.0, 4.1 Hz, 1H, F-β), 3.31 (t, J = 7.2 Hz, 2H, A), 3.96 
(dd, J = 6.0, 2.4 Hz, 1H, 4’), 4.00 (s, 3H, 4-OMe), 4.06 (dt, J = 7.5, 5.7 Hz, 1H, 3’), 4.27 (p, J = 7.0 
Hz, 1H, 5’), 4.38 (m, 1H, K-α), 4.54 (td, J = 9.5, 9.0, 4.2 Hz, 1H, F-α), 4.77 (dd, J = 5.0, 2.3 Hz, 2H, 
14), 4.87 (d, J = 3.5 Hz, 1H, OCH2N), 4.89 (d, J = 3.5 Hz, 1H, OCH2N), 4.94-5.01 (m, 2H, Bn), 5.02-
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5.10(m, 1H, 7),  5.24 (s, 2H, Bn),  5.36 (t, J = 4.3 Hz, 1H, 1’), 7.00 (s, 2H, maleimide), 7.20 – 7.37 
(m, 5H, F), 7.51 (m, 2H, PABA), 7.63 (m, 2H, PABA), 7.83 – 7.92 (m, 1H, 3, 1H, 2), 8.04 (d, J = 7.7 
Hz, 1H, 1), 8.03 (d, J = 8.4 Hz, 1H, F-NH), 8.25 (d, J = 7.8 Hz, 1H, K-NH), 10.11 (s, 1H, anilide). 
4.3 Results and Discussion 
4.3.1 Synthesis of EMCFKPABCDoxaz (EMC-FK-Doxaz) 
 In an attempt to explore routes to a commercially scalable process to EMC-FK-Doxaz, 
the historically most problematic synthetic aspect was altered in three ways.  The problematic 
deprotection of the lysine in the final step was addressed by using the allyloxycarbonyl (alloc), 
ortho-nitroveratryloxycarbonyl (Nvoc) and the azide protecting groups on the ε-amino of L-
lysine.  The 9-fluoroxycarbonyl (Fmoc) protected versions of each lysine are shown in Figure 
4.3.1.1.  A general synthetic scheme for the desired prodrug is shown in Scheme 4.3.1.1. 
 
Figure 4.3.2.1 Fmoc and ε-amino protected lysines used 
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Scheme 4.3.1. 1  General scheme for the synthesis of EMCFKPABCDoxaz (EMC-FK-Doxaz). 
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4.3.1.1 EMCFK(alloc)PABCDoxaz 
 Synthesis of the maleimide-peptide-spacer was accomplished using established solid 
phase peptide synthetic techniques.  Standard Fmoc deprotection methodology, and the 
loading of 6-maleimidocaproic acid as an amino acid allowed facile synthesis on a robotic 
peptide synthesizer.  Cleavage from resin using TFA, and subsequent precipitation of the 
maleimide-peptide-spacer conjugate from water went smoothly, and in 91% yield.  
Interestingly, the activation of the benzyl alcohol with p-nitrophenylchloroformate (pNP-
chloroformate) under varying conditions with this molecule, led to advancements in other 
syntheses previously described.  Effort was expended on the investigation of various solvent 
systems and reagent stoichiometry in an attempt to create a clean, scalable reaction.  It was 
learned that the use of a mixed anhydrous solvent system of tetrahydrofuran (THF) and 
methylene chloride in varying ratios, while effective at solvating the reagents, especially the 
peptide conjugate, impeded the reactions progress.  With mixed solvent systems, and varying 
amounts of pyridine and pNP-chloroformate, yields of 40 – 76% were obtained.  We also 
observed that formation of the stable and difficult to remove bis-p-nitrophenyl carbonate, was 
prevalent in the mixed solvent systems.  The observation that the final products, however 
impure, were seemingly quite soluble in THF, as was pNP-chloroformate, led to the 
heterogeneous reaction described in section 4.2.  The addition of pNP-chloroformate and 
pyridine to a suspension of EMCFK(alloc)PABA in anhydrous THF, quickly led to the solvated 
product.   
 As previously described, the coupling of Doxaz to the mixed carbonate continues to be 
inefficient due to the poor reactivity of the oxazolidine nitrogen; however, reaction conditions 
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and yields were on par with previous observations.  There was some concern that Michael 
addition to the maleimide could occur; however, if this did occur, it did not change the overall 
yield based on previous experience.   
 Deprotection of the alloc protecting group with tetrakistriphenlphosphine Pd(0) was 
attempted in THF, methylene chloride, chloroform and mixtures in varying ratios to no avail.  
Use of catalytic to stoichiometric amounts of palladium presented a reaction that could only 
partially proceed, or form multiple side products, and possibly polymerize based on HPLC 
observations.  We hypothesized that the ε-amino of lysine, once deprotected, would react 
quickly by 1,4-addition to the maleimide.  The large amount of observed products made this a 
difficult hypothesis to prove, and the aim of the project was to find a scalable reaction, so this 
method was quickly abandoned.  Use of N-iodosuccinimide and trifluoroacetic acid  as 
described in Chapter 2 was also attempted, leading once again to multiple products that were 
not characterized.  
4.3.1.2 EMCFK(Nvoc)PABCDoxaz 
 The use of ortho-nitroveratryloxycarbonyl (Nvoc) was next explored.  The manufacturing 
utility of a photocleavable amino acid protecting group was not clear.  Fmoc-Lys(Nvoc)-OH was 
used for SPPS.  It had previously been shown that the Nvoc group was compatible with the 
maleimide.60  Photodeprotection can be achieved using ultraviolet irradiation at λ > 280 nm and 
occurs through a p-nitrobenzyl photocleavage  reaction as outlined in See Scheme 4.3.1.2.1.  
Fmoc-Lys(Nvoc)-OH was not commercially available, and a commercial shortage of Nvoc 
chloroformate coupled with the desire to create a safe scalable method led to an improved 
synthetic procedure.  Elimination of gaseous phosgene by using triphosgene was first 
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attempted in dioxane.  This led to formation of large amounts of the bis-Nvoc carbonate.  A 
simple switch to anhydrous THF and stepwise addition of the benzyl alcohol to a phosgene 
solution led to quantitative formation of the Nvoc chloroformate after off-gassing of the 
unreacted phosgene and the newly formed HCl gas.  See Scheme 4.3.1.2.2.  Large scale 
production in this manner would require careful handling due to the production of the highly 
toxic HCl and phosgene gasses.   
The literature procedure for the addition of the Nvoc chloroformate to Fmoc-Lys(OH) in 
mixed solvent system of dioxane/acetonitrile/water in the presence of sodium carbonate60 was 
problematic in our hands.  Formation of multiple viscous products that exhibited no solubility in 
standard solvents was observed.  It was hypothesized that under these conditions, reaction of 
the lysine carboxylic acid with the Nvoc chloroformate occurred more quickly than reaction at 
the lysine ε-amino, and once the mixed carbonate was formed, the lysine ε-amino could 
displace the 2-nitro-4,5-dimethoxybenzyl alcohol forming a complex mixture of polymers of 
varying length.  Based on the observations that Nvoc chloroformate was easily formed, and 
highly soluble in THF, and the problematic deprotonation of the lysine carboxylic acid under 
basic conditions, a heterogeneous reaction was attempted.  The rationale was that unlike the 
Nvoc chloroformate the ε-amino protonated HCl salt of Fmoc lysine (Fmoc-Lys(HCl)-OH) would 
only be very partially soluble in THF.  The small equilibrated amount of the free ε-amino lysine 
would react quickly with the Nvoc chloroformate, and remain solvated.  This would push the 
equilibrium toward the desired, and now solvated product.  Initially this procedure seemed to 
have only a small statistical chance for success, but based on previous success with 
heterogeneous solutions in THF, it was attempted, and in fact was highly successful.   
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 With Fmoc-Lys(Nvoc)-OH in hand, SPPS of the desired maleimide-peptide-spacer 
conjugate and activation to the EMCFK(Nvoc)-pNP carbonate went smoothly and analogously 
to the procedures described in section 4.3.1.1 for EMCFK(alloc)-pNP.  Coupling to Doxaz also 
proceeded similarly to previous procedures, and afforded yields of 55% as expected.  
Deprotection by ultraviolet irradiation in acetonitrile/water solvent systems were ineffective.  
Dissolution of the protected Doxaz conjugate in five parts methylene chloride and one part 
acetic acid yielded one major product as observed by HPLC after ultraviolet irradiation at 270 
nm for 45 min.  Purification by either preparative TLC or preparative HPLC produced the desired 
product in 74% yield as calculated by optical density.   
 
 
Scheme 4.3.1.2. 1  Proposed mechanism for p-nitrobenzyl photodeprotection of the Nvoc 
group. 
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Scheme 4.3.1.2.2 Formation of Nvoc chloroformate using triphosgene. 
4.3.1.3 EMCFK(azide)PABCDoxaz 
 In an attempt to explore alternate protecting strategies for Doxaz prodrugs containing 
lysine, Fmoc-Lys(azide)-OH was employed.  This reagent recently became commercially 
available, but at an exorbitantly high cost.  The final reaction of the azide to primary amine is 
through the use of a Staudinger reaction using triphenylphosphine.  The mechanism for the 
Staudinger deprotection is shown in Scheme 4.3.1.3.1.  As can be seen, triphenylphosphine 
oxide is a byproduct of the reaction.  Triphenylphosphine oxide is notoriously difficult to 
remove; however, the chemoselective reaction was attractive for our needs.  Peptide synthesis 
using standard Fmoc procedures was performed, and unexpectedly, the yield of final peptide 
was very low at 42%.  Activation using similar methods as above, only yielded 52% of a very 
impure product.  Many byproducts were observed by HPLC.  Additionally, peptide stored at -20 
:C was also showing degradation over time.  We hypothesized that the azide was reacting, even 
in the solid phase, with the maleimide.  Instability upon storage has been observed by 
manufacturers of azide-peg4-maleimide molecules used for click and bioconjugate chemistries.  
These manufactures now sell these molecules as a kit that can assemble in situ.  With a high 
price, low yields and unpredictable reactivity, the azide protecting group on lysine was 
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determined to be ineffective for the projects goal of scalable, high yielding chemistries, and 
further investigation was not warranted.   
 
Scheme 4.3.1.3.1 Mechanism of Staudinger deprotection of azide protected Lysine. 
 
4.4 Conclusions 
 The purpose of this project was to demonstrate that simple, scalable prodrugs of Doxaz 
of the type EMC-PAD-Doxaz could be synthesized.  In this respect the project was a success.  
The exploration of alternate reaction pathways is critical to the success of any Doxaz 
commercialization endeavor.  EMCPPDoxaz will be tested in more in vivo models soon, and 
funding for a second species of animal is being explored.  The Koch group is currently seeking 
collaborative partners and funding to examine EMCFKPABCDoxaz.  In vitro  experiments are 
ongoing at the time of this writing.   
4.5 References 
1. Elsadek, B.; Kratz, F. Impact of albumin on drug delivery — New applications on the 
horizon. J. Control. Release. 2012, 157, 4–28. 
2. Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and 
nanoparticles. J. Control. Release. 2008, 132, 171–183. 
3. Park, K. Albumin: A versatile carrier for drug delivery.  J. Control. Release. 2012, 157, 3. 
(Epub 2011.  
 114 
4. Kratz, F.; Roth, T.; Fichiner, I.; et al. In vitro and in vivo efficacy of acid-sensitive 
transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-
MB-435 mamma carcinoma model, J. Drug. Target. 2000, 8, 305–318. 
5. Maeda, H.; Ueda, M.; Morinaga, T.; et al. Conjugation of poly(styrene-comaleic acid) 
derivatives to the antitumor protein neocarzinostatin: pronounced improvements in 
pharmacological properties. J. Med. Chem. 1985, 28, 455–461. 
6. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer 
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent 
smancs.  Cancer. Res. 1986, 46, 6387–6392. 
7. Lindholm, A. New insulins in the treatment of diabetes mellitus. Best. Pract. Res. Clin. 
Gastroenterol. 2002, 16, 475-492. 
8. Hamilton-Wessler, M.; Ader, M.; Dea, M.; et al. Mechansim of protracted metabolic 
effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. 
Diabetologia. 1999, 42, 1254-1263. 
9.  Standl, E. Insulin analogues - state of the art.  Horm. Res. 2002, 57, Suppl 1:40-45. 
10. Wootten, D.; Savage, E.E.; Valant, C.; et al. Allosteric modulation of endogenous 
metabolites as an avenue for drug discovery. Mol. Pharmacol. 2012, May 10. [Epub ahead of 
print]. 
11. Flisiak, R.; Flisiak, I. Albinterferon-alpha 2b: a new treatment option for hepatitis C. 
Expert. Opin. Biol. Ther. 2010, 10, 1509–1515. 
12. Nelson, D.R.; Benhamou, Y.; Chuang, W.L.; et al. Albinterferon Alfa-2b was not inferior 
to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus 
genotype 2 or 3. Gastroenterology. 2010, 139, 1267–1276. 
13. Zeuzem, S.; Sulkowski, M.S.; Lawitz, E.J.; et al. Albinterferon Alfa-2b was not inferior to 
pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus 
genotype 1. Gastroenterology. 2010, 139, 1257–1266.         
14. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin 
Pharmacother. 2006. 7, 1041-1053. 
15. Cortes J.; Saura C. Nanopartcle albumin-bound (nab™)-paclitaxel: improving efficacy and 
tolerability by targeted drug delivery in metastatic breast cancer. Eur. J. Cancer. Suppl. 2010, 8, 
1-10. 
16. Taxotere (docetaxel) Injection Concentrate [Package Insert]. Aventis Pharmaceutical 
Products, Inc.; Bridgewater, NJ: 2003. 
17. Taxol (paclitaxel) Injection [Package Insert]. Brystol-Meyers Squibb Co.; Princeton, NJ: 
2003. 
 115 
18. Weiss, R.B.; Donehower, R.C.; Wiernik, P.H.; et al. Hypersensitivity reactions from taxol. 
J. Clin. Oncol. 1990, 8, 1263-1268. 
19. ten Tije, A.J.; Verweij, J.; Loos, W.J.; et al. Pharmacological effects of formulation 
vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 2003, 42, 665-685. 
20. Authier, N.; Gillet, J.P.; Fialip, J.; et al. Assessment of neurotoxicity following repeated 
cremophor/ethanol injections in rats. Neurotox. Res. 2001, 3, 301-306. 
21. Postma, T.J.; Vermorken, J.B.; Liefting, A.J.M.; et al. Paclitaxel-induced neuropathy. Ann. 
Oncol. 2004, 6, 484-494. 
22. Gelderblom, H.; Verweij, J.; Nooter, K.; et al. Cremophor EL: the drawbacks and 
advantages of vehicle selection for drug formulation. Eur. J. Cancer. 2001, 37, 1590-1598. 
23. Winer, E.P.; Berry, D.A.; Woolf, S.; et al. Failure of higher-dose paclitaxel toimprove 
outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J. 
Clin. Oncol. 2004, 22, 2061-2068. 
24. Gradishar, W.J.; Krasnojon, D.; Cheporov, S.; et al. Significantly longer progression-free 
survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast 
cancer. J. Clin. Oncol. 2009, 27, 3611–3619. 
25. Hawkins, M.J.; Soon-Shiong, P.; Desai, N. Protein nanoparticles as drug carriers in clinical 
medicine. Adv. Drug. Deliv. Rev. 2008, 60, 876–885. 
26. Desai, N.; Trieu, V.; Damascelli, B.: et al. SPARC expression correlates with tumor 
response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2009, 2, 
59–64. 
26. Tiruppathi, C.; Song, W.; Bergenfeldt, M.; et al. Gp60 activation mediates albumin 
transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J. Biol. Chem. 1997, 272, 
25968–25975. 
27. Schnitzer, J.E. gp60 is an albumin-binding glycoprotein expressed by continuous 
endothelium involved in albumin transcytosis. Am. J. Physiol. 1992, 262, (1 Pt 2) H246–H254. 
28. Wang, Z.; Tiruppathi, C.; Minshall, R.D.; et al. Size and dynamics of caveolae studied 
using nanoparticles in living endothelial cells. ACS. Nano. 2009, 3, 4110–4116. 
29. Sage, H.; Johnson, C.; Bornstein, P. Characterization of a novel serum albuminbinding 
glycoprotein secreted by endothelial cells in culture. J. Biol. Chem. 1984, 259, 3993–4007. 
30. Podhajcer, O.L.; Benedetti, L.G.; Girotti, M.R.; et al. The role of the matricellular protein 
SPARC in the dynamic interaction between the tumor and the host.  Cancer. Metastasis. Rev. 
2008, 27, 691–705. 
 116 
31. Kratz, F.; Müller-Driver, R.; Hofmann.; et al. A novel macromolecular prodrug concept 
exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J. Med. 
Chem. 2000, 43, 1253–1256. 
32. Kratz, F.; Warnecke, K.; Scheuermann, C.; et al. Probing the cysteine-34 position of 
endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an 
acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that 
of the parent compound. J. Med. Chem. 2002, 45, 5523–5533. 
33. Graeser, R.; Esser, N.; Unger, H.; et al. INNO-206, the (6-maleimidocaproyl hydrazone 
derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in 
different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest. New. 
Drugs. 2010, 28, 14–19. Epub 2009, Jan 8.  
34. Unger, C.; Häring, B.; Medinger, M.; et al. Phase I and pharmacokinetic study of the (6-
maleimidocaproyl) hydrazone derivative of doxorubicin. Clin. Cancer. Res. 2007, 13, 4858–4866. 
35. Kratz, F.; Fichtner, I.; Graeser, R. Combination therapy with the albumin-binding prodrug 
of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves 
tolerability in an ovarian A2780 xenograft model. Invest. New. Drugs. 2011, [Epub ahead of 
print]. 
36. Calderón, M.; Welker, P.; Licha,K.; et al. Development of efficient acid cleavable 
multifunctional prodrugs derived from dendritic polyglycerol with a poly(ethylene glycol) shell. 
J. Control. Release. 2011, 151, 295–301.  
37.  Hofmann, U.B.; Westphal, J.R.; van Muijen, G.N.P.; et al. Matrix metalloproteinases in 
human melanoma. J. Investig. Dermatol. 2000, 115, 337–344.  
38.  Curran, S.; Murray, G.I. Matrix metalloproteinases in tumour invasion and metastasis. J. 
Pathol. 1999, 189, 300–308.  
39. Chambers, A.F.; Matrisian, L. M. Changing views of the role of matrix metalloproteinases 
in metastasis. J. Natl. Cancer. Inst. 1997, 89, 1260–1270. 
40. Hofmann, U.B.; Westphal, J.R.; Waas, E.T.; et al. Matrix metalloproteinases in human 
melanoma cell lines and xenografts: increased expression of activated matrix 
metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br. J. Cancer. 1999, 81, 
774–782. 
41. Sun, W.; Schuchter, L.M. Metastatic melanoma. Curr. Treat. Options. Oncol. 2001, 2, 
193–202. 
42. Kurschat, P.; Zigrino, P.; Nischt, R.; et al. Tissue inhibitor of matrix metalloproteinase-2 
regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix 
metalloproteinaseactivity in high and low invasive melanoma cell lines. J. Biol. Chem. 1999, 274, 
21056–21062. 
 117 
43. Fiebig, H.H.; Klostermeyer, A.; Schüler, J.B.; et al. Characterization of matrix 
metalloproteinases in 47 human tumor xenografts show high expression of MMP-2 in 
melanomas and sarcomas. Proc. Am. Assoc. Cancer. Res. 1999, 40, 463. 
44. Väisänen, A.; Tuominen, H.; Kallioinen, M.; et al. Matrix metalloproteinase-2 (72 kD type 
IV collagenase) expression occurs in the early stage of human melanocytic tumour progression 
and may have prognostic value. J. Pathol. 1996, 180, 283–289. 
45. Mansour, A.M.; Drevs, J.; Esser, N.; et al. A New Approach for the Treatment of 
Malignant Melanoma: Enhanced Antitumor Efficacy of an Albumin-binding Doxorubicin Prodrug 
That Is Cleaved by Matrix Metalloproteinase 2. Cancer. Res. 2003, 63, 4062-4066. 
46. Abu Ajaj, K.; Graeser, R.; Fichtner, I.; et al. In vitro and in vivo study of an albumin-
binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer. Chemother. Pharmacol. 
2009, 64, 413–418.  
47. Turk, B.; Turk, D.; Turk, V. Lysosomal cysteine proteases: more than scavengers. 
Biochim. Biophys. Acta. 2000, 1477, 98–111. 
48. Buck, M.R.; Karustis, D.G.; Day, N.A.; et al. Degradation of extracellular-matrix proteins 
by human cathepsin B from normal and tumour tissues. Biochem. J. 1992, 282, 273–278. 
49. Mai, J.; Sameni, M.; Mikkelsen, T.; et al. Degradation of extracellular matrix protein 
tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol. Chem. 
2002, 383, 1407–1413. 
50. Barthel, B.L.; Zhang, Z.; Rudnicki, D.L.; et al. Preclinical efficacy of a carboxylesterase 2-
activated prodrug of Doxazolidine. J. Med. Chem. 2009, 52, 7678-7688. 
51. Barthel, B.L.; Torres, R.C.; Hyatt, J.L.; et al. Identification of human intestinal 
carboxylesterase as the primary enzyme for activation of a doxazolidine carbamate prodrug. J. 
Med. Chem. 2008, 51, 298-304. Epub 2008 Jan 4. 
52. Burkhart, D.J.; Barthel, B.L.; Post, G.C.; et al. Design, Synthesis, and Preliminary 
Evaluation of Doxazolidine Carbamates as Prodrugs Activated by Carboxylesterases.  J. Med. 
Chem. 2006, 49, 7002-7012. 
53. Burke, P.J.; Koch, T.H. Design, synthesis, and biological evaluation of doxorubicin-
formaldehyde conjugates targeted to breast cancer cells. J. Med. Chem. 2004, 47, 1193-1206. 
54. Burke, P.J.; Koch, T.H. Doxorubicin-formaldehyde conjugate, doxoform: induction of 
apoptosis relative to doxorubicin. Anticancer. Res. 2001, 21, 2753-2760. 
55. Walko, C.M.; Lindley, C. Capecitabine: a review. Clin. Ther. 2005, 27, 23-44. 
56. Parker, W.B.; Y.C. Cheng. Metabolism and mechanism of action of 5-fluorouracil. 
Pharmacol. Ther. 1990, 48, 381-95. 
 118 
57. Wagstaff, A.J.; Ibbotson, T.; Goa, K.L. Capecitabine: a review of its pharmacology and 
therapeutic efficacy in the management of advanced breast cancer. Drugs. 2003, 63, 217-236.  
58. Post, G. C.; Barthel, B. L.; Burkhart, D. J.; Hagadorn, J. R.; Koch, T. H. Doxazolidine, a 
proposed active metabolite of doxorubicin that cross-links DNA. J Med Chem. 2005, 48, 7648-
57. 
59. Gude, M.; Ryf, J.; White, P. An accurate method for quantitation of Fmoc-derivitized 
solid phase supports. Letters in Peptide Science. 2002, 9, 203-206. 
60. Rusiecki, V.K.; Warne,S.A. Synthesis of Nα-Fmoc-Nε-Nvoc-Lysine and use in the 
preparation of selectively functionalized peptides. Bioorg. Med. Chem. Lett. 1993. 3, 707-710. 
  
 119 
Collected Bibliography 
Chapter 1 Introduction 
1. Weiss, R.B. The anthracyclines: will we ever find a better doxorubicin?. Semin. Oncol. 
1992, 19, 670-686. 
 
2. Tan, C.; Tasaka, H.; Yu, K.P.; Murphy, M.L.; et al. Daunomycin, an antitumor antibiotic, in 
the treatment of neoplastic disease. Clinical evaluation with special reference to 
childhood leukemia. Cancer. 1967, 20, 333-353. 
 
3. Arcamone, F.; Cassinelli, G.; Fantini, G.; et al. Adriamycin, 14-hydroxydaunomycin, a new 
antitumor antibiotic from S. peucetius var. caesius. Biotechnol. Bioeng. 1969, 11, 1101-
1110. 
 
4. Di Marco, A.; Gaetani, M.; Scarpinato, B. Adriamycin (NSC-123,127): a new antibiotic 
with antitumor activity. Cancer. Chemother. Rep. 1969, 53, 33-37. 
 
5. Young, R.C.; Ozols, R.F.; Myers, C.E. The anthracycline antineoplastic drugs. N. Engl. J. 
Med. 1981, 305, 139-153. 
 
6. Merck pharmaceuticals Home Page. http://Merck.com (accessed January 2012).  
 
7. Von Hoff, D.D.; Layard, M. Risk factors for the development of daunorubicin 
cardiotoxicity. Cancer. Treat. Rep. 1982, 65, 19-24. 
 
8. Bristow, M.R.; Mason, J.W.; Billingham, M.E.; et al: Doxorubicin cardiomyopathy: 
Evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. 
Ann. Intern. Med. 1978, 88, 168-175. 
 
9. Von Hoff, D.D.; Layard, M.W.; Basa, P.; et al. Risk factors for doxorubicin-induced 
congestive heart failure. Ann. Intern. Med. 1979, 91, 710-717.  
 
10. Praga, C.; Beretta, G.; Vigo, P.L.; et al. Adriamycin cardiotoxicity: A survey of 1,273 
patients. Cancer. Treat. Rep. 1979, 63, 827-834. 
 
11. Suzuki, T.; Kanda, H.; Kawai, Y.; et al. Cardiotoxicity of anthracycline antineoplastic 
drugs-Clinicopathological and experimental studies. Jpn. Circ. J. 1979, 43, 1000-1008. 
 
12. Gralla, E.J.; Fleischman, R.W.; Luthra, Y.K.; et al. The dosing schedule dependent 
toxicities of Adriamycin in beagle dogs and rhesus monkeys. Toxicology. 1979, 13, 263-
273. 
 120 
13. Chlebowski, R.T.; Paroly, W.S.; Pugh, R.P.; et al. Adriamycin given as a weekly schedule 
without a loading dose: Clinically effective with reduced incidence of cardiotoxicity. 
Cancer. Treat. Rep. 1980, 64, 47-51. 
 
14. Minow, R.A.; Benjamin, R.S.; Gottlieb, J.A. Adriamycin (NSC-123127) cardiomyopathy-An 
overview with determination of risk factors. Cancer. Chemother. Rep. 1975, 6, 195-201. 
 
15. Buzdar, A.U.; Legha, S.S.; Tashima, C.K.; et al. Adriamycin and mitomycin C: Possible 
synergistic cardiotoxicity. Cancer. Treat. Rep. 1978, 62, 1005-1008. 
 
16. Bhanot, P.; Cushing, B.; Philippart, A.; et al. Hepatic irradiation and adriamycin 
cardiotoxicity. J. Pediatr. 1979, 95, 561-563. 
 
17. Beretta, G.; Villani, F. Cardiomyopathy in adults after combination Adriamycin and D1IC 
(Letter). Cancer. Treat. Rep. 1980, 64, 353. 
 
18. Mosijczuk, A.D.; Ruymann, F.B.; Mease, A.D.; et al. Anthracycline cardiomyopathy in 
children:report of two cases. Cancer. 1979, 44, 1582-1587. 
 
19. Steinherz, L.J.; Steinherz, P.G.; Mangiacasale, D.; et al. Cardiac abnormalities after AMSA 
administration. Cancer. Treat. Rep. 1982, 66, 483-488. 
 
20. Gottlieb, S.L.; Edmiston, A.; Haywood, l.J. Late, late doxorubicin cardiotoxicity. Chest 
1980, 78, 880-882. 
 
21. Lefrak, E.A.; Pitha, J.; Rosenheim, S., et al. Adriamycin (NSC-123127) cardiomyopathy. 
Cancer. Chemother. Rep. 1975, 6, 203-208. 
 
22. Doroshow, J.H.; Locker, G.Y.; Myers, C.E. Experimental animal models of adriamycin 
cardiotoxicity. Cancer. Treat. Rep. 1979, 63, 855-860. 
 
23. Doroshow, J.H.; Locker, G.Y.; Myers, C.E. Enzymatic defenses of the mouse heart against 
reactive oxygen metabolites: alterations produced by doxorubicin. J. Clin. Invest. 1980, 
65, 128-135. 
 
24. Myers, C.E.; McGuire, W.P.; Liss, R.H.; et al. Adriamycin: The role of the lipid 
peroxidation in cardiac toxicity and tumor response. Science. 1977, 197, 165-167. 
 
25. Stuart, M.J.; deAlarcon, P.A.; Oski, F.A. Inhibition of Adriamycin(ADR) induced lipid 
peroxidation by α-tocopherol (α-T) and acetylsalicylic acid (ASA) (abstr). Pediatr. Res. 
1978, 12, 474. 
 
26. Flohé, L.; Zimmermann, R. The role of GSH peroxidase in protecting the membrane of 
rat liver mitochondria. Biochem. Biophys. Acta. 1970, 223, 210-213. 
 121 
 
27. Chow, C.K.; Tappel, A.L. Response of glutathione peroxidase to dietary selenium in rats. 
J. Nutr. 1974, 104, 444-451. 
 
28. Thayer, W.S. Adriamycin stimulated superoxide formation in submitochondrial particles. 
Chem. Biol. Interact. 1977, 19, 265-278. 
 
29. Olson, R.D.; MacDonald, J.S.; vanBoxtel, C.J.; et al. Regulatory role of glutathione and 
soluble sulfhydryl groups in the toxicity of adriamycin. J. Pharmacol. Exp. Ther. 1980, 
215, 450-454. 
 
30. Kosower, E.M. A role for glutathione in muscle contraction. Experientia. 1970, 26, 760-
761. 
 
31. Kishi, T.; Folkers, K. Prevention by coenzyme Q1O (NSC-140865) of the inhibition by 
adriamycin (NSC-123127) of coenzyme Q10 enzymes (Letter). Cancer. Treat. Rep. 1976, 
60, 223-224. 
 
32. Kishi, T.; Watanabe, T.; Folkers, K. Bioenergetics in clinical medicine: Prevention by 
forms of coenzyme Q of the inhibition by adriamycin of coenzyme Q10-enzymes in 
mitochondria of the myocardium. Proc. Natl. Acad. Sci .USA. 1976, 73, 4653-4656. 
 
33. Minotti, G; Recalcati, S; Mordente, A.; et al. The secondary alcohol metabolite of 
doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic 
fractions from human myocardium. Faseb J. 1998, 12, 541-552.  
 
34. Hentze, M.W.; Kühn, L.C. Molecular control of vertebrate iron metabolism: mRNA-based 
regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. 
Sci. USA. 1996, 93, 8175–8182. 
 
35. Minotti, G.; Cavaliere, A.F.; Mordente, A.; et al. Secondary alcohol metabolites mediate 
iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer 
anthracyclines  Novel linkage between anthracycline metabolism and iron-induced 
cardiotoxicity. J. Clin. Invest. 1995, 95, 1595–1605. 
 
36. Minotti, G.; Cairo, G.; Monti, E. Role of iron in anthracycline cardiotoxicity: new tunes 
for an old song?. Faseb J. 1999, 13, 199-212. 
 
37. Kühn, L.C.; Hentze, M.W. Coordination of cellular iron metabolism by post-
transcriptional gene regulation. J. Inorg. Biochem. 1992, 47, 183-195. 
 
38. Mascotti, D.P.; Rup, D.; Thach, R.E. Regulation of iron metabolism: translational effects 
mediated by iron, heme, and cytokines.  Annu. Rev. Nutr. 1995, 15, 239-261. 
 
 122 
39. Taatjes, D.J.; Gaudiano, G.; Koch, T.H.  Production of formaldehyde and DNA-adriamycin 
or DNA-daunomycin adducts, initiated through redox chemistry of dithiothreitol/iron, 
xanthine oxidase/NADH/iron, or glutathione/iron. Chem. Res. Toxicol. 1997, 10, 953-
961. 
 
40. Capranico, G.; Zunino, F. DNA topoisomerase-trapping antitumor drugs. Eur. J. Cancer. 
1992, 28, 2055-2060. 
 
41. Zunino, F.; Capranico, G. Sequence-selective groove binders. In: Tericher B (ed) Cancer 
therapeutics: experimental and clinical agents(Humana press, Totowa New Jersey 1997). 
 
42. Capranico, G.; Binaschi, M.; Borgnetto, M.E.; et al. A protein-mediated mechanism for 
the DNA sequence-specific action of topoisomerase II poisons. Trends. Pharmacol. Sci. 
1997, 18, 323-329. 
 
43. Gewirtz, D.A. A critical evaluation of the mechanisms of action proposed for the 
antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. 
Biochem. Pharmacol. 1999, 57, 727-741. 
 
44. Yoda, Y.; Nakazawa, M.; Abe T.; et al. Prevention of doxorubicin myocardial toxicity in 
mice by reduced glutathione. Cancer. Res. 1986, 46, 2551-2556. 
 
45. Cervantes, A.; Pinedo, H.M.; Lankelma, J.; Schuurhuis, G.J. The role of oxygen-derived 
free radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive 
human ovarian cancer cells. Cancer. Lett. 1988, 41, 169-177. 
 
46. Shimpo, K.; Nagatsu, T.; Yamada, K.;  et al. Ascorbic acid and adriamycin toxicity. Am. J. 
Clin. Nutr. 1991, 54, 1298S-1301S. 
 
47. Myers, C.; Bonow, R.; Palmeri, S.; et al. A randomized controlled trial assessing the 
prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. 1983, 10, 
Suppl 1, 53-55. 
 
48. Wang, A.H.; Gao, Y.G.; Liaw, Y.C.; Li, Y.K. Formaldehyde cross-links daunorubicin and 
DNA efficiently: HPLC and X-ray diffraction studies. Biochemistry. 1991, 30, 3812-3815. 
 
49. Podell, E.R.; Harrington, D.J.; Taatjes, D.J.; Koch T.H. Crystal structure of epidoxorubicin-
formaldehyde virtual crosslink of DNA and evidence for its formation in human breast-
cancer cells. Acta. Crystallogr. D. Biol. Crystallogr. 1999, 55, Pt 9, 1516-1523.  
 
50. Taatjes, D.J.; Gaudiano, G.; Resing, K.; Koch T.H. Alkylation of DNA by the anthracycline, 
antitumor drugs adriamycin and daunomycin. J. Med. Chem. 1996, 39, 4135-4138. 
 
 123 
51. Swift, L.P.; Rephaeli, A.; Nudelman, A.; et al. Doxorubicin-DNA adducts induce a non-
topoisomerase II-mediated form of cell death. Cancer. Res. 2006, 66, 4863-4871.    
 
52. Nielsen, D.; Maare, C.; and Skovsgaard, T. Cellular resistance to anthracyclines. Gen. 
Pharmacol. 1996, 27, 251-255. 
 
53. Longley, D.B.; Johnston, P.G. Molecular mechanisms of drug resistance. J. Pathol. 2005, 
205, 275-292. 
 
54. Higgins, C.F. ABC transporters: from microorganisms to man. Annu. Rev. Cell. Biol. 1992, 
8, 67-113.  
 
55. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug resistance mediated by the 
multidrug transporter. Annu. Rev. Biochem. 1993, 62, 385-427. 
 
56. Arcamone, F. Doxorubicin Anticancer Antibiotics: Medicinal Chemistry, a Series of 
Medicinal Chemistry, Vol 17, (Academic Press, New York, 1981) 
 
57. Kharsaw, M.; Bell, R.; Dang, C. Epirubicin: Is it like doxorubicin in breast cancer? A 
clinical review. Breast. 2012, 21, 142-149. Jan 17 [Epub ahead of print]. 
 
58. Fields, S.M.; Koeller, J.M. Idarubicin: a second-generation anthracycline. Dicp, 199,. 25, 
505-517. 
 
59. Mross, K.B.; Langenbuch, T.; Burk, K.;. Hossfeld, D.K. [Iodo-doxorubicin, a new 
anthracycline derivative. Current state of progress]. Onkologie, 1990, 13, 346-351. 
 
60. Koeller, J.; Eble, M. Mitoxantrone: a novel anthracycline derivative. Clin Pharm, 1988, 7 
574-581. 
 
61. Onrust, S.V. and H.M. Lamb, Valrubicin. Drugs Aging, 1999, 15, 69-75. 
 
62. Goebel, M., Oral idarubicin--an anthracycline derivative with unique properties. Ann 
Hematol, 1993, 66, 33-43. 
 
63. Yoo, H.S.; Park, T.G. Folate receptor targeted biodegradable polymeric doxorubicin 
micelles. J. Control. Release. 2004, 96, 273-283. 
 
64. Shmeeda, H.; Mak, L.; Tzemach, D.; et al. Intracellular uptake and intracavitary targeting 
of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate 
receptors. Mol. Cancer. Ther. 2006, 5, 818-824. 
 
 124 
65. Xiong, X.B.; Huang, Y.; Lu, W.L.; et al. Enhanced intracellular delivery and improved 
antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a 
synthetic RGD mimetic. J. Control. Release. 2005, 107, 262-275. 
 
66. Schiffelers, R.M.; Koning, G.A.; ten Hagen, T.L.; et al. Anti-tumor efficacy of tumor 
vasculature-targeted liposomal doxorubicin. J. Control. Release. 2003, 91, 115-122. 
 
67. Dvorak, H.F. Leaky tumor vessels: consequences for tumor stroma generation and for 
solid tumor therapy. Prog. Clin. Biol. Res. 1990, 354A, 317-330. 
 
68. Maeda, H.; Wu, J.; Sawa, T.; et al. Tumor vascular permeability and the EPR effect in 
macromolecular therapeutics: a review. J. Control. Release. 2000, 65, 271-284. 
 
69. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood 
vessels for drug delivery, factors involved, and limitations and augmentation of the 
effect. Adv. Drug. Deliv. Rev. 2011, 63, 136-151. 
 
70. Florent, J.C.; Monneret, C. Doxorubicin Conjugates for Selective Delivery to Tumors. Top. 
Curr. Chem. 2008, 283, 99-140. 
 
71. Trail, P.A.; King, H.D.; Dubowchik, G.M. Monoclonal antibody drug immunoconjugates 
for targeted treatment of cancer. Cancer. Immunol. Immunother. 2003, 52, 328-337.  
 
72. Dubowchik, G.M.; Radia, S.; Mastalerz, H.; et al. Doxorubicin immunoconjugates 
containing bivalent, lysosomally-cleavable dipeptide linkages. Bioorg. Med. Chem. Lett. 
2002, 12, 1529-1533. 
 
73. Denny, W.A. Tumor activated prodrugs-a new approach to cancer therapy. Cancer. 
Invest. 2004, 22, 604-619.      
 
74. Dang, L.H.; Bettegowda, C.; Huso, D.L.; et al. Combination bacteriolytic therapy for the 
treatment of experimental tumors. Proc. Natl. Acad. Sci. USA. 2001, 98, 15155-15160. 
 
75. Chakravarty, P.K.; Carl, P.L.; Weber, M.J.; and Katzenellenbogen, J.A. Plasmin-activated 
prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl 
derivatives of doxorubicin.  J. Med. Chem. 1983, 26, 638-644. 
 
76. de Groot, F.M.; de Bart, A.C.; Verheijen, J.H.; et al. Synthesis and biological evaluation of 
novel prodrugs of anthracyclines for selective activation by the tumor-associated 
protease plasmin. J. Med. Chem. 1999, 42, 5277-5283. 
 
77. Albright, C.F.; Graciani, N.; Han, W.; et al. Matrix metalloproteinase–activated 
doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less 
toxicity. Mol. Cancer. Ther. 2005, 4, 751-760. 
 125 
 
78. Liu, C.; Sun, C.; Huang, H.; et al. Overexpression of legumain in tumors is significant for 
invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer. Res. 
2003,  63, 2957-2964. 
 
79. Kato, S.; Burke, P. J.; Koch, T.H.; et al. Mass spectrometric measurement of 
formaldehyde generated in breast cancer cells upon treatment with anthracycline 
antitumor drugs. Chem. Res. Toxicol. 2000, 13, 509-516.  
 
80. Post, G. C.; Barthel, B. L.; Koch, T.H.; et al. Doxazolidine, a proposed active metabolite of 
doxorubicin that cross-links DNA. J. Med. Chem. 2005, 48, 7648-7657. 
 
81. Kato, S.; Burke, P. J.; Koch, T.D.; et al. Mass spectrometric measurement of 
formaldehyde generated in breast cancer cells upon treatment with anthracycline 
antitumor drugs. Chem. Res. Toxicol. 2000, 13, 509-516. 
 
82. Fenick, D. J.; Taatjes, D. J.; Koch, T. H. Doxoform and Daunoform: Anthracycline-
formaldehyde conjugates toxic to resistant tumor cells. J. Med. Chem. 1997, 40, 2452-
2461. 
 
83. Cogan, P. S.; Fowler, C. R.; Post, G. C.; Koch, T. H. Doxsaliform:  A novel N-Mannich base 
prodrug of a doxorubicin formaldehyde conjugate. Lett. Drug Des. Dis. 2004, 1, 247-255. 
 
84. Meyer, A.; Auernheimer, J.; Modinger, A.; et al. Targeting RGD recognizing integrins: 
drug development, biomaterial research, tumor imaging and targeting. 2006, 12, 2723-
2747. 
 
85. Kalet, B.T.; McBryde, M.B.; Espinosa, J.M.; Koch, T.H. Doxazolidine induction of 
apoptosis by a topoisomerase II independent mechanism. J. Med. Chem. 2007, 50, 4493-
4500. 
 
Chapter 2 Protease Activated Prodrugs of Doxazolidine 
1. López-Otín, C.; Matrisian, L.M. Emerging roles of proteases in tumour suppression. Nat. 
Rev.  Cancer. 2007, 7, 800-808. 
2. Gabriel, D.; Zuluaga, M.F.; van den Bergh, H.; et al. It is all about proteases: From drug 
delivery to in vivo imaging and photomedicine. Curr. Med. Chem. 2011, 18, 1785–1805. 
3. Pollard, J.W. Tumour-educated macrophages promote tumour progression and 
metastasis. Nat. Rev. Cancer. 2004, 4, 71–78. 
4. Coussens, L.M.; Werb,  Z. Inflammation and cancer. Nature. 2002, 420, 860–867. 
 126 
5. Nyberg, P.; Salo, T.; Kalluri, R. Tumor microenvironment and angiogenesis. Front. Biosci. 
2008, 13, 6537-6553. 
6. Borgoño, C.A.; Diamandis, E.P. The emerging roles of human tissue kallikreins in cancer. 
Nat. Rev. Cancer. 2004, 4, 876–890. 
7. Kalluri, R. Basement membranes: structure, assembly and role in tumour angiogenesis. 
Nat. Rev. Cancer. 2003, 3, 422-433.  
8. Sund, M.; Xie, L.; Kalluri, R.  The contribution of vascular basement membranes and 
extracellular matrix to the mechanics of tumor angiogenesis. Apmis, 2004, 112, 450- 462. 
9. Bernik, M.B.; Kwaan, H.C. Plasminogen activator activity in cultures from human tissues. 
An immunological and histochemical study. J. Clin. Invest. 1969, 48, 1740–1753. 
10. Bernik, M.B.; Kwaan, H.C. Origin of fibrinolytic activity in cultures of the human kidney. J. 
Lab. Clin. Med. 1967, 70, 650–661. 
11. Blasi, F.; Carmeliet, P. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell. Biol.  
2002, 3, 932–943. 
12. Wall, M.E.; Wani, M.C.; Cook, C.E.; et al. Plant antitumor agents, I: the isolation and 
structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca 
acuminate. J. Am. Chem. Soc. 1966, 88, 3888-3890. 
13. Hsiang, Y.H.; Hertzberg, R.; Hecht, S.; et al. Camptothecin induces protein-linked DNA 
breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985, 260, 14873-14878. 
14. Rivory, L.P.; Bowles, M.R.; Robert, J.; et al. Conversion of irinotecan (CPT-11) to its active 
metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. 
Biochem. Pharmacol. 1996, 52, 1103-1111. 
15. Bencharit, S.; Morton, C.L.; Xue, Y.; et al. Structural basis of heroin and cocaine 
metabolism by a promiscuous human drug-processing enzyme. Nat. Struct. Biol. 2003, 10, 349-
356. 
16. Sanghani, S.P.; Quinney, S.K.; Fredenburg, T.B.; et al.  Hydrolysis of irinotecan and its 
oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] 
carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, 
by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, 
CES3. Drug. Metab. Dispos. 2004, 32, 505-511. 
17. Durand, M.K.; Bødker, J.S.; Christensen, A.; et al. Plasminogen activator inhibitor-I and 
tumour growth, invasion, and metastasis. Thromb. Haemost. 2004, 91, 438–449. 
18. Mignatti, P.; Rifkin, DB. Biology and biochemistry of proteinases in tumor invasion. 
Physiol. Rev. 1993, 73, 161–195. 
 127 
19. Kwaan, HC. The plasminogen-plasmin system in malignancy. Cancer. Metastasis. Rev. 
1992, 11, 291–311. 
20. Danø, K.; Andreasen, P.A.; Grøndahl –Hansen, J.; et al. Plasminogen activators, tissue 
degradation, and cancer. Adv. Cancer. Res. 1985, 44, 139–266. 
21. Kirchheimer, J.C.; Wojta, J.; Christ, G.; et al. Proliferation of a human epidermal tumor 
cell line stimulated by urokinase. Faseb.J. 1987, 1, 125–128. 
22. Kirchheimer, J.C.; Wojta, J.; Hienert, G.; et al. Effect of urokinase on the proliferation of 
primary cultures of human prostatic cells. Thromb. Res. 1987, 48, 291–298. 
23. Kwaan, H.C.; Wang, J.; Svoboda, K.; et al. Plasminogen activator inhibitor 1 may promote 
tumour growth through inhibition of apoptosis. Br. J. Cancer. 2000, 82, 1702–1708.  
24. Soff, G.A.; Sanderowitz, J.; Gately, S.; et al. Expression of plasminogen activator inhibitor 
type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumorassociated 
angiogenesis, and metastasis to lung and liver in an athymic mouse model. J. Clin. Invest. 1995, 
96, 2593–2600. 
25. Madsen, C.D.; Ferraris, G.M.; Andolfo, A.; et al. uPAR-induced cell adhesion and 
migration: vitronectin provides the key. J. Cell. Biol. 2007, 177, 927–939. 
26. Caiolfa, V.R.; Zamai, M.; Malengo, G.; et al. Monomer dimer dynamics and distribution 
of GPI-anchored uPAR are determined by cell surface protein assemblies. J. Cell. Biol. 2007, 179, 
1067–1082. 
27. Cunningham, O.;  Andolfo, A.; Santovito, M.L.; et al.  Dimerization controls the lipid raft 
partitioning of uPAR/CD87 and regulates its biological functions. EMBO. J. 2003, 22, 5994–6003. 
28. Choi, K.Y.; Swierczewska, M.; Lee, S.; et al. Protease-Activated Drug Development. 
Theranostics. 2012, 2, 156–178. 
29. Cao, Y.; Cao, R.; Veitonmäki, N. Kringle structures and antiangiogenesis. Curr. Med. 
Chem. Anticancer. Agents. 2002, 2, 667-681.  
30. Albright, C.F.; Graciani, N.; Han, w.; et al. Matrix metalloproteinase-activated 
doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less 
toxicity. Mol. Cancer. Ther. 2005, 4, 751-760. 
31.  Kline, T.; Torgov, M.Y.; Mendelsohn, B.A.; et al. Novel antitumor prodrugs designed for 
activation by matrix metalloproteinases-2 and -9. Mol. Pharm. 2004, 1, 9-22. 
32. Kratz, F.; Drevs, J.; Bing, G.; et al. Development and in vitro efficacy of novel MMP2 and 
MMP9 specific doxorubicin albumin conjugates. Bioorg. Med. Chem. Lett. 2001, 11, 2001-2006. 
 128 
33. Dubowchik, G.M.; Mosure, K.; Knipe, J.O.; et al. Cathepsin B-sensitive dipeptide 
prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. 
Bioorg. Med. Chem. Lett. 1998, 8, 3347-3352. 
34. Warnecke, A.; Fichtner, I.; Sass, G.; et al.  Synthesis, cleavage profile, and antitumor 
efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and 
cathepsin B. Arch Pharm (Weinheim). 2007, 340, 389-395. 
35. Chakravarty, P.K.; Carl, P.L.; Weber, M.J.; et al. Plasmin-activated prodrugs for cancer 
chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. J. Med. 
Chem. 1983, 26, 638-644. 
36. de Groot, F.M.; de Bart, A.C.; Verheijen, J.H.; et al. Synthesis and biological evaluation of 
novel prodrugs of anthracyclines for selective activation by the tumor-associated protease 
plasmin. J. Med. Chem. 1999, 42, 5277-5283. 
37. Devy, L.; de Groot, F.M.; Blacher, S.; et al. Plasmin-activated doxorubicin prodrugs 
containing a spacer reduce tumor growth and angiogenesis without systemic toxicity. Faseb. J. 
2004, 18, 565-567. 
38. Post, G. C.; Barthel, B. L.; Burkhart, D. J.; Hagadorn, J. R.; Koch, T. H. Doxazolidine, a 
proposed active metabolite of doxorubicin that cross-links DNA. J Med Chem. 2005, 48, 7648-
57. 
39. Gude, M.; Ryf, J.; White, P. An accurate method for quantitation of Fmoc-derivitized 
solid phase supports. Letters in Peptide Science. 2002, 9, 203-206. 
40. Low, T. L.; Goldstein, A. L. The chemistry and biology of thymosin. II. Amino acid 
sequence analysis of thymosin alpha1 and polypeptide beta1. J. Biol. Chem. 1979, 254, 987-95. 
41. Abiko, T.; Sekino, H. Synthesis of an immunologically active fragment analog of 
prothymosin alpha with enhanced enzymatic stability. Chem Pharm Bull (Tokyo). 1991, 39, 752-
756. 
42. Nguyen, L. T.; Chau, J. K.; Perry, N. A.; de Boer, L.; Zaat, S. A.; Vogel, H. J. Serum 
stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS One. 2010, 
5. 
43. Huang, Y.; Tan, M.; Gosink, M. Wang, K.W.; Sun, Yi. Histone deacetylase 5 is not a p53 
target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Cancer 
Res. 2002. 62, 2913-2922. 
44. Wilson, A.J.; Byun, D.S.; Nasser, S.; et al. HDAC4 Promotes growth of colon cancer cells 
via repression of p21. Mol. Bio. Cell. 2008, 19, 4062-4075. 
45. Gallinari, P.; Di Marco, S.; Jones, P.; Pallaoro, M.; Steinkühler, C. HDACs, histone 
deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res. 
2007, 17, 195-211.  
 129 
46. Matsuoka, H.; Fujimura, T.; Hayashi, M.; et al. Disruption of HDAC4/N-CoR complex by 
histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. Biochem. Pharm. 
2007, 74, 465-476.  
47. Avvakumov, N. Cóté. The MYST family of histone acetyltransferases and their intimate 
links to cancer. Oncogene. 2007, 26, 5395-5407.  
48. Lahm, A.; Paolini, C.; Pallaoro, M.; et al. Unraveling the hidden catalytic activity of 
vertebrate classIIa histone deacetylases. PNAS. 2007, 104, 17335-17340. 
49. Dekker, G.J.; Haisma, H.J. Histone acetyl transferases as emerging drug targets. Drug 
Discov. Today. 2009, 14, 942-948. 
 
Chapter 3 Prodrugs Activated by Hypoxic Conditions 
1.  Dewhirst, M. W.; Cao, Y; Moeller, B. Cycling hypoxia and free radicals regulate 
angiogenesis and radiotherapy response. Nature. Rev. Cancer. 2008, 8, 425–437. 
2.  Wilson, W.R; Hay, M.P. Targeting hypoxia in cancer therapy. Nature. Rev. Cancer. 11, 4, 
393-410. 
3.  Erler, J.T.; Cawthorne, C.J.; Williams, K.J.; et al. Hypoxia-mediated down-regulation of 
Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent 
mechanisms and contributes to drug resistance. Mol. Cell. Biol. 2004, 24, 2875–2889. 
4.  Cairns, R. A., Harris, I. S.; Mak, T. W. Regulation of cancer cell metabolism. Nature Rev. 
Cancer. 2011, 11, 85–95. 
5. Wang, Y.; Ohh, M. Oxygen-mediated endocytosis in cancer. J. Cell. Mol. Med. 2010, 14, 496–
503. 
6.  Kioi, M.; Vogel, H.; Schultz, G.; et al. Inhibition of vasculogenesis, but not angiogenesis, 
prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 2010, 120, 695–
705. 
7.  Hill, R.P.; Marie-Egyptienne, D.T.; Hedley, D.W. Cancer stem cells, hypoxia and 
metastasis. Semin. Radiat. Oncol. 2009, 19, 106–111. 
8.  Guzy, R.D.; Hoyos, B.; Robin, E.; et al. Mitochondrial complex III is required for hypoxia-
induced ROS production and cellular oxygen sensing. Cell. Metab. 2005, 1, 401–408. 
9.  Bristow, R.G.; Hill, R.P. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer. 
2008, 8, 180–192. 
10.  Semenza, G.L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer. 2003, 3, 721–732. 
 130 
11.  Li, F.; Sonveaux, P.; Rabbani, Z.N.; et al. Regulation of HIF-1α stability through S-
nitrosylation. Mol. Cell. 2007, 26, 63–74. 
12.  Chandel, N.S.; McClintock, D.S.; Feliciano, C.E.; et al. Reactive oxygen species generated 
at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia: a mechanism 
of O2 sensing. J. Biol. Chem. 2000, 275, 25130–25138. 
13.  Tozer, G.M.; Everett, S.A. Nitric oxide in tumor biology and cancer therapy. Part 2: 
Therapeutic implications. Clin. Oncol. (R. Coll. Radiol). 1997, 9, 357–364. 
14.  Tozer, G.M.; Everett, S.A. Nitric oxide in tumour biology and cancer therapy. Part 1: 
Physiological aspects. Clin. Oncol. (R. Coll. Radiol). 1997, 9, 282–293. 
15.  Bell, E.L.; Klimova, T.A.; Eisenbart, J.: et al. The Qo site of the mitochondrial complex III is 
required for the transduction of hypoxic signaling via reactive oxygen species production. J. Cell 
Biol. 2007, 177, 1029–1036. 
16.  Brown, J. M. Clinical trials of radiosensitizers: what should we expect? Int. J. Radiat. 
Oncol. Biol. Phys. 1984, 10, 425–420. 
17.  Connors, T.A.; Whisson, M.E. Cure of mice bearing advanced plasma cell tumours with 
aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. 
Nature. 1966, 210, 866–867. 
18.  Knox, R.J.; Boland, M.P.; Friedlos F.; et al. The nitroreductase enzyme in Walker cells 
that activates 5-(aziridin-1-yl)-2,4-dinitro-benzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxyla-
mino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. 
Pharmacol. 1988, 37, 4671–4677. 
19.  Long, D.J.; Jaiswal, A.K. NRH: quinone oxidoreductase2 (NQO2) Chemino-Biol. Interact. 
2000, 129, 99-112. 
20.  Skelly, J.V.; Knox, R.J.; Jenkins, T.C. Aerobic nitroreduction by flavoproteins: enzyme 
structure, mechanism and role in cancer chemotherapy. Mini. Rev. Med. Chem. 2001, 1, 293-
306. 
21.  Bianchet, M.A.; Faig, M.; Amzel, L.M. Structure and mechanism of NAD(P)H: quinone 
accpetor oxidoreductases (NQO). Methods. Enzymol. 2004, 382, 144-174. 
22.  Niculescu-Duvaz, I.; Cooper, R.G.; Stribbling, S.M.; et al. Recent developments in 
genedirected enzyme prodrug therapy (GDEPT) for cancer. Curr. Opin. Mol. Ther. 1999, 4, 480-
486. 
23.  Knox, R.J.; Jenkins, T.C.; Hobbs, S.M.; et al. Bioactivation of 5-(Aziridine-1-yl)-2,4-
dinitrobenzamide (CB1954) by human NADPH Quinone Oxidoreductase 2: A Novel Cosubstrate-
mediated Antitumor Prodrug Therapy. Cancer. Res. 2000, 60, 4179-4186. 
 131 
24.  Knox, J.R.; Burke, P.J.; Chen, S.; et al. CB 1954: from the Walker tumor to NQO2 and 
VDEPT. Curr. Pharm. Des. 2003, 9, 2091-2104. 
25.  AbuKhader, M.; Heap, J.; De Matteis, C.; et al. Binding of the anticancer prodrug CB1954 
to the activating enzyme NQO2 revealed by the crystal structure of their complex. J. Med. 
Chem. 2005, 48, 7714-7719. 
26.  Patterson, A.V.; Ferry, D.M.; Edmunds, S.J.; et al. Mechanism of action and preclinical 
antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin. Cancer. 
Res. 2007, 13, 3922-3932.  
27.  McKeage, M.J.; Gu, Y.; Wilson, W.R.; Hill, A.; Amies, K.; Melink, T.J.; Jameson, M.B. 
McKeage et al. BMC Cancer 2011, 11, 432-446. 
28.  Guise, C.P.; Abbattista, M.R.; Singleton, R.S.; et al. The bioreductive prodrug PR-104A is 
activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer. Res. 2010, 70, 
1573–1584. 
29.  Birtwistle, J.; Hayden, R.E.; Khanim, F.L.; et al. The aldo-keto reductase AKR1C3 
contributes to 7,12-dimethylbenz(a) anthracene-3,4-dihydrodiol mediated oxidative DNA 
damage in myeloid cells: implications for leukemogenesis. Mutat. Res. 2009, 662, 67–74. 
30.  Guise, C.P. et al. Identification of human oxidoreductases involved in the hypoxia-
dependent activation of bioreductive prodrugs. Proc. Am. Assoc. Cancer. Res. 2010, 51, Abstract 
453. 
31.  Hodnick, W.F.; Sartorelli, A. C. Reductive activation of mitomycin C by 
NADH:cytochrome b5 reductase. Cancer. Res. 1993, 53, 4907–4912. 
32.  Miskiniene, V.; Dickancaite, E.; Nemeikaite, A.; et al. Nitroaromatic betulin derivatives as 
redox cycling agents. Biochem. Mol. Biol. Int. 1997, 42, 391–397. 
33.  Yan, C.; Kepa, J.K.; Siegel, D.; et al. Dissecting the role of multiple reductases in 
bioactivation and cytotoxicity of the antitumor agent 2, 5-diaziridinyl-3-
(hydroxymethyl)-6-methyl-1,4-benzo quinone (RH1). Mol. Pharmacol. 2008, 74, 1657–1665. 
34.  Kutcher, W.W.; McCalla, D.R. Aerobic reduction of 5-nitro-2-furaldehyde semicarbazone 
by rat liver xanthine dehydrogenase. Biochem. Pharmacol. 1984, 33, 799–805. 
35.  Seow, H.A.; Penketh, P.G.; Shyam, K.; et al. A.C. 1,2-Bis(methylsulfonyl)-1-(2-
chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting 
hypoxic cells. Proc. Natl. Acad. Sci. USA. 2005, 102, 9282-9287. 
36.  Erler, J.T.; Giaccia, A.J. Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res. 
2006, 66, 10238–10241. 
 132 
37.  Dawson, D.A.; Rinaldi, A.C.; Pöch, G. Biochemical and toxicological evaluation of agent-
cofactor reactivity as a mechanism of action for osteolathyrism. Toxicology. 2002, 177, 267–
284. 
38.  Bachhuber, T.E.; Lalich, J.J.; Angevine, D.M.; Schilling, E.D.; Strong, F.M. Lathyrus factor 
activity of beta-aminopropionitrile and related compounds. Proc. Soc. Exp. Biol. Med. 1955, 89, 
294–297. 
39.  Granchi, C.; Funaioli, T.; Erler, J.T.; et al. Bioreductively activated lysyl oxidase inhibitors 
against hypoxic tumours. Chem. Med. Chem. 2009, 4, 1590–1594. 
40.  Giglio, J.; Patsis, G.; Pirmettis, I.; et al. Preparation and characterization of technetium 
and rhenium tricarbonyl complexes bearing the 4-nitrobenzyl moiety as potential bioreductive 
diagnostic radiopharmaceuticals. In vitro and in vivo studies. Eur. J. Med. Chem. 2008, 43, 741-
748. 
41.  Mauger, A.B.; Burke, P.J, Somani, H.H.; et al. Self-Immolative prodrugs: Candidates for 
Antibody-Directed Enzyme Prodrug Therapy in Conjunction with a Nitroreductase Enzyme. J. 
Med. Chem. 1994, 37, 3452-3458. 
42.  Hay, M.P.; Wilson, W.R.; Denny, W.A. Nitroarylmethylcarbamate prodrugs of 
doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy. Bioorg. Med. 
Chem. 2005, 13, 4043–4055. 
43.  Post, G.P.; Barthel, B.L.; Koch, T.H.; et al. Doxazolidine, a proposed active metabolite of 
Doxorubicin that cross-links DNA. J. Med. Chem. 2005, 48, 7648-7657. 
 
Chapter 4 Prodrug Albumin Conjugates 
1. Elsadek, B.; Kratz, F. Impact of albumin on drug delivery — New applications on the 
horizon. J. Control. Release. 2012, 157, 4–28. 
2. Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and 
nanoparticles. J. Control. Release. 2008, 132, 171–183. 
3. Park, K. Albumin: A versatile carrier for drug delivery.  J. Control. Release. 2012, 157, 3. 
(Epub 2011.  
4. Kratz, F.; Roth, T.; Fichiner, I.; et al. In vitro and in vivo efficacy of acid-sensitive 
transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-
MB-435 mamma carcinoma model, J. Drug. Target. 2000, 8, 305–318. 
5. Maeda, H.; Ueda, M.; Morinaga, T.; et al. Conjugation of poly(styrene-comaleic acid) 
derivatives to the antitumor protein neocarzinostatin: pronounced improvements in 
pharmacological properties. J. Med. Chem. 1985, 28, 455–461. 
 133 
6. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer 
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent 
smancs.  Cancer. Res. 1986, 46, 6387–6392. 
7. Lindholm, A. New insulins in the treatment of diabetes mellitus. Best. Pract. Res. Clin. 
Gastroenterol. 2002, 16, 475-492. 
8. Hamilton-Wessler, M.; Ader, M.; Dea, M.; et al. Mechansim of protracted metabolic 
effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. 
Diabetologia. 1999, 42, 1254-1263. 
9.  Standl, E. Insulin analogues - state of the art.  Horm. Res. 2002, 57, Suppl 1:40-45. 
10. Wootten, D.; Savage, E.E.; Valant, C.; et al. Allosteric modulation of endogenous 
metabolites as an avenue for drug discovery. Mol. Pharmacol. 2012, May 10. [Epub ahead of 
print]. 
11. Flisiak, R.; Flisiak, I. Albinterferon-alpha 2b: a new treatment option for hepatitis C. 
Expert. Opin. Biol. Ther. 2010, 10, 1509–1515. 
12. Nelson, D.R.; Benhamou, Y.; Chuang, W.L.; et al. Albinterferon Alfa-2b was not inferior 
to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus 
genotype 2 or 3. Gastroenterology. 2010, 139, 1267–1276. 
13. Zeuzem, S.; Sulkowski, M.S.; Lawitz, E.J.; et al. Albinterferon Alfa-2b was not inferior to 
pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus 
genotype 1. Gastroenterology. 2010, 139, 1257–1266.         
14. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin 
Pharmacother. 2006. 7, 1041-1053. 
15. Cortes J.; Saura C. Nanopartcle albumin-bound (nab™)-paclitaxel: improving efficacy and 
tolerability by targeted drug delivery in metastatic breast cancer. Eur. J. Cancer. Suppl. 2010, 8, 
1-10. 
16. Taxotere (docetaxel) Injection Concentrate [Package Insert]. Aventis Pharmaceutical 
Products, Inc.; Bridgewater, NJ: 2003. 
17. Taxol (paclitaxel) Injection [Package Insert]. Brystol-Meyers Squibb Co.; Princeton, NJ: 
2003. 
18. Weiss, R.B.; Donehower, R.C.; Wiernik, P.H.; et al. Hypersensitivity reactions from taxol. 
J. Clin. Oncol. 1990, 8, 1263-1268. 
19. ten Tije, A.J.; Verweij, J.; Loos, W.J.; et al. Pharmacological effects of formulation 
vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 2003, 42, 665-685. 
 134 
20. Authier, N.; Gillet, J.P.; Fialip, J.; et al. Assessment of neurotoxicity following repeated 
cremophor/ethanol injections in rats. Neurotox. Res. 2001, 3, 301-306. 
21. Postma, T.J.; Vermorken, J.B.; Liefting, A.J.M.; et al. Paclitaxel-induced neuropathy. Ann. 
Oncol. 2004, 6, 484-494. 
22. Gelderblom, H.; Verweij, J.; Nooter, K.; et al. Cremophor EL: the drawbacks and 
advantages of vehicle selection for drug formulation. Eur. J. Cancer. 2001, 37, 1590-1598. 
23. Winer, E.P.; Berry, D.A.; Woolf, S.; et al. Failure of higher-dose paclitaxel toimprove 
outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J. 
Clin. Oncol. 2004, 22, 2061-2068. 
24. Gradishar, W.J.; Krasnojon, D.; Cheporov, S.; et al. Significantly longer progression-free 
survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast 
cancer. J. Clin. Oncol. 2009, 27, 3611–3619. 
25. Hawkins, M.J.; Soon-Shiong, P.; Desai, N. Protein nanoparticles as drug carriers in clinical 
medicine. Adv. Drug. Deliv. Rev. 2008, 60, 876–885. 
26. Desai, N.; Trieu, V.; Damascelli, B.: et al. SPARC expression correlates with tumor 
response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2009, 2, 
59–64. 
26. Tiruppathi, C.; Song, W.; Bergenfeldt, M.; et al. Gp60 activation mediates albumin 
transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J. Biol. Chem. 1997, 272, 
25968–25975. 
27. Schnitzer, J.E. gp60 is an albumin-binding glycoprotein expressed by continuous 
endothelium involved in albumin transcytosis. Am. J. Physiol. 1992, 262, (1 Pt 2) H246–H254. 
28. Wang, Z.; Tiruppathi, C.; Minshall, R.D.; et al. Size and dynamics of caveolae studied 
using nanoparticles in living endothelial cells. ACS. Nano. 2009, 3, 4110–4116. 
29. Sage, H.; Johnson, C.; Bornstein, P. Characterization of a novel serum albuminbinding 
glycoprotein secreted by endothelial cells in culture. J. Biol. Chem. 1984, 259, 3993–4007. 
30. Podhajcer, O.L.; Benedetti, L.G.; Girotti, M.R.; et al. The role of the matricellular protein 
SPARC in the dynamic interaction between the tumor and the host.  Cancer. Metastasis. Rev. 
2008, 27, 691–705. 
31. Kratz, F.; Müller-Driver, R.; Hofmann.; et al. A novel macromolecular prodrug concept 
exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J. Med. 
Chem. 2000, 43, 1253–1256. 
32. Kratz, F.; Warnecke, K.; Scheuermann, C.; et al. Probing the cysteine-34 position of 
endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an 
 135 
acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that 
of the parent compound. J. Med. Chem. 2002, 45, 5523–5533. 
33. Graeser, R.; Esser, N.; Unger, H.; et al. INNO-206, the (6-maleimidocaproyl hydrazone 
derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in 
different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest. New. 
Drugs. 2010, 28, 14–19. Epub 2009, Jan 8.  
34. Unger, C.; Häring, B.; Medinger, M.; et al. Phase I and pharmacokinetic study of the (6-
maleimidocaproyl) hydrazone derivative of doxorubicin. Clin. Cancer. Res. 2007, 13, 4858–4866. 
35. Kratz, F.; Fichtner, I.; Graeser, R. Combination therapy with the albumin-binding prodrug 
of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves 
tolerability in an ovarian A2780 xenograft model. Invest. New. Drugs. 2011, [Epub ahead of 
print]. 
36. Calderón, M.; Welker, P.; Licha,K.; et al. Development of efficient acid cleavable 
multifunctional prodrugs derived from dendritic polyglycerol with a poly(ethylene glycol) shell. 
J. Control. Release. 2011, 151, 295–301.  
37.  Hofmann, U.B.; Westphal, J.R.; van Muijen, G.N.P.; et al. Matrix metalloproteinases in 
human melanoma. J. Investig. Dermatol. 2000, 115, 337–344.  
38.  Curran, S.; Murray, G.I. Matrix metalloproteinases in tumour invasion and metastasis. J. 
Pathol. 1999, 189, 300–308.  
39. Chambers, A.F.; Matrisian, L. M. Changing views of the role of matrix metalloproteinases 
in metastasis. J. Natl. Cancer. Inst. 1997, 89, 1260–1270. 
40. Hofmann, U.B.; Westphal, J.R.; Waas, E.T.; et al. Matrix metalloproteinases in human 
melanoma cell lines and xenografts: increased expression of activated matrix 
metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br. J. Cancer. 1999, 81, 
774–782. 
41. Sun, W.; Schuchter, L.M. Metastatic melanoma. Curr. Treat. Options. Oncol. 2001, 2, 
193–202. 
42. Kurschat, P.; Zigrino, P.; Nischt, R.; et al. Tissue inhibitor of matrix metalloproteinase-2 
regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix 
metalloproteinaseactivity in high and low invasive melanoma cell lines. J. Biol. Chem. 1999, 274, 
21056–21062. 
43. Fiebig, H.H.; Klostermeyer, A.; Schüler, J.B.; et al. Characterization of matrix 
metalloproteinases in 47 human tumor xenografts show high expression of MMP-2 in 
melanomas and sarcomas. Proc. Am. Assoc. Cancer. Res. 1999, 40, 463. 
 136 
44. Väisänen, A.; Tuominen, H.; Kallioinen, M.; et al. Matrix metalloproteinase-2 (72 kD type 
IV collagenase) expression occurs in the early stage of human melanocytic tumour progression 
and may have prognostic value. J. Pathol. 1996, 180, 283–289. 
45. Mansour, A.M.; Drevs, J.; Esser, N.; et al. A New Approach for the Treatment of 
Malignant Melanoma: Enhanced Antitumor Efficacy of an Albumin-binding Doxorubicin Prodrug 
That Is Cleaved by Matrix Metalloproteinase 2. Cancer. Res. 2003, 63, 4062-4066. 
46. Abu Ajaj, K.; Graeser, R.; Fichtner, I.; et al. In vitro and in vivo study of an albumin-
binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer. Chemother. Pharmacol. 
2009, 64, 413–418.  
47. Turk, B.; Turk, D.; Turk, V. Lysosomal cysteine proteases: more than scavengers. 
Biochim. Biophys. Acta. 2000, 1477, 98–111. 
48. Buck, M.R.; Karustis, D.G.; Day, N.A.; et al. Degradation of extracellular-matrix proteins 
by human cathepsin B from normal and tumour tissues. Biochem. J. 1992, 282, 273–278. 
49. Mai, J.; Sameni, M.; Mikkelsen, T.; et al. Degradation of extracellular matrix protein 
tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol. Chem. 
2002, 383, 1407–1413. 
50. Barthel, B.L.; Zhang, Z.; Rudnicki, D.L.; et al. Preclinical efficacy of a carboxylesterase 2-
activated prodrug of Doxazolidine. J. Med. Chem. 2009, 52, 7678-7688. 
51. Barthel, B.L.; Torres, R.C.; Hyatt, J.L.; et al. Identification of human intestinal 
carboxylesterase as the primary enzyme for activation of a doxazolidine carbamate prodrug. J. 
Med. Chem. 2008, 51, 298-304. Epub 2008 Jan 4. 
52. Burkhart, D.J.; Barthel, B.L.; Post, G.C.; et al. Design, Synthesis, and Preliminary 
Evaluation of Doxazolidine Carbamates as Prodrugs Activated by Carboxylesterases.  J. Med. 
Chem. 2006, 49, 7002-7012. 
53. Burke, P.J.; Koch, T.H. Design, synthesis, and biological evaluation of doxorubicin-
formaldehyde conjugates targeted to breast cancer cells. J. Med. Chem. 2004, 47, 1193-1206. 
54. Burke, P.J.; Koch, T.H. Doxorubicin-formaldehyde conjugate, doxoform: induction of 
apoptosis relative to doxorubicin. Anticancer. Res. 2001, 21, 2753-2760. 
55. Walko, C.M.; Lindley, C. Capecitabine: a review. Clin. Ther. 2005, 27, 23-44. 
56. Parker, W.B.; Y.C. Cheng. Metabolism and mechanism of action of 5-fluorouracil. 
Pharmacol. Ther. 1990, 48, 381-95. 
57. Wagstaff, A.J.; Ibbotson, T.; Goa, K.L. Capecitabine: a review of its pharmacology and 
therapeutic efficacy in the management of advanced breast cancer. Drugs. 2003, 63, 217-236.  
 137 
58. Post, G. C.; Barthel, B. L.; Burkhart, D. J.; Hagadorn, J. R.; Koch, T. H. Doxazolidine, a 
proposed active metabolite of doxorubicin that cross-links DNA. J Med Chem. 2005, 48, 7648-
57. 
59. Gude, M.; Ryf, J.; White, P. An accurate method for quantitation of Fmoc-derivitized 
solid phase supports. Letters in Peptide Science. 2002, 9, 203-206. 
60. Rusiecki, V.K.; Warne,S.A. Synthesis of Nα-Fmoc-Nε-Nvoc-Lysine and use in the 
preparation of selectively functionalized peptides. Bioorg. Med. Chem. Lett. 1993. 3, 707-710.
 137 
 
 
 
 
Appendix I Selected NMR Spectra 
 
 
 138 
 
b
isA
cG
aFK
P
A
B
C
D
o
xaz 
5
0
0
 M
H
z in
 D
M
SO
-d
6
 at 
5
5
:C
 
 139 
 
b
isTFA
G
aFK
P
A
B
C
D
o
xaz 
5
0
0
 M
H
z in
 D
M
SO
-d
6
 at 
5
5
:C
 
 140 
 
P
N
B
D
o
xaz 
5
0
0
 M
H
z in
 C
D
C
l3  at 5
9
:C
 
 141 
 
P
N
B
P
A
B
A
D
o
xaz 
5
0
0
 M
H
z in
 C
D
C
l3  at 5
9
:C
 
 142 
 
em
caFK
(allo
c)P
A
B
A
 
5
0
0
 M
H
z in
 D
M
SO
-d
6
 at 
am
b
ien
t tem
p
eratu
re 
 143 
 
em
caFK
(allo
c)P
A
B
A
P
N
P
 
5
0
0
 M
H
z in
 D
M
SO
-d
6
 at 
am
b
ien
t tem
p
eratu
re 
 144 
 
em
caFK
(allo
c)P
A
B
C
D
o
xaz 
5
0
0
 M
H
z in
 D
M
SO
-d
6
 at 
5
5
:C
 
 145 
 
em
caFK
(P
O
4 )P
A
B
C
D
o
xaz 
5
0
0
 M
H
z in
 D
M
SO
-d
6
 at 
5
5
:C
 
 146 
 
A
cG
aFK
P
A
B
C
D
o
xazz 
5
0
0
 M
H
z in
 D
M
SO
-d
6
 at 
5
5
:C
 
 147 
 
A
cG
aFK
(allo
c)P
A
B
C
D
o
xazz 
5
0
0
 M
H
z in
 C
D
C
l3  at 5
5
:C
 
